Blood and Blood Components Transfusion Modalities

#### **Chapter 7**

## Optimizing Blood Transfusion Service Delivery across the West African Sub-Region

*Osaro Erhabor, Josephine O. Akpotuzor, Edward Yaw Afriyie, Godswill Chikwendu Okara, Tosan Erhabor, Donald Ibe Ofili, Teddy Charles Adias, Idris Ateiza Saliu, Evarista Osime, Alhaji Bukar, Oyetunde B. Akinloye, Zakiya Abdul-Mumin, John Ocquaye-Mensah Tetteh, Edwin G. Narter-Olaga, Andrews Yashim-Nuhu, Folashade Aturamu, Ayodeji Olusola Olayan, Adeyinka Babatunde Adedire, Oyeronke Suebat Izobo, Kolawole A. Fasakin, Onyeka Paul, Collins Ohwonigho Adjekuko, Elliot Eli Dogbe and Uloma Theodora Ezeh*

#### **Abstract**

The sub-continent of West Africa is made up of 16 countries: Benin, Burkina Faso, Cape Verde, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, The Gambia and Togo. As of 2018, the population of the sub-continent was estimated at about 381 million. The main challenge associated with blood transfusion service delivery across the sub-region concerns adequacy and safety. In this chapter, we highlighted the challenges associated with the delivery of a quality blood transfusion service in countries in the sub-region including: implementation of component therapy rather than whole blood transfusion, effective cold chain management of blood and blood products, alloimmunization prevention, implementation of column agglutination and automation rather than the convention manual tube method in blood transfusion testing, effective management of major haemorrhage, optimization of screening for transfusion transmissible infections, optimizing blood donation, implementation of universal leucodepletion of blood and blood products, effective management of transfusion-dependent patients, pre-operative planning and management of surgical patients, management of Rhesus D negative pregnancy and women with clinically significant alloantibodies, implementation of haemovigilance system, implementation of alternatives to allogenic blood, availability

and use of specialized blood products, optimizing safe blood donation, enhancing blood transfusion safety, operating a quality management system-based blood transfusion service and implementation of non-invasive cell-free foetal DNA testing. There is the urgent need for the implementation of evidence-based best practices in blood transfusion service delivery across the sub-region to allow for excellent, safe, adequate and timely blood transfusion service delivery across the sub-region.

**Keywords:** blood transfusion, service delivery, West Africa, optimization, sub region

#### **1. Introduction**

Blood transfusion has life-saving potential and can improve the wellbeing and quality of life of anaemic and bleeding patients [1]. However, the major challenge to blood transfusion service delivery across the West African sub region is access to adequate, safe and timely blood transfusion service [2]. Effective blood transfusion requires that blood sourced from the right voluntary non-remunerated blood donor, is rightly screened, processed, stored and distributed. It is the right blood given to the right patient in the right quantity, in the right condition, at the right time, in the right place, for the right clinical indication and that is effective [3, 4]. There are several challenges associated with blood transfusion service delivery across the West African subregion. In 2016, WHO global status report on blood safety and availability indicated that an insignificant 5.6 million units of blood (4% of the global supply) were collected in Africa with 38 African countries collecting <10 whole-blood donations per 1,000 populations [5]. The West African sub-region and other developing countries have a significantly increased need for blood and constitute a significant part of the global population, yet it contributes an insignificant number of units to the global allogenic blood pool. The rate of blood donation across the sub-region and other developing countries is significantly lower and often from less safe family replacement and commercial remunerated donor rather than from safer, benevolent and altruistic voluntary nonremunerated blood donors. There are 4.6, 11.7 and 33.1 donations per 1000 population in low- income developing, middle -income and high-income countries respectively [5]. In addition, there is a significant variation in the groups that are most frequently transfused in developing and developed countries. In West Africa and other developing countries, a significant 65% of transfusions are given to children <5 years and to manage pregnancy-related complications including ante and post-partum bleeding compared to 76% of blood transfused to patients >65 years of age in developed countries.

The provision of safe, adequate, and timely blood should ideally be the responsibility of the National blood transfusion service (NBTS) and should be an essential part of every nation's national health care policy. The WHO recommends that every nation should have a centrally coordinated and regionally based National Blood Transfusion Service governed by national blood policy and legislative framework to allow for the maintenance of standards and consistency in the quality and safety of blood and blood products [6]. The NBTS sole responsibility is to coordinate all activities related to blood collection, testing, processing, storage and distribution blood collected from safe voluntary non-remunerated blood donors who form a reliable, safe, assured and stable base of blood donors [7]. Although the national blood transfusion services are present in member countries across the sub region, they have not been able to solve the challenge of ensuring the safety, adequacy and timely blood transfusion service delivery [8, 9].

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

Blood supply across the sub region is still predominantly dependent on family/ replacement and some commercial remunerated donors. Only few donors across the region donate blood voluntarily. The West African sub-region does not seem to be as altruistic as their counterpart in the developed world regarding voluntary blood donation [10].

WHO recommends that all blood donations should be screened mandatorily for transfusion transmissible diseases including, HIV, hepatitis B, hepatitis C and syphilis and that such screening should meet quality management system requirements. The prevalence of TTIs is considerably higher in the West African sub region compared to the high-income developed nations. In the West African sub region, the challenge has been the availability of screening measures, adequately trained personnel and relevant infrastructure that is required to reduce the risk of introducing potentially infected blood from donor in the window phase of infection in the allogenic blood pool. Use of antibody-based screening with its limitation is prevalent for screening of blood donors for HIV and HCV. Blood donor screening most times is not monitored through external quality assessment (EQA) schemes, there is irregular supply and sometimes stock out of screening kits and other consumables [11, 12].

Suboptimal utilization of the limited allogenic bloodstock is another a major challenge. Whole blood transfusion rather than universally leucodepleted component therapy is prevalent across the sub region [13, 14]. National haemovigilance systems and Hospital Transfusion Committees (HTC) required to monitor, improve, and ensure the rational use and by extension the safety of the blood transfusion process are often non-existent in many setting across the sub region [15]. Adverse events, reactions and near misses are not reported and investigated properly. The root causes are not determined neither are the corrective and preventive action implemented in a timely and action-planned format. Clinical audits are seldom implemented and unnecessary non-clinically indicated and unsafe transfusion practices that expose patients to the risk of serious adverse transfusion reactions and TTIs and that reduces the availability of blood products for patients in whom it is clinically indicated are prevalent. There is absence of indication coding tool required to guide the safe, appropriate, and clinical use of blood across the sub region [16]. The decision to transfuse a patient across the sub region should ideally be based on clinical judgement, laboratory-based evidence and the patient's risk/benefit ratio including risks associated with transfusion and anaemia [17]. There is need to ensure that all transfusion across the region is clinically effective, prevent mortality in acute situations, ensure the reversal of a physiological transfusion trigger, restores adequate tissue perfusion and ensures maintenance of optimum coagulation [18]. There is an urgent need to solve the challenges associated with timely access to a safe and adequate supply of blood products. The aim of this chapter is to highlight the challenges associated with blood transfusion service delivery in the West African sub region and advocate for the implementation of realistic, pragmatic and evidence-based best practices required to optimize blood transfusion service ensuring that there is universal access to safe blood and blood products.

#### **2. Urgent need for the implementation of component therapy in the West African sub-region**

Traditionally, blood can be transfused either as whole blood or as one of its components. Blood components include red cell concentrates (RCCs), fresh frozen plasma (FFP), platelet concentrates (PCs) and cryoprecipitate. However, global safety initiatives and evidence-based best practice advocate that donation be separated into components for safety reasons and to facilitate optimal utilization of scarce allogenic blood stock [19]. Blood component therapy (BCT) is the therapeutic use of blood components rather than the wasteful use of whole blood to manage patients. Patients seldom need all the components of in whole blood. Anaemic patients require red cell concentrate, coagulopathy patients with raised international normalized ration (INR) above 1.5 require fresh frozen plasma, thrombocytopenic patients require platelet concentrate while bleeding patients with significantly low fibrinogen level (< 2 g/L for obstetric haemorrhage and < 1 g/L in non-obstetrics haemorrhage) requires cryoprecipitate. BCT involves whole blood being leucodepleted, divided into individual components, and delivered separately. It often requires that a patient receives the specific blood component required to treat their specific deficiency or condition [20]. Component separation was first developed in 1960 aimed at separating blood products from a unit of whole blood using refrigerated centrifuges and controlled conditions of gravitational force and temperature [19]. A considerable number of literatures has accumulated over the past decade indicating that leukocytes present in allogeneic cellular blood components, intended for transfusion, are associated with adverse effects to the recipient [21]. These include the development of febrile transfusion reactions, graft-versus-host disease, alloimmunization to leukocyte antigens and the immunomodulatory effects that might influence the prognosis of patients with malignancy and HIV. Moreover, it has become evident that leukocytes present in whole blood may be the vector of infectious agents such as cytomegalovirus (CMV), Human T-Lymphotrophic Virus 1/11 (HTLV-I/II), and Epstein Barr (EBV) as well as other viruses. Effective stewardship of blood ensuring that several patients potentially benefit from components derived from one unit of donated whole blood is important for economic, supply/ demand reasons and to protect the national inventory at times of national blood shortage [22]. Blood safety in developing countries can be improved by more appropriate use of blood components rather than whole blood transfusion and the provision of alternatives such as oral and intravenous iron, erythropoietin, saline and colloids to manage anaemic and bleeding patients. This will facilitate the optimal use of the limited blood supply. Political will and open-mindedness to innovative ways to improve supply, appropriateness, optimal use and safety of blood from blood donors are essential to promote more evidence-based approaches to blood transfusion practice in sub-Saharan Africa. A recent review on blood transfusion in sub-Saharan Africa highlights the gaps in the area of quality, safety, supply and efficacy of blood and plasma products [23]. BCT is evidence-based best practice and constitutes effective stewardship in the management of our scarce blood resource. BCT allows for targeted therapy and maximum utilization of donated whole blood ensuring that several patients potentially benefit from components derived from the unit. It makes economic, supply/demand sense to implement BCT across the West African sub region- a region where there is high demand, but little supply coupled with the challenge of safety of blood and blood products [24, 25]. BCT can potentially protect regional inventory at times of national blood shortage [20]. Evidence-based clinical decision is crucial in ensuring appropriate transfusion practice. Education, training, and competency testing of all healthcare personnel involved in the blood transfusion process is vital in ensuring effective and appropriate clinical use of blood and components. In countries across the West African sub-region, non-leucodepleted whole blood transfusion thrives rather than

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

component derived from leucodepleted whole blood [26]. Previous report indicates that the utility of cryoprecipitate platelet concentrate and other plasma products is low in many settings in sub-Saharan Africa. This is often due to multiple factors; unavailability due to lack of equipment in NBTS for blood product preparation [27] and lack of education and knowledge among physicians on evidence-based best practices on blood management principles. Other factors include logistical issues and lack of laboratory infrastructure to produce blood components. A previous report that investigated the knowledge and practices of physicians on blood component therapy in two tertiary hospitals in Nigeria indicated that although majority of the physicians have a good knowledge concerning BCT, there is however a knowledge-practice mismatch attributable to the unavailability of the various blood components thus limiting optimal practice of BCT [28]. In each country across the sub region, the blood collection service should have the technical capabilities and financial resources required to facilitate the supply of a range of safe blood products adapted to the specific clinical needs in the country, in particular and for labile therapeutic cellular components. Use of blood products should rely on evidencebased clinical practice, a concept which requires a well- structured and operational clinical interface between blood establishments and care centres. Transfusion committees are an operational tool to monitor and record transfusion epidemiology, patient blood management and blood product use within hospitals. A previous report that investigated the clinical utility of component therapy in sub-Saharan Africa indicated that a total of 40 out of the 43 countries studied reported that they have capacity to produce blood components with red cell concentrates being prepared in 35 of the 40 countries while platelets and fresh frozen plasma were prepared in 27 and 30 countries respectively. In most countries in West Africa an insignificant proportion of blood collection is separated into components; Benin 39.2%, Cameroon 2.8%, Burkina Faso 98.4, Central African Republic100, Congo 20.5, Côte d'Ivoire 86.2, DRC45.0, Sao Tome and Principe 85.2, Senegal 20.5, Mauritius 47.6, Gambia0.0, Ghana 2.6, Nigeria 0.0, Guinea 0.4, Madagascar 38.6, Mali 30.4, Togo 72.2, Mauritania 100, Niger 7.2, Tanzania 1.7 and Sierra Leone 0.0 [29]. In Burkina Faso, the blood transfusion centre produces red cell concentrates (RCC) from whole blood by centrifugation or simple gravity to meet the blood component demand for patients suffering from severe anaemia, such as pregnant women and children with malaria [30]. Separating blood into red cell concentrates, platelet concentrates, plasma and cryoprecipitate is a tool that can be implemented across the West African sub region along with universal leucodepletion and possibly virus inactivation treatments. It is vital that the preparation of blood components be guided by clinical requirements, especially to prevent unnecessary wastage of recovered plasma. One practical way to avoid wasting plasma would require costeffective and tightly controlled processing of qualified plasma from throughout the West Africa sub region to produce polyvalent and hyperimmune immunoglobulins, VIII (to treat patients with haemophilia A and albumin [31]. Fractionation of plasma can generate a range of purified, virally inactivated, protein therapeutics that can potentially reduce some adverse effects (fevers, chills, transfusion-transmitted infections like CMV, HTLV-1 and 2 as well as prevent volume overload) while providing a better treatment for people suffering from haemophilia or immunodeficiency and other diseases that requires plasma derived proteins for the management. The plasma derived from blood component can be fractionated to produce various Plasma-derived Medicinal Products (PDMPs) of significant economic and therapeutic value [32, 33]. The effective implementation of BCT across the West African

region is a huge but surmountable technological challenge hindered in many cases by the lack of a fit for purpose and structured national blood transfusion service, suboptimal number of qualified and skilled health workers, uninterrupted power supply challenges and challenge associated with cold-chain management of blood components. These challenges, although daunting, is surmountable and will require the political will by government of ECOWAS countries working together as a team and taking bold steps to implement BCT (**Figures 1**–**6**).

*Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

#### **Figure 2.**

*Cold chain management of blood and blood products.*

**Figure 3.** *Alloantibody screening and panel cells.*

**Figure 4.** *Column agglutination technique.*

**Figure 5.**

*Blood products and pharmacologic agent used to manage major haemorrhage.*

**Figure 6.**

*Evidence-based best practice in the management of transfusion-dependent patients.*

#### **2.1 Getting cold chain management of blood and blood products right across the West African sub-region**

Blood transfusion is an indispensable part of modern medicine. The efficient and effective use of appropriately stored blood has lifesaving potential. Effective transfusion requires the implementation of several integrated strategies for blood safety including effective cold chain of blood and blood products. A cold chain is a temperature-controlled supply chain of perishable products such as blood, medicines, vaccines that are sensitive to temperature fluctuations and for which a break in the cold chain can affect its clinical effectiveness and potentially cause harm to the patient. The cold chain for the hospital transfusion laboratory is 24 hours a day, 7 days a week and 365 days a year projects that starts from the receipt of the blood from the blood centre to the time the unit is transfused to the patients or otherwise disposed. Good Distribution Practice (GDP) requires that optimum storage conditions

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

are always observed, including during transportation. The ambient temperatures should be measured continually (24 hours, 7-days a week and 365-days a year) for temperature alarm conditions [34]. The optimum storage temperature for red cell concentrate, plasma and platelet concentrate in blood bank refrigerator, freezers and platelet incubator are 2–6°C, −35°C and 20–24°C respectively. In countries with restricted economies including setting across the West African sub region, the poor practice of using domestic refrigerators and freezers for the storage of blood and blood components is prevalent [35]. Although generally affordable, they are not suitable for blood storage because they are not designed for this purpose. The insulation in domestic fridges and freezers are poor and, in the event of power outage, they will not hold temperatures adequately. Furthermore, domestic refrigerators do not have temperature monitoring devices, such as audio-visual alarms for temperatures outside the set limits for the products being stored. In many settings across the West African sub region especially in remote rural areas, hospitals are often dependent on fuel-driven generators for their electricity supplies which may be inadequate to meet their power needs, particularly the special requirements of blood bank refrigerators and freezers that must function round the clock. Frequent power outages sometimes for long duration are prevalent in hospitals that are on the national power grid with a significant negative implication on the quality, safety and wastage of the scarce blood resource. Also, sensitive blood bank refrigerators are often damaged because of power surges that are common in many settings across the sub region. One of the main reasons of ensuring optimum storage of blood and blood products is to minimize the risk of bacterial growth. If blood is kept at temperature higher than the defined limit bacteria that have infiltrated into blood during collection from the blood donor will quickly grow and proliferate [36, 37]. Also, the suboptimum storage of blood at a temperature less than the defined lower limit predisposes the red cell membrane to damage, release of the free radical haemoglobin contained in the cytoplasm with resultant haemolysis that will increase mortality and morbidity [38]. The transportation of blood between and within blood banks and hospitals is often dependent on the availability of cooler boxes that can maintain temperature over long distances and in relatively high ambient temperatures [39]. Across West Africa the use of domestic type (picnic) cooler boxes or other containers that are not validated and are not reliable in maintaining ambient storage temperature is prevalent. The absence of safe validated blood transport boxes can affect the safe movement of blood and blood products and compromise the quality and potentially cause harm to the patient [40]. Scientific evidence exists that indicates that transfusion of RBC units that exceeding defined temperature is associated with a greater degree of haemolysis and septic transfusion reactions [41, 42]. Evidence-based best practice recommend that all boxes used for the transport of blood and blood products be validated with documentary evidence to show that temperature during storage are ambient [34]. Validation is a documented assessment to prove that the requirement for a specific intended use is reliably fulfilled. It is evidence-based best practice that validation of all blood transport boxes be performed in advance to ensure that transport of components is at the right storage conditions and to ensure that the integrity of the blood product is not compromised. Also, the need for regular mapping of blood fridges cannot be overemphasized. The aim for temperature mapping of blood fridges and freezers is to demonstrate by way of documented evidence that the chosen storage area is suitable for the optimum storage of temperature sensitive blood and blood products [43]. There is also the need for blood transfusion laboratories across the sub region to have

back up fridges and freezers where products can be transferred in a timely manner (30 minutes' rule is not compromised) when the routine fridges and freezers malfunctions or are not keeping optimum temperature. The prevailing temperature across the West African sub region is high. The time it takes for the temperature of blood to rise above +6°C when the power supply to the equipment is cut off or when the fridge is left open (holdover time) is dependent on the quality of the insulation of the cabinet and the prevailing temperature in the environment. In the West African sub region where there is a high tendency to use domestic refrigerators and freezers with poorer insulated cabinet for storage of blood and blood product, the challenge is even worse. Temperatures in the lowlands of West Africa are high throughout the year, with annual means usually above 18°C. In the Sahel, the maximum temperatures can reach above 40°C. The hold-over time in these hot environments will likely be shorter and could be worse when there are power outages. The hold-over time is however less critical for plasma freezers, since plasma are stored frozen at −35°C and will usually take about 24 hours before it begins to thaw. Cold chain management of blood and blood products is expensive, complicated, comprehensive, and associated with several logistical challenges [44]. There is a need for countries in West Africa sub region to develop a cost-effective blood cold chain programme that is technologically appropriate, affordable and accessible at all levels of the health care delivery (primary, secondary and tertiary) system. The equipment must meet international standards, together with WHO minimum performance specifications and be correctly used and maintained by all personnel involved. The West African sub region is blessed with a vast amount of green renewable energy potential that is adequate to ensure a universal access to uninterrupted electricity. Heads of State and Government of the Economic Community of West African States (ECOWAS) will need to invest in solar energy to enable her to maximize the solar energy potential in the management of critical infrastructure including the cold chain management of blood and blood products.

#### **2.2 Alloimmunization prevention and antenatal management of pregnant women in West Africa**

Currently, there are about 400 red blood cell antigens in 33 blood group systems. Of these, there are 50 different antigens that have the capacity to cause maternal alloimmunization and haemolytic disease of the foetus and the newborn (HDFN). The most clinically significant blood group system is the ABO blood group system followed by the Rhesus and then Kell blood group system [45]. Of the antigens of the Rhesus blood group system the D antigen is the most immunogenic. Individuals positive for the Rhesus D antigen are referred to as Rhesus D positive while those who are negative are Rhesus D negative. The prevalence of Rh D negative group varies in different ethnic populations, with approximately 15.8% of Caucasians, 8% of Blacks, and 1% of Asians being RhD negative [46–50]. Alloantibodies are produced because of blood group incompatibility between a mum and her developing foetus or because of the transfusion of a foreign red cell antigen to a patient. These alloantibodies are low molecular weight immunoglobulin G (IgG) that can cross the placenta and causing haemolytic disease of the foetus and the newborn (HDFN) as well as haemolytic transfusion reaction (HTR) if the patient is exposed to a red cell antigen in the donor unit to which the patient has the group specific alloantibody. About 1.5–2% of pregnant show the presence of alloantibodies at booking [51] and a further 0.18% of women who had no alloantibodies at booking become immunized and show the

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

presence of alloantibodies at 28-week gestation [52]. Commonly encountered alloantibodies include the Rhesus (Anti-D, anti-C, anti-c, anti-E, or anti-e), anti-K, anti-Kidd (Jka and b), Duffy (Fya and b) and anti-S. Of all these the most encountered are the Rhesus antibodies with anti-D and c predominating [53]. A previous report among Cameroonian women of reproductive age has indicated an anti-D prevalence of 4% among Rh-negative African women [54]. Evidence-based best practices in the management of pregnant women requires the routine antenatal determination of the ABO and Rh D group of pregnant women and alloantibody screening during antenatal booking. This alloantibody screen facilitates the identification of Rhesus D negative women who have developed alloantibodies. Those that are Rhesus D negative and are previously non-sensitized are enrolled into the routine antenatal anti-D prophylaxis (RAADP) program and are universally administered anti- D prophylaxis at the 28th-week gestation and a postpartum injection of anti-D within 72 hours of delivering an RhD-positive infant. This protects the woman from being sensitized by foetal red cells containing the D antigen during the transplacental bleeding that can potentially occur during pregnancy or delivery [54, 55].

Transplacental or fetomaternal haemorrhage (FMH) that occur during pregnancy or during delivery can predispose the mum to sensitization leading to development of anti-D that can cause haemolytic disease of the foetus and newborn (HDFN) in subsequent D-positive pregnancies [56]. Also evidenced best practices in the West recommend that mass foetal blood group by analysis of cell-free foetal DNA in the maternal plasma should be carried out based on the finding that 38% of Rhesus D negative women are likely to be carrying an RhD-negative foetus and would receive the treatment unnecessarily [57]. There are several advantages associated with this practice, firstly, there would be a substantial reduction in the use of anti-RhD immunoglobulin, an expensive blood product in short supply. Secondly, women with an RhD-negative foetus would be spared unnecessary exposure to this pooled human blood product with its associated pain and perceived risk from viral or prion contamination. Also, these women can be spared FMH that would have been carried out following a potentially sensitizing event that occur during such pregnancy [58]. Evidence-based best practice recommend availability of facilities for the determination of FMH (acid elution method, or the Kleihauer-Betke (KB) or Flow cytometry) to enable the quantification of Rhesus D foetal red cells that potentially enters the maternal circulation of a Rhesus D negative mother following a potentially sensitizing event post 20-week gestation or post-delivery of a Rhesus D positive baby. This is to enable the administration of the adequate dose of anti-D prophylaxis to be issued within 72 hours of the sensitizing event to clear the foetal red cells from the maternal circulation and thus prevent the mother from being sensitized to produce immune anti-D that can cause HDFN in subsequent D positive pregnancy [59]. Previous report indicates that a dose of anti-D of 125iu is required to clear 1 ml of Rhesus D positive foetal cell from maternal circulation. Implementation of preventive screening programs for antenatal care in the West has led to a significant reduction in maternal and infant mortality rates to approximately 1 in 7000 compared to 1 in 23 for women living in parts of Africa where antenatal care is poor or sometimes non-existent [60]. In many settings across the West African sub region these evidence-based best practices are often not available. Other challenges include; the absence of universal access to anti-D immunoglobulin for the Rh-negative women and following potentially sensitizing events [amniocentesis, cordocentesis, antepartum haemorrhage, vaginal bleeding during pregnancy, external cephalic version (ECV), abdominal trauma, intrauterine death and stillbirth, miscarriage, and therapeutic termination

of pregnancy (TOP)] [61, 62], unaffordability of anti-D prophylaxis [62, 63], lack of facilities for alloantibody screening and identification during antenatal booking [64, 65], lack of alloimmunization prevention during illegal abortions and poor documentation [66]. Knowledge of anti-D prophylaxis among biomedical scientist, obstetricians, pharmacists, midwives, nurses, and traditional birth attendant across the West African sub region needs to be improved [67]. This will facilitate quality antenatal and postnatal care to be offered to Rh-negative pregnant population as well as pregnant women with alloantibodies and improve perinatal outcomes.

#### **2.3 Paradigm shift from convention tube method to column agglutination technique and automation in blood transfusion service delivery in the West African sub-region**

Over the years, the conventional test tube (CTT) was being used for pre-transfusion testing [ABO and Rhesus D blood group, Direct antiglobulin test (DAT) alloantibody screen and identification and compatibility testing]. However, recent scientific development in the field of transfusion has led to the discovery of semi-automated and fully automated equipment using Column agglutination technology (CAT) [68]. This technique often includes the use of column agglutination-based cards, centrifugation, and incubation. Larger laboratories are moving towards automation of all the hitherto manual techniques using CTT. The advantages of these automated techniques include elimination of human associated errors, reduction in the risk of exposure to bio-hazardous samples, allows for better traceability, reliability, improved turnaround time (TAT) and throughput [69–71]. The principle of the CAT is based on the sieving effect of glass microspheres and gel of agglutinated red cells while allowing non-agglutinated cells to filter to the bottom. In principle, the test is performed in a micro column in which red blood cells containing red cell antigens suspended in low ionic strength saline and serum-containing antibodies are pipetted into the microtubes, incubated, and then centrifuged. RBC agglutinates are trapped in the glass bead matrix during centrifugation and the non-agglutinated cells form a pellet at the bottom of the column. The gel or glass microspheres within each column act as a sieve, trapping agglutinated red cells and allowing non-agglutinated red cells to pass through the pores of the gel or glass microspheres to the bottom of the column. A previous report indicated a sensitivity and specificity of 100% with CAT and concluded that the gel technique is better and should be introduced as a replacement to the CTT [72]. The CAT has several advantages compared to the CTT [73]. The antiglobulin testing used for the detection of clinically significant red cell antibodies can be performed using the CAT card impregnated with AHG without the need to wash with the CTT thus eliminating the potential errors associated with suboptimal washing and potential neutralization of anti-human globulin (AHG). Other advantages of this techniques over the CTT is that it allows for the detection of Ig and complement in diagnosis of HDFN, it can be used for ABO, Rh, Kell phenotype, DAT, ABs screen and XM, it is paediatric friendly as only a small quantity of cells and serum is required, no washing is required as in CTT, it is not subjective and the results are clear and readable and does not require a microscope, it is easy to automate, the risk of miss-up is minimal, it is more sensitive and specific and can detect weaker antibodies, it reduces the turnaround time to make compatible units available, result is standardized and can be automated [74–77]. The CAT, although more expensive than the CTT, has several advantages. Many Blood transfusion laboratories across the West African sub region still rely on the less sensitive CTT. It is highly recommended that government

of West African countries should implement the CAT for routine pretransfusion testing across the region to enhance the quality of blood transfusion service delivery.

#### **2.4 Implementing evidence-based best practices in the management of major haemorrhage across the West African sub-region**

Haemorrhage from post-traumatic bleeding, intra and post-operative, gastrointestinal, ante and post-partum remains a leading cause of potentially preventable death particularly in the West African sub region. Major haemorrhage is defined as: loss of more than one blood volume within 24 hours (around 70 mL/kg, >5 litres in a 70 kg adult), loss of 50% of total blood volume in less than 3 hours and bleeding more than 150 mL/minute [78]. Experience has shown that early recognition and intervention is critical for survival. In major haemorrhage situation the immediate priorities include prompt arrest or control of bleeding (use of surgical and interventional radiology), ensure optimum tissue perfusion by transfusing red cells concentrate and maintaining optimum blood volume to prevent hypovolaemic shock. A protocol-driven multidisciplinary team approach involving trained, and competency tested major stakeholders (medical, anaesthetic, surgical, transfusion staff and porters) reinforced by clear and effective communication between clinicians, transfusion laboratory and porters. Availability of safe, adequate, and promptly delivered blood components is a key factor in the effective management of MH. Major obstetric haemorrhage (MOH) is prevalent and is a leading cause of maternal mortality accounting for one-third of maternal deaths in Africa [79]. Sub Saharan Africa ranks first in the incidence of maternal mortality globally [80]. Postpartum haemorrhage (PPH) is a common factor responsible for 30 to 50% of Maternal mortality in sub-Saharan Africa [81]. PPH is defined as blood loss ≥500 mL during vaginal delivery and ≥ 1000 mL during caesarean section [82]. It is advocated that low income developing countries can reduce PPH related mortality by approximately 30% if the antifibrinolytic agent (tranexamic acid) is administered promptly at the commencement of bleeding [83]. This treatment is simple and relatively inexpensive and can have a significant effect of survival of women in the West African region [84]. There are several factors that complicates the effective management of haemorrhages (ante- and post-partum) in pregnant women across west Africa; medical records are often incomplete and does not have information on haemorrhage risk and past haemorrhage-related risk associated with patients, absence of routine coagulation test to identify patient that are coagulopathic and are prone to bleeding, absence of blood and products (red cell concentrate, fresh frozen plasma, cryoprecipitate and platelet concentrate), pharmacologic (vitamin K, Prothrombin complex concentrate, tranexamic acid) and nonpharmacologic (surgical and explorative) measures to management haemorrhage, poor management of bleeding- related anaemia in an environment of pre-existing anaemia, timely access to emergency interventions, availability of trained healthcare staff, financial and infrastructural factors, absence and lack of awareness of massive transfusion and major haemorrhage protocols, poor collaborations and communication between local teams responsible for the management of haemorrhage (haematology, blood banking, obstetrics and porters), suboptimal training of obstetricians, nurses, anaesthetists and other relevant health workers on the evidence-based management of obstetrics haemorrhage especially in rural clinics [85–90]. The three main causes of major obstetrics haemorrhage (MOH) are placental abruption, complications during or after Caesarean Section (CS) and uterine atony [91]. The availability, appropriate cold chain management and appropriate and consistent use

of oxytocin as an effective, affordable, and safe drug of first choice in the prevention and treatment for Post-Partum Haemorrhage (PPH) particularly in the third stage of labour is advocated [92]. The biggest obstacle to oxytocin quality is storage and handling before patient use. The storage condition of oxytocin has been widely reported as inappropriate. Oxytocin is a heat-sensitive medicine and should be kept between 2 and 8°C. Challenges associated with the effective use of oxytocin in developing countries include procurement issues, poor supply chain, logistics, suboptimal cold chain management during transport and storage and lack of stable electricity). There is need to optimize the haemorrhage management training for all stakeholders involved in the management of obstetric haemorrhage across the West African sub-region as a way of significantly reducing the detrimental effects of obstetric haemorrhage in the sub-region. Correction of pre-existing anaemia among pregnant women should be incorporated in the strategy for preventing deaths from PPH across the sub region. An enabling environment (human and infrastructural) needs to be created across the sub-region in urban and rural areas that facilitate regular attendance to antenatal clinics to curb the attendant dangers associated with home deliveries. The need to optimize the number of skilled birth attendants (SBA) and community midwives cannot be overemphasized. Government of West African states must take objective, strategic and effective steps to ensure the prevention, early diagnosis and improved clinical management of MOH in furtherance of achieving the Sustainable Development Goals aimed at reducing maternal mortality. Every minute of every day a woman dies from complications of pregnancy or childbirth with about 99% of deaths occurring in the developing world [93–95]. The maternal mortality ratio of sub-Saharan Africa is more than a hundred times that of the UK with haemorrhage not only accounting for approximately 30% of cases but also the leading cause of maternal death worldwide [96, 97]. PPH is the leading cause of maternal deaths in individual countries in Africa and collectively on the continent [98, 99]. Major haemorrhage protocols (MHP) were introduced to improve the speed and consistency of delivery of red blood cells (RBCs) and other blood components to severely haemorrhaging patients and have been shown in several observational studies to improve outcomes, including mortality providing a clear framework to facilitate a co-ordinated response by a large multi-disciplinary team during the critical time of bleeding [100]. Blood components (red cell concentrate, fresh frozen plasma, cryoprecipitate and platelet concentrate) can play a role in the management of coagulopathy, disseminated intravascular coagulation and thrombocytopenia. For immediate transfusion, group O red cells should be issued after samples are taken for blood grouping and crossmatching. Females less than 50 years of age should receive RhD negative red cells to avoid sensitization. The use of Kell negative red cells is also desirable in this group. Group O red cells must continue to be issued if patient or sample identification is incomplete or until the ABO group is confirmed on a second sample according to local policy. The higher ratio of Fresh Frozen Plasma (FFP): Red blood cells (RBC) is associated with reduced mortality in a major haemorrhage [101, 102] with FFP providing a source of coagulation factors necessary for thrombin generation in the early phase after injury [103]. Cryoprecipitate or fibrinogen concentrate are a good source of fibrinogen. Fibrinogen is critical for effective haemostasis in MOH. Low fibrinogen level is an independent predictor of mortality as well as bleeding [104– 106]. Coagulation is also impaired by hypothermia, acidosis and reduced ionized calcium (Ca2+) concentration [107]. Evidence-based best practice indicates that an early and individualized goal-directed treatment improves the outcome among severely injured and bleeding patients [108]. The aim of treatment in major

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

haemorrhage is to rapidly and effectively restores adequate blood volume, prevent hypovolemic shock, allow for adequate haemostasis, optimize the oxygen carrying capacity and blood biochemistry to allow for an early and aggressive correction of coagulopathy, allow for optimal resuscitation and to reduce potentially preventable deaths [109]. The recombinant activated factor VII (FVII, rFVIIa, FXIII), prothrombin complex concentrates (PCC) and antifibrinolytics (tranexamic acid, epsilon aminocaproic acid and aprotinin) have been used for the management of traumatic bleeding [110] and found to produce a reduction in RBC use but not necessarily improvement in mortality. More recently, viscoelastic assays (rotational thromboelastometry – ROTEM or thromboelastography– TEG) have been advocated [111]. Early recognition of a coagulopathy and subsequent monitoring is vital to both initiate and maximize resuscitation therapy. Massive transfusion guidelines use laboratory tests such as prothrombin time (PT), activated partial thromboplastin time (APTT) and fibrinogen to monitor major haemorrhage and guide blood component replacement [112]. Targeting coagulopathy alongside changes to surgical and anaesthetic practices (damage control surgery/damage control resuscitation) has led to a significant reduction in mortality rates [113]. The transfusion of large volumes of red cells and other intravenous fluids that contain no coagulation factors or platelets causes dilutional coagulopathy and hyperfibrinolysis). Non-blood components and nonpharmacologic measures to manage major haemorrhage include; direct pressure/ tourniquet if appropriate, stabilization of fractures, surgical interventions (damage control surgery, interventional radiology, use of endoscopic and obstetrics techniques and thromboelastometry [114, 115]. Government of West African States will need to implement evidence-based best practices; implementation of major haemorrhage protocols, availability of coagulation testing to diagnose coagulopathy and to provide evidence-based indication for blood products to manage coagulopathy. Thromboelastometry, use of tranexamic acid and other relevant pharmacologic agents required to effectively manage coagulopathy and fibrinolysis is advocated along with the implementation of component therapy in a bid to reduce the incidence of preventable major haemorrhage-related death in the sub-region.

#### **2.5 Optimizing screening for transfusion transmissible infections (TTI's) in the West African sub-region**

Safe appropriately screened and clinically indicated blood transfusion saves lives and improves the quality of life and life expectancy of millions of patients globally [116]. However, donor blood that has not been properly screened is an important mode of transmission of TTI's including HIV, hepatitis B, hepatitis C and syphilis and other transfusion-transmissible infections [117]. Also, these infections can also be transmitted through several different routes; sexual contact, injection practices and cosmetic treatments and rituals (piercing, tattooing, scarification, injections with collagen or botulinum toxoid (botox), electrolysis and semi-permanent make-up). Strict donor selection criteria minimize the risk of transmission of infections from blood donors to recipients [118]. Transfusion safety begins with the recruitment of healthy voluntary non-remunerated blood donors. A fundamental part of preventing TTI is to notify and counsel reactive donors. Donor notification and counselling protect the health of the donor, prevent secondary transmission of infectious diseases to sexual partners, reduces risk of vertical transmission and provide feedback about the effectiveness of donor selection procedures such as pre-donation education and medical history [119]. There is need for government of West African States to

implement WHO recommendation to implement holistically across the sub region and as a minimum the screening of all blood donations for TTIs [Viral (HBV, HCV, HIV), Bacteria (syphilis) or Protozoan (malaria)]. The screen of all blood donations should be mandatory using the following markers as a minimum requirement; HIV-1 and HIV-2 (a combination of HIV antigen-antibody or HIV antibodies); Hepatitis B (hepatitis B surface antigen (HBsAg); Hepatitis C (a combination of HCV antigenantibody or HCV antibodies) and Syphilis (*Treponema pallidum pallidum*): screening for specific treponemal antibodies [120]. Although screening of blood donors is a way to potentially reduce the risk of transmission of TTI's to recipient, however screening process alone irrespective of how high-quality the assays and systems, cannot eliminate the risk of the donor being in the window phase of infection, failure due to assay sensitivity or testing errors. Also, there is the possibility that a blood donor may be infected with an infectious agent for which donations are not routinely screened. Other factors to consider include the timing of infection, the length of the window period (time between exposure to an infective agent and the first detection of a defined marker of infection), the incubation period (time between exposure to an infective agent and the onset of associated symptoms). Screening of blood donors must be implemented as an adjunct to effective donor selection process to further enhance blood transfusion safety. Blood donor selection is the first crucial step in the process of ensuring blood safety as it helps to significantly reduce risk through the deferral process prior to donation, of individuals with identified risks that may be associated with infection [121, 122]. A fundamental part of preventing TTIs is to notify and counsel reactive donors. Donor notification and counselling protect the health of the donor and prevent secondary transmission of infectious diseases [123]. Although transmissions of viruses (HIV-1 and HCV) had occurred as late as 2009 due to nucleic acid testing (NAT) failures because of low level of viraemia and/ or suboptimal amplification efficiency [124]. Blood transfusion is safer now than it has ever been through the implementation of evidence-based best practices and continuous improvements in donor recruitment, screening, testing of donated blood using increasingly sensitive and specific assays and by implementing appropriate and safe clinical use of blood [125]. Serologic testing for TTI's had historically been the foundation of blood donor screening, while newer strategies like nucleic acid testing (NAT) have helped to further shorten the challenge of the window period and by extension enhance blood safety [126]. Currently, no technology exists to completely detect all window period donations. No matter how sensitive NAT becomes, we may never be able completely eradicate the risk of exposure-to-seroconversion window period. An ambitious policy for the collection of 100% of blood from safe voluntary non-remunerated donors who donate blood out of altruism should be implemented universally across the sub-region. There is the urgent need for the implementation of the use of the more sensitive NAT testing for transfusion transmissible viral infection across the West African sub region to reduce the risk of potentially introducing donor blood in the window phase of infection and to further improve blood safety. Donors should universally undergo pre-donation counselling to educate them about the risk of infections and the window period. There is an urgent need to formulate a subregional policy guideline for notification of all reactive blood donors.

#### **2.6 Changing the narrative about blood donation in the West African sub-region**

Urgent concerted efforts are needed in the West African sub region to correct the blood supply deficit and increase the pool of voluntary non-remunerated

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

blood donors. This is expected to significantly improve blood transfusion safety and positively impact the health indices in the sub region [126]. The World Health Assembly in its resolution WHA.63.12 recommended that all countries begin to use only voluntary, non-remunerated blood donors (VNRDs) [127]. The WHO has consistently emphasized blood sourcing from VNRDs, due to their markedly reduced chances of harbouring and transferring TTIs [128]. This recommendation has been reiterated and supported by an increasing body of evidence from researchers in the sub region [129–131]. Unfortunately, several studies in Nigeria in the last couple of years have shown that VNRDs constituted a small fraction of the blood donor pool, this obviously has serious implications for transfusion safety [132, 133]. A previous report [134] chronicled the social demographic information of blood donors in sub-Saharan Africa and reported that commercial blood donors were all males while the median ages of voluntary and family donors were 18 years and 30 years, respectively. Similar studies in Nigeria had equally identified a male dominated donor pool as well as young adults as the predominant donor age group [135]. Unfortunately, this age distribution has also been associated with the highest carriage rates of TTIs (arising most probably from increased involvement in high-risk sexual behaviours and experimentation). This factor poses a huge challenge to the subcontinent's efforts towards attaining blood transfusion safety [136]. VNRD are the safest because they are altruistic and have the highest tendency to self-deferral when they are exposed to a risk of contracting TTIs. In SSA, most blood donors are family replacement donors [137]. Mauritius is one good example nation in the sub-Saharan Africa that has done remarkably well with implementation of the guidelines. About 86.2% of the blood donors in that country were VNRDs as of 2016. Mauritius has also embarked on use of nucleic acid testing as opposed to enzyme-linked immunosorbent assay (ELISA) that was previously in use and since 2010 has embarked on aphaeresis method of blood collection and separation. These developments have made transfusion medicine in Mauritius very safe [138]. Government of countries across the West African sub-region will need to learn from the excellent practice in Mauritius by investing significantly in education, mass mobilization and campaign to facilitate a significant increase in the number of voluntary blood donors in a bid to bridging the wide gap between demand and supply of blood and blood product as well as enhance blood transfusion safety across the sub-region.

#### **2.7 Universal leucodepletion of blood and blood products and prevention of development of anti- leukocyte antibodies**

The average content of leucocytes in donated human whole blood is 109 /unit. Leukoreduction is the reduction to ≤1 × 106 or < 5 × 106 / leucocytes per unit after preparation and with a minimum of 85% of red cells still retained [139, 140]. Clinical evidence indicates that the risk of non-haemolytic febrile transfusion reactions is significantly reduced by leucodepletion. This procedure prevents alloimmunization to HLA antigens in transfusion-dependent patients [141]. Leucocyte antibodies due to alloimmunization by a foreign HLA antigen can cause febrile transfusion reaction in subsequent transfusion involving HLA and granulocyte specific antigens [142]. Leucocyte depletion can be achieved by using filters (cotton, cellulose acetate etc.), apheresis, red cell washing, buffy coat removal after centrifugation and freezing and subsequent glycerol removal of red cells [143]. Leucodepletion of donor blood using leucodepletion filters is considered the threshold for reducing the risk of alloimmunization against leucocyte antigens and potentially eliminating transfusion reaction

associated with leucocyte antibodies. The importance of transfusion of leucodepleted blood products cannot be over emphasized. Apart from reducing the incidence on non-haemolytic febrile transfusion reaction, it reduces the risk of alloimmunization to platelet antigens that can predispose patients to develop platelet antibodies and becoming refractory to platelet transfusions (critical for MDS and aplastic anaemia patients who requires long- term platelet). It also significantly reduces the risk of transmission of variant Creutzfeldt Jacobs Disease (vCJD) and Cytomegalovirus (CMV) infection. Leucocytes is vector of CMV, HTLV-I/II, EBV & other viruses that can potentially to infection particularly in neonates, pregnant women, HIV patients and organ transplant patients. Leuko reduction is also associated with reduction in the risk of transfusion associated graft versus host disease (TA-GVHD) in immunocompromised patients [142]. Leucocytes in whole blood are believed to have immunomodulatory effects that can potentially influence the prognosis of patients with malignancy, increase the risk of post-operative infection and HIV progression [20]. Government of West African countries need to implement a policy on universal leucodepletion of all blood and blood products transfused across the sub region. This has the potential to prevent primary alloimmunization to HLA antigens and its attendant negative effects and make transfusion safer.

#### **2.8 Optimum management of transfusion dependent patients across the West African sub-region**

Transfusion dependence (TD) is a term that usually describes patients receiving regular red cell concentrate and/or platelet concentrate transfusions more frequently than every 8 weeks due to persistent anaemia and thrombocytopenia. Regular transfusion of red cells and platelets are required in these patients to reduce the symptoms of anaemia and thrombocytopenia by increasing the number functional red cells and platelets in the recipient's circulation. Various diseases can lead to transfusiondependency, most notably myelodysplastic syndromes (MDS), aplastic anaemia and thalassemia). Platelet transfusion is clinically indicated in thrombocytopenic patients with chronic bone marrow failure including patients on low dose oral chemotherapy, to manage patients with chronic bleeding of WHO grade 2, above, or as prophylaxis for patients with low platelet count who are going for invasive procedure that is associated with bleeding [144]. The wellbeing and the quality of life of TD patients across the West African sub region can be optimized by the radical implementation of evidence-based best practices; blood intended for TD patients should be sourced from regular voluntary non-remunerated blood donors; unit should be universally leucodepleted, appropriately screened used sensitive assays and technology to reduce the risk of transfusing donor blood in the window phase; extended red cell phenotyping must be implemented for Rhesus (C, c, E, e) and Kell as a minimum; patients should be transfused ABO, Rhesus and Kell antigen compatible unit; effective pre-transfusion testing including alloantibody screening and a full IAT cross-match particularly for patients with history of alloantibodies as well as implementation of the use of chelating agent to reduce the iron overload related challenges in these patients [145]. Single donor apheresis platelets offer several advantages over random pooled platelets, including the potential for crossmatching, reduction in net donor exposures, maintenance of ABO-compatibility, improved inventory management, diminished rate of alloimmunization and better platelet increments in the recipient [145]. The use of apheresis platelets in TD patients can prevent the incidence of platelet refractoriness often associated with poor post-transfusion platelet increments resulting from the

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

presence of platelet alloantibodies. Evidence-based best practice in preventing alloimmunization to platelet antigens is limiting recipients' exposure to human leukocyte antigen specificities by using single-donor apheresis platelets, filtration to reduce the number of human leukocyte antigen-bearing leukocytes as well as pre-transfusion of gamma irradiation to decrease platelet antigen immunogenicity [146]. Transfusion dependent patients who require platelet transfusion on a regular basis should ideally be transfused apheresis rather than pooled platelets. The advantages are numerous; reduction of donor exposures may decrease the risk of TTIs as well as reduce the risk of developing alloimmunization to foreign platelet antigens in the pooled platelets. The platelet yield from apheresis unit is 6 times higher than from pooled platelets and other transfusion-related complications [2]. Evidence-based best practice from the developed economies recommend the determination of extended phenotyping for TD patients at a minimum for the most clinically significant blood group antigens; Rhesus (C, c, D, E, e) and Kell and where feasible a full red cell phenotype/genotype panel for all clinically significant red cell antigens. For non-transfusion naïve patients, molecular testing rather than serologic testing is indicated. These patients should ideally receive as a minimum requirement ABO, Rhesus (C, c, D, E, e) and Kell compatible red cell product. The aim of this best practice is to reduce the risk of alloimmunization against these clinically relevant red cell antigens [147]. Government of West African States need to urgently develop policies, guidelines as well as promote the implementation of evidence-based best practices that will enhance the management of TD patients and reduce morbidity. Extended phenotype should be carried out prior to commencement of transfusion therapy to ensure that they receive clinically significant antigen negative donor blood that can commonly cause alloimmunization in a particular population. Extended red cell typing is required for the management of TD patients to confirm the identity of suspected alloantibodies or determine the specificity of potential additional antibodies that may be formed in the future [148]. Effective pretransfusion testing including alloantibody screening, panel testing for those whose alloantibody screen is positive and crossmatch of antigen negative units using appropriate technologies (IAT and column agglutination technique) should be implemented universally across the sub region. TD patients who require platelet transfusion on a regular basis should ideally be transfused apheresis instead of pooled platelets.

#### **2.9 Best practices in pre-operative planning and management of the transfusion needs of patients**

There are certain priorities in meeting the blood transfusion needs in surgical patients; the need for pre-operative optimization of the haemoglobin level (management of anaemia), pre-operative management of coagulopathy and bleeding predisposition to minimize blood loss intraoperatively and post operatively and avoidance of unnecessary transfusion post operatively [149]. In patients scheduled for elective surgeries, it is critical that blood management is planned even before a patient is referred for surgery at the primary care levels working collaboratively with the preoperative assessment clinic at the hospital. A full blood count should be done at least 6 weeks prior to surgery. If anaemia is identified, effort should be made to identify the cause of anaemia (iron deficiency, chronic kidney disease) and remedial action taken to treat the anaemia and potentially optimize the haemoglobin level using pharmacologic alternatives like oral, IV iron, erythropoietin and in some cased red cell transfusion. Patients who are anaemic pre-operatively are more likely to be transfused with allogenic blood [150]. Evidence has shown that pre-operative anaemia is an independent risk factor for increased morbidity and mortality in surgical patients [151]. In patients with severe anaemia and acute coronary syndromes red cell transfusion is a significant predictor of mortality (there is need to optimize tissue (perfusion to vital organs) when the use of pharmacologic agent will not produce a timely optimization of haemoglobin of the patients). Also, the preoperative assessment clinic should also be able to identify patients who are going for significant bleed prone surgery and those with increased risk of bleeding (patients with liver disease, those on anticoagulants therapy like warfarin, low molecular weight heparins (LMWHs) and direct oral anticoagulants like dabigatran, apixaban and rivaroxaban as well as those on antiplatelet therapy like clopidogrel or aspirin for whom remedial actions such as use of prothrombin complex concentrate (PCC), antifibrinolytic agents, fibrinogen concentrate, fresh frozen plasma, cryoprecipitate, platelet concentrate and temporary withdrawal of haemorrhage prone medication where possible and safe [152, 153]. Patients going for bleeding prone elective surgeries can be identified who potentially can be candidates for Pre-deposit autologous donation (PAD). This is vital particularly in patients who do not accept allogenic blood transfusion based on their religious beliefs, patients that have a rare blood group and those that have alloantibodies against a high incidence antigen for which it may be difficult to source blood for transfusion [154]. It is evidence-based practice to evaluate patient predisposition (coagulopathic status) to bleeding prior to surgery. This is vital to possibly take remedial actions prior to surgery in a bid to minimize significant blood loss during surgery. Basic laboratory testing includes determination of international normalized ratio (INR), activated partial thromboplastin time (APTT) and fibrinogen levels (FIBC). Patients with INR and APTT ratio > 1.5 as well as fibrinogen level < 1 g/L are at a high risk of bleeding during surgery [155]. The results of these laboratory test will provide justification to take remedial steps to correct identified coagulopathic status and clinically indicated pharmacologic (antifibrinolytic agents like tranexamic acid, vitamin K, prothrombin complex concentrate, fibrinogen concentrate) or management with blood products (FFP, cryoprecipitate and platelet concentrate). It is also vital to identify patients that can potentially benefit from blood-sparing techniques like acute nomovolaemic haemodilution (ANH) and perioperative cell salvage (PCS) [156, 157]. It is evidence-based best practice to ensure that patient scheduled for surgery has pre transfusion test for the ABO, Rh D group and alloantibodies screen and that patient meet the 2-sample rule (patients' blood group and alloantibody screen must have been tested on 2 samples taken from two separate venipuncture by two different clinical staff at least a minimum of 15 minutes apart to ensure we have a confirmed group on the patient). By the implementation of this best practice, we can identify patients with rare blood groups and those with alloantibodies for which efforts has to be made in advance to identify the alloantibodies present as well as source antigen negative donor units and possibly crossmatch the units prior to surgery. This is to ensure timely provision of blood if patients begin to bleed intraoperatively or post operatively [158]. It is best practice that we are avoiding unnecessary transfusion post operatively by being conservative and not liberal by the evidence-based use restrictive transfusion triggers ensuring individualized management to prevent unnecessary transfusion particularly in patients that are haemodynamically stable while ensuring safety and effectiveness [159, 160]. This can mean utilizing blood test and presence of symptoms to minimize blood loss and prevent unnecessary transfusion, use of endoscopic radiology and sealants to minimize blood loss, use of post-operative cell salvage and reinfusion if clinically indicated and use of pharmacologic agents (oral or IV iron,

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

and erythropoietin) to optimize the haemoglobin level of patients post operatively and by so doing achieve a reduction in exposure to allogenic blood [161–165]. Patient blood management (PBM) in surgical patients is important for a number of reasons; to optimize the patient's erythropoiesis and haemoglobin level, minimizing blood loss in the patients intra and post-operative and optimizing and exploiting the patients physiological reserve to ability to tolerate anaemia [166]. Many of these best practices are not being implemented in many settings across the West African sub region. This is often the cause of suboptimal management of surgical patients in the subregion that is responsible for preventable deaths from haemorrhage. Government of West African nations will need to implement evidenced best practices to ensure the optimum management of surgical patient, reduce the need for unnecessary transfusion and facilitate the optimum utilization of our limited allogenic bloodstock.

#### **3. Evidence-based management of rhesus negative pregnancy and patients clinically significant alloantibodies**

Human red blood cells carry many antigens on their surfaces. The most important of these antigens belong to the ABO system and the Rhesus (Rh) blood group system. The D antigen is the most important antigen of the Rhesus system. People with the Rhesus D (RhD) antigen are referred to as RhD positive, and those without it as RhD negative. A baby inherits its blood type from both parents. Therefore, a mother who is RhD negative can carry a baby who is RhD positive. During pregnancy, because of trans placental bleeding, a small amount of foetal blood can enter the maternal circulation [an event called feto-maternal haemorrhage (FMH)]. The presence of foetal RhD-positive cells in mum's circulation can sensitize the mum triggering an immune response leading to the production of alloantibodies against the RhD antigen (anti-D antibodies). This process is called sensitization or alloimmunization. There are over 600 red cell antigens, which are separated into 30 blood group systems. The presence or absence of these antigens in an individual is important, because they determine the type of blood that should be given if they require a red cell transfusion. If a woman is exposed to red cells containing a foreign red cell antigen which they themselves lacks, it can trigger an immune response leading to the formation against the foreign red cell antigen. Such an antibody can cause extravascular and/or intravascular haemolysis when the recipient is subsequently exposed to the same antigens. Antibodies can either be allo (antibody to an antigen that an individual lacks) or autoantibodies (antibody to an antigen a person has). Alloantibodies are formed in response to pregnancy (blood group incompatibility between the mum and her developing foetus), transfusion (donor red cell containing antigens that are foreign to the recipient), or transplantation (graft containing antigens that are foreign to the recipient). Alloimmunization resulting in the development of one or more clinically significant red cell, leucocyte and platelet antibodies is a vital complication in chronically transfused patients [167–170]. Multiple red cell transfusion could predispose to the formation of clinically significant titres of lytic antibodies, which may cause haemolytic disease of the foetus and newborn (HDFN) or haemolytic transfusion reaction (HTR). Patients with haemoglobinopathies and other TD patients that require regular blood transfusions are particularly at a higher risk of sensitization and development of red cell alloantibodies [2, 171]. The magnitude of red cell sensitization in Nigeria was highlighted in the independent reports by Ugwu and Colleagues (Benin City, Midwestern Nigeria) [172], Kangiwa and Colleagues (Enugu, Southeast

Nigeria) [173], and Jeremiah and Colleagues (Port Harcourt, South-South Nigeria) [174] in which prevalence rates of 9.3, 18.7, and 3.4%, respectively were observed in multiply- transfused patient populations. The presence of these alloantibodies may cause a delay in selecting compatible blood products. Countries in the West African sub region tend to have multiple- ethnic groups, race and genetic heterogeneity. Such multi-ethnic populations are prone to having racial variation in the red cell antigen spectrum that are prevalent with attendant wide variation in commonly identified alloantibodies [65, 175]. Other common factors that facilitate alloantibody formation in persons include: the immune competence, the dose of the antigen the person is exposed to, the route of exposure and how immunogenic the foreign antigen is [176, 177]. Evidence-based best practice in the developed economies requires that alloantibody testing is carried out routinely on all pregnant women presenting to antenatal clinic at booking as well as all patients in whom a red cell transfusion is clinically indicated. The intent of this test is to detect the presence of unexpected red cell antibody in the patient's serum [178, 179]. Once these antibodies are detected during the alloantibody screening, every effort must be made to identify the specificity of the alloantibody by doing a panel test. The purpose of the panel test is to; facilitate the identification of the alloantibody, determine whether the antibody can potentially cause HTR (to allow for the selection of antigen negative red cells for crossmatch) of HDFN (to allow the monitoring of the titre or quantification of the antibody every 4 weeks from booking until 28 weeks' gestation and every 2 weeks thereafter until delivery) [180]. The monitoring of the titre or quantification of the antibody helps to determine to what extent the developing foetus is affected by HDFN, to monitor the baby for anaemia along with Doppler ultrasound determination of the peak systolic velocity of blood through the median cerebral artery, determine whether the baby will require intrauterine transfusion (IUT) and to enable the obstetricians make an informed decision to possibly deliver the baby earlier. These evidence-based best practices are not yet completely implemented in many settings in the West African sub region. Testing of pregnant women and donors for other clinically relevant red cell antigens other than ABO and Rhesus D is not routinely carried out. Also, donor units particularly those intended for transfusion to pregnant women and neonates are also not routinely screened for other blood borne transmissible diseases such as CMV, Hepatitis E virus and others like it is routinely done in more advanced countries of the world.

The clinically significant antibodies are those antibodies that are active at 37°C and/or detected by the indirect antiglobulin (IAT) test. Nine blood group systems (ABO, Rhesus, Kell, Kidd, Duffy, MNS, P, Lewis, and Lutheran) are clinically significant as these are known to cause HTR and HDFN. These antibodies are caused predominantly by maternal alloimmunization to blood group antigens expressed by foetal red blood cells. In severe cases, it may result in foetal anaemia with increased risks of foetal death, severe neonatal hyperbilirubinaemia, and kernicterus, jaundice, intellectual retardation, premature birth, abortion, and stillbirth. Most severe cases of HDFN were attributed to Rh(D) incompatibility between a Rh(D)-negative woman and her Rh(D)-positive foetus, with Rh(D) alloimmunization having occurred during a previous pregnancy [65]. HDFN is an important cause of neonatal morbidity and death [181]. Sensitization can happen at any time during pregnancy but is most common in the third trimester and during childbirth. Sensitizations are commonly associated with events during pregnancy that are associated with FMH, such as medical interventions (chorionic villus sampling, amniocentesis, or external cephalic version), terminations, late miscarriages, antepartum haemorrhage, and abdominal

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

trauma [181]. The risk of sensitization is affected by the ABO blood type of the foetus, with a lower risk if it is compatible with the mother's ABO type. Sensitization depends on the volume of foetal blood entering the mother's circulation, the magnitude of mother's immune response and the immune competence of the mum's immune system. The risk of sensitization is greatest in the first pregnancy and decreases with each subsequent pregnancy. Once sensitization has occurred, it is irreversible. The process of sensitization has no adverse health effects for the mother and usually does not affect the pregnancy during which it occurs. However, if the mother is exposed to the same foreign antigen during a subsequent pregnancy, the immune response is quicker, greater and results in the antibody level being boosted. The anti-D antibodies produced by a Rhesus D negative mother in response to the D positive foetal cells are often low molecular weight IgG antibodies that can cross the placenta and bind to RhD antigen on the surface of foetal red blood cells. These antibody-coated foetal red blood cells are removed from the foetal circulation by the reticuloendothelial system, predominantly the spleen and liver. This is the cause of hepatosplenomegaly commonly seen in babies with HDFN. Foetal anaemia results if the red blood cells are removed faster than they are produced. Severe anaemia can lead to foetal heart failure, fluid retention and swelling (hydrops), and intrauterine death. Before birth, anaemia and hydrops can be managed with intrauterine transfusions, but this carries a 2% risk of foetal loss [182].

Women presenting for antenatal booking are screened for the ABO, Rh D group and for the presence of alloantibodies. The Rh D group categorizes pregnant women into Rh D positive if their red cell contains the Rhesus D antigen and Rh D negative if their red cell lacks the D antigens. The alloantibody screen also determines whether the antibody screen is positive or negative. Those with a positive alloantibody screen are tested for panels to identify the specificity of the alloantibody present. It is evidence-based best practice to recruit all Rhesus D negative non-previously sensitized women into the Routine Antenatal Anti-D Prophylaxis (RAADP) programme and universally offer them universally anti-D prophylaxis at 28-week gestation. The half-life of the anti-D is about 12 weeks, and the aim of the administration is to facilitate the mopping up of all the foetal D positive red cells that enter the maternal circulation as a result of fetomaternal haemorrhage and thus prevent the foreign D positive foetal red cells from sensitizing the mother. By this implementation the risk of anti-D related HDFN in subsequent pregnancy is avoided. This prophylaxis has been used to prevent postpartum disease in Rh D-negative women and has greatly reduced HDFN- related morbidity as well as foetal and neonatal mortality. In the 1960s, studies in the United States and in Great Britain determined that passive immunization of Rh(D)-negative mothers with IgG anti-Rh(D), soon after parturition, could protect women from sensitization against Rh(D) + positive red blood cells of her foetus [183, 184]. This then led to the licensing of IgG anti-Rh(D) for routine post-partum prophylaxis in 1968, however, in 1977 it was demonstrated that, despite adequate post-natal prophylaxis, about 10% of Rh(D)-negative women continued to develop anti-Rh(D) antibodies, presumably due to small, transplacental, foetalmaternal bleed during pregnancy. To manage this challenge, the issue of antenatal administration of IgG anti-Rh (D) preparations was instituted in combination with standard post-partum prophylaxis [185]. Current guidelines recommend that immunoprophylaxis with IgG anti-Rh(D) be given to every non-sensitized Rh(D)-negative woman, as follows; at 28-week gestation during each pregnancy; immediately after delivery of every Rh(D)-positive neonate and following any potentially sensitizing event in pregnancy that could expose the mother to the Rh(D) antigen of the foetus

(abortion, miscarriage, abdominal trauma) [186]. The only settings in which antenatal anti-D IgG administration is not necessary is when conception is certain, and the father is also Rh(D)-negative or if the foetus is successfully typed for Rh(D) status by antenatal cell-free DNA testing using maternal plasma [65]. Feto-maternal haemorrhage (FMH) may occur during pregnancy or at delivery. The Kleihauer-Betke (KB) test is a blood test used to measure the amount of foetal red cells that is transferred from a foetus into the maternal circulation [178]. FMH occurs in up to 28% of pregnancies after trauma and the amount of Rh-positive foetal blood required to sensitize the Rh-negative mother is variable, but most patients are sensitized by as little as 0.01 ml of blood [187]. The test utilizes a stain that identifies foetal red blood cells with haemoglobin F in maternal blood. The ratio of foetal: maternal red blood cells can be assessed [188]. The use of flow cytometry for the quantification of haemoglobin F is also available. The aim of the test is to determine the volume of foetal red cells that entered the maternal circuiting following a FMH to facilitate the administration of optimum dose of RhIG required to remove them from the maternal circulation and thus prevent the mother from being sensitized to produce alloantibodies. The Kleihauer-Betke tests have numerous limitations, including low sensitivity, poor reproducibility, and a tendency to overestimate the volume of haemorrhage [188]. An important limitation of the Kleihauer-Betke test is the inability to differentiate between maternal and foetal F cells. This is particularly a challenge in the second trimester of pregnancy when maternal F cells may occasionally reach 5 to 10% as well as in women that hereditary persistence of foetal haemoglobin (HPFH) in whom the count will be falsely raised. Haemoglobin F quantitation by flow cytometry has been reported to be simple, reliable, and more precise than the Kleihauer-Betke test [189]. It is recommended that prophylaxis be within 72 hours of the potential sensitizing event occurring [190]. To prevent sensitization, all D-negative non sensitized women who deliver a D-positive foetus should receive at least a single 300-μg dose of Anti-D within 72 hours of delivery. In addition to the prophylaxis giving during pregnancy, it is recommended that a maternal sample should be obtained post-delivery of a Rhesus D positive baby (approximately1hour after delivery) and tested for evidence of a FMH [191]. Approximately 17% of Rh D–negative women who deliver Rh D–positive foetus become alloimmunized if Anti- D prophylaxis is not administered appropriately and adequately. Anti- D prophylaxis has been reported to reduce the overall risk of Rh immunization from 13.2 to 0.2%, and testing for large FMH has also further decreased the risk to 0.14% [192]. It is part of modern antenatal care currently in developed countries to offer universally all Rh D-negative pregnant women anti-RhD immunoglobulin IgG injection at about 28-week gestation with a booster at 34-week gestation [193]. However, in countries across the West Africa sub region this evidencebased best practice is not universally implemented due majorly to unaffordability of anti-RhD immunoglobulin [65]. In many of these settings, facility for the effective management of foetuses and babies affected by HDFN such as Doppler ultrasound for diagnosis of foetal anaemia in utero, exchange blood transfusion and ultrasonography guided intrauterine transfusion (IUT) are often unavailable resulting in the preventable deaths of many of the sub region's future generations [194]. Blood meant for exchange and intrauterine transfusion must meet certain requirements (< 5 days old, free from clinically significant irregular blood group antibodies including high-titre anti-A and anti-B, negative for antibodies to CMV, must be gamma irradiated and transfused within 24 hours of irradiation, the donor should be Haemoglobin S screen negative, and the unit must be leucocyte depleted). Many of which are often not available in many settings across the sub region [65]. These implementations will

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

facilitate the effective management of severely anaemic foetuses earlier in gestation and increase the chances of survival of more severely affected foetuses with the potential for poor neurodevelopmental outcome such as cerebral palsy, deafness, and motor and speech delay [187]. This anti-D immunoglobulin which is administered routinely in the third trimester attaches to the Rhesus D positive foetal cells and are promptly removed from the maternal circulation by the reticuloendothelial system (RES) before they can sensitize the mum to produce alloantibodies. This is known as RAADP. RAADP can be given as two doses of anti-D immunoglobulin of 500 IU (one at 28-week and one at 34-week gestation), as two doses of anti-D immunoglobulin of 1000–1650 IU (one at 28-week and one at 34-week gestation), or as a single dose of 1500 IU either at 28 weeks or between 28- and 30-week gestation [195]. There are several technologies, formulations, and doses of anti- D in use in the United Kingdom [196–199]. Anti-D immunoglobulin are produced by deliberating immunizing Rhesus D negative men or women donors without childbearing potential who are carefully screened for transfusion transmissible infections [200]. There is need for the universal access to anti D prophylaxis to be provided for all non-sensitized Rh D negative women across the subregion under the RAADP programme and to cover every potentially sensitizing event that takes place during pregnancy and following the delivery of a Rhesus D positive baby. Facilities for determining fetomaternal haemorrhage should be readily available. Cell free foetal DNA testing should be implemented to determine Rhesus D negative women who are carrying Rhesus D negative babies who could be spared prophylactic anti-D. Facility for non-invasive Doppler ultrasound determination of the peak systolic velocity (PSV) through the median cerebral artery (MCA) of foetuses should be available for the diagnosis of foetal anaemia. Blood that meets the minimum requirement for use for intrauterine (IUT) and exchange transfusion should be readily available. There is also the need to optimize the knowledge of Biomedical Scientists, Obstetricians and Neonatologist in the subregion on the effective management of Rhesus D negative pregnancies as well as the prevention and management of HDFN.

#### **3.1 Haemovigilance implementation in the West African sub-region**

Haemovigilance is used to describe a set of surveillance procedures that scrutinizes the entire blood transfusion process from the point of collection of blood and blood components from a blood donor to the point of transfusion in the recipient ensuring that all unexpected or undesirable adverse reactions, events reactions, accidents, errors and near misses are reported, investigated in a timely manner and preventive and corrective actions are implemented to prevent their future occurrence. Haemovigilance system facilitates the delivery of a continually improving blood transfusion service [201, 202]. Haemovigilance encompasses the entire blood transfusion process; blood donation, processing, transfusion, post transfusion monitoring as well as reporting and investigation of all adverse events, reactions and near misses related to the blood donation and transfusion. Haemovigilance is indispensable with relation to safety and quality of blood transfusions, and it cuts across any action in the blood transfusion process that directly harm the blood donor [203] or potentially compromises the quality of the blood taken from the donor that put the recipient potentially at risk [204]. An adverse reaction or event is used to describe any unintended response in a blood donor, or a recipient observed during the collection or transfusion of blood and blood components that is fatal, life-threatening, disabling, incapacitating or results in hospitalization or morbidity [205]. Apart from Japan, many Asian countries do

not have a fit for purpose haemovigilance system. Many including India are in the process of establishing a haemovigilance system [206]. Haemovigilance is aimed at improving the quality and safety of blood transfusion. In most developed economies haemovigilance is governed by responsible legal authorities [207, 208]. Many countries including the United Kingdom (Serious Hazards of Transfusion [SHOT]), Canada (Transfusion Transmitted Injuries Surveillance System [TTISS]), Netherlands (Transfusion Reactions in Patients [TRIP]), Japan, Russia, Switzerland and the United States of America have dedicated organizations responsible for haemovigilance with the primary responsibility of improving blood safety. International Haemovigilance Network (IHN) is responsible for developing and maintaining haemovigilance and safety of blood and blood components globally [209]. Blood transfusion services in the West African sub region are not as organized and regulated as it is in the West. This has a negative implication on the adequacy and safety of blood and blood products. There are several challenges militating against an effective haemovigilance system across the sub region; lack of standardized tools for data capturing, poor integrity of data captured, poor governance issues, lack of functional hospital transfusion committee (HTC) in general, specialist and teaching hospitals, suboptimal coordination of the NBTS and lack of relevant policies for transfusion practices, lack of indication coding tool to guide the evidence-based clinical use of blood and blood products, lack of policy in place for clinical use of blood, high incidence and increased risk of TTIs, traceability challenges, training-related challenges, poor culture of documentation, incident reporting and investigation of adverse events, poor implementation of recall and quarantining of suboptimal blood and blood products, reaction and near misses associated with the blood transfusion process [210]. There is need for government across the West African sub region to develop a well-organized haemovigilance system in a bid to enhance transfusion safety. Member States of ECOWAS must take all necessary measures to ensure 100% traceability of all blood and blood components collected, tested, processed, stored, released and transfused across the sub region from vein to vein from the blood donor to the recipient. Effective haemovigilance implementation across the West African sub region will require collaboration, effective communication and cooperation between the National Blood Transfusion Centre and the Health establishment on one hand as well as among all the healthcare professionals involved in blood transfusion service delivery [211]. Haemovigilance practice was observed to be lacking in previous studies on transfusion practice in Africa [212]. There is need to put in place a haemovigilance system across the sub region that facilitate the prompt, accurate, efficient, and provable withdraw from distribution chain of blood or blood components that is suboptimal and has a potential to cause harm to the recipient. This is an urgent need to train health workers across the West African sub region on best practices in various aspects of transfusion medicine; blood donation, screening, transportation, storage and transfusion as well as monitoring and documentation of adverse event and reactions with the hope of reporting, investigating transfusion related incident and implementing corrective action and by so doing learning from mistakes and building a culture of continuous quality improvement in blood transfusion service delivery across sub region.

#### **3.2 Suboptimal use of alternatives to allogenic blood across the West African subregion**

Not all anaemic and bleeding patients require allogenic blood. Some can benefit from pharmacologic and non- pharmacologic alternatives. The implementation of

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

these alternatives can potentially reduce the dependence and facilitate the optimum utilization of our scare allogenic blood stock. The need for allogenic blood has continued to increase significantly, particularly in developing countries. There are several factors that affect matching demand with supply in sub-Saharan Africa. Escalating elective surgery, increased fatalities from road traffic accidents, poor management of traumatic injuries, intraoperative, post-operative and obstetric haemorrhage, communal crisis, insurgency, banditry, high incidence of malaria related anaemia, sub-optimal management of bleeding predisposition in surgical patients, pregnancyrelated complications, suboptimal national blood transfusion services, appropriate infrastructure, trained personnel, and financial resources to support the running of a voluntary non-remunerated donor transfusion service, high incidence of transfusiontransmitted infection, predominance of family replacement and commercially remunerated blood donors, rather than VNRDs [2]. Evidence has shown that not all anaemic or bleeding patients require blood and blood products. Many can benefit from alternatives. Concerns about adverse events associated with allogenic blood transfusion should prompt a review of transfusion practices and justify the need to search for transfusion alternatives to decrease or avoid the use of allogenic blood. There are pharmacologic alternatives that help to stimulate erythropoiesis (iron, folic acid, erythropoietin) and non-pharmacologic alternatives. Strategies to reduce allogenic blood use include the correction of anaemia using pharmacological agents (oral, IV iron and erythropoietin) and management of coagulopathy and bleeding (use of antifibrinolytics, vitamin K and fibrinogen concentrate). Non-pharmacologic measures including preoperative autologous blood transfusion, perioperative red blood cell salvage and normothermia can help to reduce blood loss in surgical patients. Similarly, the use of surgical and endoscopic technology can minimize blood loss and by extension limit the need for allogenic blood. All these strategies can help countries across the West African sub-region in optimizing the use of our limited allogenic blood stocks [213]. There are several challenges associated with allogenic blood transfusion [risk of TTIs (viral, bacterial, parasitic and prion), non-infectious risks including febrile, allergic/ anaphylactic and haemolytic transfusion reactions, transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) that warrants the need for the identification and use of transfusion alternatives [214].

#### **3.3 Use of oral and intravenous iron**

Iron is an essential micronutrient required for erythropoiesis. Iron deficiency is the most common nutritional deficiency particularly in developing countries. Iron deficiency is the leading cause of anaemia in both men and women [215]. It is a major concern in low-income settings, particularly among children and women of childbearing age. Factors that are responsible for iron depletion are prevalent across the West African sub region [haemorrhage (trauma, surgery, gastrointestinal, ante and postpartum) poor nutrition, age, pregnancy, low socioeconomic status, critical illness, etc.). Treatment of iron deficiency anaemia with oral iron supplements is simple, readily available and affordable. The major limiting factor for oral iron use is the gastrointestinal side-effects and long treatment times needed to resolve anaemia and replenish body iron stores. Non-adherence to therapy is common due to gastrointestinal side effects that limit its efficacy. Intravenous (IV) iron formulations provide a faster replacement, is a safer and effective alternative to oral iron for the treatment of iron deficiency anaemia (IDA) [216–218]. Allogeneic red blood cell transfusion has lifesaving potential in anaemic and haemorrhaging patients. However, a major limiting factor associated with this therapy is the risk of serious adverse events (transfusion reaction, transfusion transmissible disease, alloimmunization and immunomodulatory effect), costs and inadequacy [219]. Its use as an alternative in the management of iron deficiency is for treating critical anaemia (Hb level < 70 g/l), patients with acute myocardial ischaemia and in haemorrhaging patients who are haemodynamically unstable, patients in whom oral and IV iron is contraindicated or in cases of treatment failure nine [220]. Oral iron is a cheap and readily available option in managing patients with iron deficiency anaemia. Its use is however limited by challenge associated with gastrointestinal absorption and compliance [221]. Intravenous iron therapy, though slightly more expensive than oral iron is effective in managing patients with iron deficiency anaemia particularly when oral iron is contraindicated or ineffective [222]. Intravenous iron has the potential to reduce requirement for allogenic red blood cell transfusion [223]. The only limitations associated with the use of IV iron are adverse effects that have been associated with its use: risk of anaphylaxis, increased risk of infections, arthralgia, oxidative stress, hypophosphatemia, hypotension, headache, vomiting, chest tightness, fever, and hot flushes [224, 225]. Free iron has the potential to potentiate bacterial growth in vitro [226]. Intravenous iron therapy is effective in correcting iron deficiency anaemia (IDA) before any major surgery, and it can potentially reduce the need for allogeneic red blood cell transfusion and could help countries across the West African sub region better manage their limited allogenic blood stock for patients in whom oral and IV is contraindicated [227–229]. Oral and IV iron can have broad applicability to many patients particularly in low-income settings. There is need for more advocacy for countries in the West African sub region to promote the use of safe and affordable oral and IV iron more to manage patient with iron deficiency anaemia with the aim of reducing the need for limited allogeneic red blood cell transfusion.

#### **3.4 Erythropoietin use can limit the dependence on allogenic blood across West Africa**

Erythropoietin is a glycoprotein cytokine hormone synthesized in the kidney in response to tissue hypoxia. Its primary function is the stimulation of erythropoiesis (stimulate the division and differentiation of erythroid progenitor cells) in the bone marrow [230]. In patients with chronic kidney disease (CKD), there is damage to the kidneys and associated limited EPO production. Erythropoietin stimulating agents (ESAs) are recombinant versions of EPO produced pharmacologically via recombinant DNA technology. Examples of ESAs include epoetin alfa, darbepoetin, and methoxy polyethylene glycol-epoetin beta [231]. In patients with chronic renal failure, cancer, patients who are receiving dialysis, chemotherapy-induced anaemia and those with bone marrow suppression, the use of erythroid stimulating agents is clinically indicated in patients with haemoglobin less than 10 g/dL to increase haemoglobin levels and avoid the need for allogenic blood transfusions [232, 233]. Red blood cell (RBC) transfusion is an independent risk factor for cardiac surgery-associated acute kidney injury (CSA- AKI). Pre-operative administration of EPO may reduce the incidence of CSA-AKI, improve post-operative outcomes, decreasing the length of hospital and reduce the need for allogenic RBC transfusion in patients undergoing cardiac surgery [234]. Previous reports indicate that the administration of erythropoietin before cardiac surgery is associated with a significant reduction in the risk of exposure to allogeneic blood transfusion [235–238]. There are several factors that limit the use of Erythropoietin stimulating agents particularly in low income developing countries; cost [2], its use is contraindicated in patients with hypersensitivity to

*Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

non-human mammal-derived products [226], it has been shown to increase blood viscosity and may predispose high risk patients to DVT, pulmonary embolism and hypercoagulable state and should be used with caution in patients with history of ischaemic stroke or cardiovascular disease [227]. It is also contraindicated in neonates, peripartum mothers and breastfeeding mothers due to the risk for gasping syndrome in neonates (severe metabolic acidosis and associated gasping respirations, renal failure and neurological deterioration [228].

#### **3.5 Autologous blood transfusion can facilitate the optimum utilization of limited allogenic blood across West Africa**

Not all surgical patients require allogenic blood. Some can potentially benefit from autologous blood transfusion (ABT). Forms of ABT include predeposit autologous donation (PAD), acute normovolaemic haemodilution (ANH), and perioperative cell salvage (PCS) [239]. In PAD there is repeated preoperative phlebotomy, 4–5 weeks before surgery, during which time 4 or 5 units of in-date blood can be collected with ease. This technique reduces exposure to allogeneic blood. ANH involves a process where whole blood (1.0–1.5 l) is removed, and simultaneously intravascular volume is replaced with crystalloid or colloid, or both, to maintain blood volume. The anticoagulated blood is then reinfused during or shortly after surgical blood loss has stopped in reverse order of collection. The blood-sparing benefit of haemodilution is the result of the reduced red cell mass lost during surgical bleeding. Intraoperative RBC salvage entails the collection and reinfusion of blood lost during or after surgery. Shed blood is aspirated from the operative field into a specially designed centrifuge. Citrate or heparin anticoagulant is added, and the contents are filtered to remove clots and debris. Centrifuging concentrates the salvaged red cells, and saline washing may be used. This concentrate is then reinfused [239]. ABT is extremely safe, not associated with complications related to allogenic blood transfusion (immunological challenge associated with increase in tumour recurrence after surgical resection, increased postoperative infection rates, increased progression of HIV infection, blood transfusion reaction and multiorgan failure), crossmatching is not required; alloimmunization to foreign red cell antigen can be excluded and the fear of TTIs can be ignored [239–241]. Implementation of pre-operative autologous blood transfusion (PAD and ANH) and perioperative red blood cell salvage are strategies that can help countries in West Africa optimize the use of the limited blood stocks. Intraoperative red blood cell salvage is well recognized as a blood conservation strategy [242, 243] but it has limited applicability in critically ill patients. Postoperative recovery and transfusion of blood from sterile surgical drains in cardiac surgery has shown only marginal reduction in transfusion requirements. The feasibility and effectiveness of blood recovery techniques for other critically ill patients with acute blood loss are more limited. An autologous blood transfusion programme can be implemented as complementary to the established allogenic blood transfusion programme across the West African sub region. It has the potential to help the sub region conserve her allogenic blood stock for patients in whom autologous transfusion is contraindicated and result in more effective use of the limited allogenic blood supplies.

#### **3.6 Implementation of restrictive red cell transfusion triggers**

Anaemia is highly prevalent in critically ill and trauma patients. Two-thirds of these patients present with a haemoglobin concentration < 12 g/dl on admission and 97% of

them become anaemic by Day 8 on admission [244]. Evidence has shown that critically ill patients with cardiovascular disease risk factors can survive with low haemoglobin than originally thought. Several studies have compared the use of lower haemoglobin thresholds as restrictive transfusion triggers in critically ill patients compared to liberal transfusion triggers. Hébert and Colleagues demonstrated that a restrictive transfusion strategy would reduce transfusion requirements and would be as safe as, and possibly better than, a more liberal strategy for critically ill adults [245]. Similarly, experience from a randomized controlled trial among paediatric ICU patients has shown that a haemoglobin threshold of 70 g/L, compared with a more liberal threshold of 95 g/L, reduced transfusion requirements by 44% [246]. Haemoglobin threshold of 70 g/L seems appropriate for critically ill adult and paediatric and adult patients [247]. Strong evidence exists that shows that a restrictive transfusion strategy with a lowered haemoglobin threshold is safe compared to a liberal strategy with higher haemoglobin threshold particularly in the absence of cardiovascular disease risk factors [248]. Evidence has shown that transfusion at higher haemoglobin thresholds is only beneficial in patients with acute myocardial infarction [249]. A major challenge associated with blood transfusion service delivery across the West African sub region is the challenge of safety and adequacy. Countries across the sub region will need to implement policies on restrictive transfusion triggers to facilitate optimum use of limited allogenic blood stock. Other evidence-based best practices the sub region needs to implement includes; reducing blood loss and the need for blood transfusions, improving the appropriateness of blood transfusion and implementing blood conservation strategies including the use of laboratory test (PT, APTT and fibrinogen) to determine bleeding predisposition in patients scheduled for surgery, evidence-based use of haemostatic agents [antifibrinolytic agents (aprotinin, tranexamic acid and epsilon aminocaproic acid), desmopressin and recombinant activated factor VII), the implementation of diagnostic endoscopy to reduce blood loss as well as maintaining normal pH, temperature and calcium levels to manage coagulopathy [250], blood salvage techniques, use of erythropoietin and use of indication coding or restrictive blood transfusion triggers. These implementations will help to limit the need for transfusion and enable the sub region effectively to manage her limited allogenic blood stock.

#### **3.7 Availability and use of specialized blood products in the West African sub-region**

The last 30 years has been associated with a significant development in the field of transfusion medicine particularly with the implementation of blood component therapy and the need to provide specialized blood products to facilitate the effective management of particularly patients with haematological malignancies [251]. Commonly prescribed specialized blood components include antigen negative red cells, gamma irradiated blood products, HLA and HPA matched platelets, washed red cells and CMV negative unit.

#### **3.8 Antigen negative red cells**

Red blood cell (RBC) alloimmunization is a significant challenge in blood transfusion practice. Red blood cell alloimmunization often results from antigen disparity between donor and recipient or between a mum and her foetus. The prevalence of alloimmunization ranges from 1 to 3% in the general population and 10–70% among TD patients [252, 253]. Other factors that play a role in the alloimmunization process

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

include the immune competence of the recipient, the dose of the antigen to which the recipient is exposed, the frequency of exposure, antigen frequency in the population and the immunogenicity of the RBC antigen involved. Evidence-based best practice requires the implementation of a policy to carry out pre-transfusion alloantibody screen for all patients that require a red cell transfusion with the hope of detecting those that have atypical alloantibodies [252–254]. This implementation will facilitate the identification of the atypical antibodies and facilitate the indirect antiglobulinbased crossmatch of antigen negative red cells for the patient. Patients whose alloantibody screening test is positive should have a panel done to facilitate the identification of the alloantibody/ies present. This is to facilitate the crossmatch of units that have been phenotyped for the group specific antigen and found negative. The policy also recommends the provision of antigen negative units for patients in whom a clinically significant red cell alloantibodies was identified in the past but sub detectable in the current sample (alloantibody titre drops below detectable levels). The implementation of this policy is to ensure that the aim of giving the red cells transfusion is to optimize the haemoglobin level of the patients and by extension improve the oxygen carrying capacity or tissue perfusion in the recipient. It also reduces the risk of acute/ delayed haemolytic transfusion reaction that can result when patients with a clinically significant alloantibody is transfused with donor unit positive for the group specific antigen. The national blood transfusion service should be able to test a percentage of all donations for Rh phenotype, K and other clinically significant red cell phenotypes such as Duffy (Fya) and Kidd (Jka) negative are generally in stock. Evidencebased best practice recommend that extended phenotyping be carried out for all transfusion-dependent patients (thalassemia, sickle cell disease and myelodysplastic syndrome) who are chronically transfused for Rh (C, c, E, e) and Kell antigens before the initial RBC transfusion [255]. This is to ensure that they are transfused at least ABO, Rh (C, c, E, e) and Kell compatible units as a minimum [256–258]. The use of uncrossmatched O red cells can have a lifesaving potential in haemorrhaging patient when there is no time to carry out a full pre-transfusion testing. Blood group O negative units used in emergency for a woman of childbearing age should be rr (C-, D- and E-), K, CMV and High titre negative [259]. In many settings across the West African region red cell phenotyped for clinically significant red cell antigens are not readily available. Donors are tested for only the ABO and Rhesus D group. Many hospitals in the sub region do not routinely test patients requiring a red cell transfusion for the presence of alloantibodies and facilities for panel testing to identify the alloantibodies present are often not available. Countries across the sub region must implement best practices to prevent RBC alloimmunization and haemolytic transfusion reactions (HTRs) including routine testing of all patients that require a transfusion for the presence of alloantibodies, provision of extended phenotyping for all transfusion dependent patients, optimization of the method and scope of RBC antigen typing as well as the selection of antigen negative blood for crossmatch to facilitate the provision of timely, most compatible and safe blood for transfusion to patients.

#### **3.9 Gamma irradiated blood products**

Transfusion-associated graft-*versus*-host disease (TA-GvHD) is a rare, usually fatal, complication of transfusion that occur when the viable and potent lymphocytes in the donor engraft and destroy the host lymphocytes and by extension the host immune system. TA-GvHD can either occur when immunocompromised recipients are transfused with cellular blood components containing viable lymphocytes or when a recipient

receives blood components from a human leucocyte antigen (HLA)-haploidentical unrelated donor or from their family member. Transfusion of potent donor (related and non-related) lymphocytes to HLA haploidentical recipient is documented as the most potent risk factor for the development of TA-GvHD [260]. The transfusion of pre- storage leuco depleted blood products can reduce the risk of TA-GvHD. In the developed world all transfused units are universally leucocyte depleted. The implementation of this best practice has brought about a significant reduction in the residual cases of TA-GvHD. A previous report reported a TA-GvHD prevalence of 18·9% (66 out of the 348) between 2000 and 2013 [261]. Irradiation by exposing donor blood products to irradiation using Gamma rays and X-rays (a minimum of 25 Gy) is the principal of inactivating lymphocytes in the transfused component. Transfusion of washed red cells is not as effective in preventing TA-GvHD as irradiation. Gamma irradiated blood product is clinically indicated in the following patients groups; foetus and neonate who are immunological immature and whose lymphocytes are naive, patients needing intrauterine blood transfusion (IUT) including those requiring routine 'top-up' neonatal transfusions following IUT [262], recipients of allogeneic HSCT, adults and children with Hodgkin's Lymphoma (HL), patients treated with purine analogues (fludarabine, cladribine bendamustine and pentostatin) which are known to induce profound lymphopenia with associated low CD4 counts, CLL patients treated with alemtuzumab, aplastic anaemia patients undergoing treatment with ATG or alemtuzumab and patients receiving ATG or other T-lymphocyte-depleting serotherapy for rare types of immune dysfunction) [263–266]. The median time from transfusion to presentation among TA- GvHD patients is 11 days and commonly associated symptoms include rash (80·2%), fever (67·5%), elevated liver enzymes (66·4%), pancytopenia (65·2%), diarrhoea (43·1%), bone marrow aplasia (22·7%) and hypocellularity (17·2%) and hepatomegaly (13·5%). Laboratory information management systems (LIMS) should be updated with relevant information for patients in whom gamma irradiated blood products are clinically indicated. Evidence-based best practice in the management of patients in whom irradiated blood products are indicated requires the following; effective communication among those involved in the care of these patients (clinical areas and transfusion laboratories) as well as between transfusion laboratories particularly during patient transfers from one hospital to another and carrying of treatment information cards to facilitate the provision of appropriate components [267]. In emergency situations, where non-irradiated components are unavailable and where delay in sourcing gamma irradiated red cells or platelets can be life- threatening, leuco depleted blood or platelets can be sourced promptly as a minimum requirement. The justification for this must be included in the patient case note and such a patient should be observed for possible evidence of TA-GvHD for few weeks. Many of the above best practices are not readily available in blood centres in the sub-region. There is urgent need for the implementation of gamma irradiated products for patients in whom gamma irradiated red cell, platelet and granulocyte components is clinically indicated across the West African sub region as a way of optimizing the transfusion service delivery in the sub region and reduce the risk of TA-GvHD.

#### **4. HLA and HPA matched platelets**

Platelets are anucleate cellular elements that play a role in haemostasis. Platelet concentrate is used to manage thrombocytopenic patients with haematological oncological disorders including the management of haemorrhaging patients. Platelet

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

can be transfused either as apheresis platelet concentrate (APC) or pooled platelet concentrate (RPC) [268]. The absolute clinical indications for apheresis platelets include patients who require HLA compatible and/or HPA matched platelets (platelet refractoriness due to the presence of HLA and/or HPA antibodies), patients with neonatal alloimmune thrombocytopenia (NAIT) and patients who require IgA deficient platelets. Apheresis derived platelets concentrate are associated with a lower risk of alloimmunization and subsequent development of platelet refractoriness, the risk of TTIs is less because the recipient is exposed to a single donor. Also, the platelet yield from apheresis is about 6 times more in pooled platelets [269–272]. The cost of producing platelet concentrate is higher with apheresis compared with pooled platelets. Also, the risk of allergic adverse reactions is about four times higher with apheresis derived platelet concentrate [273]. Other aspects may impact the decision: the fact that using APC in place of RPC reduces the total donor exposure of patients was considered critical in some countries to reduce the risk of transmission of blood transmissible disease. Finally, the cost of the components, much higher for APC, may be considered. Platelet refractoriness is a term used to describe the failure to achieve an adequate increase in platelet count of a recipient after two consecutive transfusions of random platelets. The common cause can either be immunologic (HLA - class I specific antibodies, HPA - antibodies or ABO - antibodies – mediated resulting from the transfusion of ABO incompatible platelets to a recipient who is positive for high titre anti-A or anti-B haemolysin) or non-immunologic (platelet sequestration and consumption) in nature resulting from non-immune destruction of transfused donor platelets [273]. Alloimmunization to human leukocyte antigens (HLA) class or human platelet antigens (HPA) can result in platelet refractoriness [274]. Patients with these anti-leucocyte or platelet antibodies will need to be provided HLA class I and HPA compatible/matched platelets [275, 276]. Refractoriness to platelet transfusion is usually caused by alloimmunization to either HLA/platelet antigens or as a result on non-immune destruction of platelets and is commonly seen in 14% of haematology patients receiving platelet transfusions with HLA alloimmunization as a major cause [277, 278]. Alloimmunization to HLA/platelet antigens and by extension platelet refractoriness can be reduced by transfusion of leucodepleted products, use of irradiation or transfusion of HLA/HPA matched platelet transfusions [279, 280]. Despite the importance of platelet concentrate in the management of thrombocytopenic haematology, oncology and haemorrhaging patients, the product is seldom available in most settings across the sub region. Government of West African states will need to show more commitment to the provision of a quality blood transfusion service by investing significantly in transfusion-related infrastructure with the hope of achieving improvement in transfusion service delivery.

#### **4.1 Washed red cells**

Washing of red cells is often carried out for three major clinically relevant reasons; to reduce the amount of cytokines [causes of febrile non-haemolytic transfusion reactions (FNHTRs), reduce the level of allergen proteins to reduce the risk of allergic reactions resulting from contaminating plasma proteins (including IgA) as well as to reduce the concentration of potassium that leaked from the intracellular during storage to reduce the detrimental effect of hyperkalaemia in the recipient [281]. Patients who are IgA deficient run the risk of developing allergic reaction if they are transfused with IgA- rich donor blood. Washing can potentially remove a significant 90–95% plasma resulting in a significant reduction of the IgA content to <0·05 mg/dl IgA –a

level common seen in IgA deficient patients. Washed leucodepleted red cells reduce the risk of alloimmunization to HLA. Washing is often performed by normal saline (0.9% NaCl) in either an open or a closed system. RBCs washed in an open system should be used within 24 hours (prevent bacterial contamination) of washing while that washed in a closed system have a shelf life of 14 days post washing [282]. Red cell washing increases the RBC osmotic fragility and increased haemolysis post transfusion [283]. Washed red cells are associated with less systemic inflammation and lower levels of free plasma haemoglobin with its nitric oxide scavenging property which has been shown to be independent predictor of mortality in septic patients [284].

#### **4.2 CMV negative unit**

Cytomegalovirus (CMV) infection is endemic globally. In the USA the seroprevalence of the disease range from 30 to 97% [285]. Cytomegalovirus (CMV) is a significant contributor to increased morbidity, mortality and cost of management of immunocompromised patients [286]. CMV is a highly contagious viral infection that is transmitted through close contact with bodily fluids (blood, saliva, urine and breast milk). CMV can also be transmitted by organ transplantation and blood transfusion, when the donor is CMV positive, and the recipient is CMV negative [287]. Common signs and symptoms associated with the disease include; fever, malaise, leukopenia and neutropenia. Immune-deficient individuals can suffer severe or even fatal disseminated infections. Evidence-based best practice in the developed economies recommend that the following patient's groups should be transfused with CMV negative cellular blood products, congenital immunodeficiency and HIV-infected patients, haematopoietic progenitor cell transplant recipients, low birth-weight infants, pregnant women till delivery and their foetuses (to prevent congenital CMV), severely immunosuppressed patients and recipients of solid-organ transplant recipients [288]. The risk of CMV transmission through blood transfusion can be prevented by two major ways; by transfusing vulnerable CMV naïve and profoundly immunocompromised with blood and blood products that are negative for CMV and by ensuring that cellular blood products are universally leucodepleted (fewer than 5 × 106 leukocytes per unit) [289]. CMV negative blood and components is critical to reducing the risk of transfusion- transmitted symptomatic CMV infection in recipients who are themselves CMV naïve. Other potential measures that can reduce the risk of transfusing CMV infected blood products include washing red cell units and removing the buffy coat, freezing, thawing and subsequent deglycerolizing. The major drawback associated with these measures include the fact that they are not practicable large scale and are associated with a significant cost implication [288]. The implementation of TT- CMV reduction strategies in the late 1980s requiring that seronegative marrow recipients and other high-risk groups receive CMV seronegative blood products has brought about a significant reduction in the risk of CMV infection from 28% -57 to <5% [290, 291]. Government of West African countries have a duty of care to implement CMV prevention strategies by ensuring that evidence-based best practices requiring that all cellular blood products transfused across the sub region are universally leukocyte reduced and screened serologically for CMV.

#### **4.3 Optimizing safe blood donation in the West African sub-region**

The two major challenges associated with blood transfusion service delivery across the West African sub region are access to safe and adequate supply of blood

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

and product products [2, 292]. World Health Assembly resolutions WHA28.72 [293] and WHA58.13 [294] urge member states to develop national blood transfusion services based on VNRDs. A VNRD-based NBTS is key to sustained supply of safe and adequate blood and blood products. It is the only realistic way to ensure longterm and consistent supply of blood and blood products to eliminate the chronic shortage of safe blood and blood products particularly in low- and medium-income countries. Not only is blood donation level low in the West African sub region, but it is also predominantly family replacement donor-based rather than benevolent, nonremunerated donors (VNRBDs) who give blood out of altruism. The blood donation rate in sub-Saharan Africa is significantly lower (4–5 per 1000 population) compared to the developed economies (30 donations per 1000 population). WHO recommends that blood transfusion from regular VNRBDs have the lowest risk of TTIs. There are several factors militating against the low VNRBD levels in most West African countries: lack of organization and financial resources, but also, to some extent, of sociocultural barriers such as limited levels of education, religious and mystic beliefs and misconceptions about blood use [295]. Voluntary, non-remunerated blood donation is the cornerstone of a safe and adequate national blood supply that meets the transfusion requirements of all patients. VNRBDs represent less than 50% of whole blood donations in low-income countries compared with 76–100% in high-income countries [296]. The low VNRBD levels in the sub region can be attributable to several reasons: lack of organization and financial resources, socio-cultural barriers, low levels of education, religious and erroneous beliefs and misconceptions about blood donations [297]. Government across the West African sub region must implement innovative ways to recruit and retain voluntary donors; celebration of the gift of blood donation from voluntary blood donors; increasing public awareness of voluntary non-remunerated blood donation; educating the public on the importance of regular, voluntary, non-remunerated blood donation; educating the public on the benefits of voluntary non-remunerated blood donation to recipients; promoting healthy living (nutrition, exercise, lifestyle); and provision of noncash incentives to encourage people to donate blood.

#### **4.4 Implementation of cell-free foetal DNA testing across the West African subregion**

Haemolytic disease of the foetus and newborn (HDFN) is an alloimmune disease associated with alloantibody developed by the mum triggered by a previous incompatible blood transfusion or a transplacental haemorrhage during a previous pregnancy associated with foreign red cell antigen entering the maternal circulation and sensitizing her to produce alloantibody. These alloantibodies, being low molecular weight antibodies can pass through placenta in subsequent pregnancy involving a foetus with a red cell antigen to which the maternal alloantibody is specific. This maternal alloantibody usually will cross the placenta barrier into the foetal circulation and coat the foetal red cell containing the group specific antigen and induce haemolysis. The disease often results from maternal immunological incompatibility with foetal blood groups leading to the production of alloantibodies. The rate of antibody production depends on the red cell antigen dose that enters the maternal circulation, the immune competence of the mum and the immunogenicity of the foetal antigen [297]. Clinical presentation of the disease ranges from asymptomatic mild anaemia to hydrops foetalis or stillbirth resulting from severe anaemia and jaundice. Management options include; the use of amniocentesis (an invasive procedure to obtain amniotic

fluid which is analysed for product of haemoglobin breakdown to identify the severity of the disease), serial Doppler ultrasonography measurements to diagnose foetal anaemia, in utero, intrauterine transfusion, titration and quantification of alloantibody level, controlled early delivery, top up transfusion and exchange transfusion in the management of severely alloimmunized foetuses [298, 299]. Anti-RhD is the most incriminated alloantibody responsible for the majority of HDFN. However, the availability and widespread implementation of antenatal and postpartum Rhesus immune globulin prophylaxis particularly in the West has resulted in a marked decrease in the prevalence of alloimmunization to the RhD antigen among pregnant women. Other commonly encountered antibodies include anti-c, anti-K, E, AB0, JK (Kidd), and FY (Duffy) [300]. The most important blood groups are D, c, E, and K with respect to antenatal foetal blood group determination using cell-free foetal DNA (cfDNA) [301]. cfDNA derived from the foetus circulates in maternal blood. cfDNA testing is a non-invasive prenatal screening carried out on maternal plasma of pregnant women to predict foetal blood groups with the aim of; assessing the risk of haemolytic disease of the foetus and newborn (HDFN) in previously alloimmunized women and also to determine the Rhesus D group of the baby in order to determine if a non-previously immunized mum will need to be recruited into the RAADP program and will require anti-D prophylaxis following a potentially sensitizing event during pregnancy [302]. The cfDNA test can help identify women who have red cell alloantibodies and may be affected by haemolytic disease of the foetus and newborn (HDFN). cfDNA testing is carried out on maternal blood and can predict the foetal RhD, RhC, Rhc, RhE and K status of the foetus and by extension the risk of HDFN [303]. Early in pregnancy, small amounts of foetally derived cfDNA exist, but the fraction of foetal cfDNA in the maternal circulation increases with advancing gestational age [304]. The clinical implementation of this technology should be encouraged across the West African sub region. There are many advantages associated with this implementation [305, 306]. The test is significantly sensitive and specific with diagnostic sensitivity ranging from 95 to 100% and specificities over 99% [307–309]. The prevalence of Rh D negative varies widely between Caucasians with a prevalence >14% [307–310] compared to ethnic groups of sub-Saharan Africa with a prevalence ranging between 2.4 and 4.5% [311]. Evidence has shown that 40% of Rhesus D negative women carry D Negative foetuses. It is evidence-based best practice that all Rhesus D negative pregnant women who are not previously immunized are universally offered anti-D prophylaxis at the 3rd trimester under the RAADP program. NICE guidance released in 2008 recommend that a single dose of anti-D (1500iu) given to Rhesus D negative not previously sensitized pregnant women between weeks 28 and 30 would also be costeffective in potentially preventing anti-D HDFN in subsequent pregnancy [312]. The use of cfDNA testing for the determination of the predicted Rh D group of the foetus has several advantages; allow for the rational implementation of antenatal immunoprophylaxis for women in whom it is not clinically indicated who are predicted to be carry Rh D negative foetus rather than providing the prophylaxis universally to all Rh D negative non-previous immunized women. cfDNA testing can potentially predict 40% of these women who are carrying D negative babies for which Rh D prophylaxis will be a waste of a scarce human resource [313–316]. Also, the feto-maternal haemorrhage testing carried out during a potentially sensitizing event during pregnancy and post-delivery will not be required (reagent and time to carry out the testing) if the baby is predicted to be Rhesus D negative. The prophylactic anti-D offered to these Rh D negative women is a human blood product with reduce potential to transmit hepatitis C and prion type diseases [317]. The women whose babies are predicted to

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

be Rhesus D negative with will be spared the pain and associated cost of travel to hospital to receive the anti-D prophylaxis [318]. Government across the West African sub region will need to live to their responsibility by implementing evidence-based best practices; cell-free DNA testing, provision of anti-D prophylaxis for non-previously sensitized Rh D negative women, feto maternal haemorrhage testing, non-invasive serial sonograms with Doppler of the Median Cerebral Artery (MCA) to determine the peak systolic velocity (PSV) and by extension foetal anaemia, amniocentesis and provision of blood that meet the minimum requirement for intrauterine transfusion for foetus severely affected with HDFN in utero and facility for sonographic guided intrauterine transfusion through the umbilical vein should be implemented across the sub region to optimize the obstetric and neonatal care offered.

#### **4.5 Quality management issues in blood transfusion service delivery in West Africa**

Blood transfusion process comprises a series of steps ranging from ordering of blood or blood products, administration, monitoring of the transfused patient, managing of adverse reactions and events as well as documentation of transfusion adverse events and outcomes [319]. Quality management in blood transfusion is the sum of all the processes put in place to ensure that blood products and services are produced consistent, safe, efficacious service that meet the need of the customers [320]. There is increasing advocacy to ensure the efficacy, quality and safety of blood and blood products. The sum total of all the processes in place to ensure safety of blood and blood product from the point of collection of blood and blood products from blood donors to the point of administration to the recipients [321]. Quality management in blood transfusion encompasses the organization and her quality management system, personnel and organization, quality policy, organograms with responsibilities of staff, job description for staff members, change control of documents, continuous training based on SOPs (should be approved before distribution and the correct versions should be provided at the points of use), collection of blood and blood components, non-conformance, deviations, complaints, recall, corrective and preventive actions, self-inspection, audits, and improvements [322, 323]. The blood transfusion organization must ensure that they understand and meet the current and future requirements of the customers. The Blood Service must ensure that adequate resources are provided to implement and operate the quality management system, to continually improve its effectiveness and to satisfy customer requirements. The physical resources (equipment, consumables, work areas and utilities) to undertake the work must be suitable to attain the required standards.

#### **4.6 Personnel and organization**

It is a general requirement that all personnel responsible for blood transfusion service delivery should have the right skills, experience, education/training, certification, competence and regularly trained and retrained [324]. It is expected that appropriate staffing levels involvement should ensure the safe and effective delivery of all transfusion service activities and be subjected to annual review [325]. All personnel shall have up-to-date job descriptions that clearly set out their tasks and responsibilities. Blood transfusion organizations shall have separate persons as training officer and quality manager. Provision of training to the personnel on safe blood transfusion, hazards, and appropriate implementation of corrective and preventative measures,

as well as abiding with standard safety guidelines are vital and must be implemented throughout the entire blood transfusion process [326]. In every step in the blood transfusion process there are potential risks, such as errors in patient identification, blood typing, cross-matching, administration and other human errors. Many errors which result in serious morbidity or mortality that occur in the blood transfusion process and by extension in healthcare delivery are related to human error with training and competency issues a major contributory factor [327, 328]. All personnel should be appropriately trained, and their competency assessed before being allowed to work unsupervised. The contents of training being implemented should be periodically assessed and the competence of personnel evaluated regularly. Employers must develop personal development plan (PDP) for all staff involved in the blood transfusion process that ensures that staff develop in a continual format to enable the delivery of a continually improving quality service tailored towards meeting the present and strategic future needs of the organization and her customers. Personnel are required to participate in a lifelong continuing professional development (CPD). There is also the need to ensure that transfusion staff are adequately remunerated. Efforts should be made to employ, motivate and retain the best staff, adequate number of staff and mix as well as ensuring that there are opportunities for professional growth and development and that staff are not working excess unsocial hours with inadequate recovery time. Previous report indicates that these issues can affect staff turnaround, result in burn out, low morale, high sickness absences, increased error rate, poor team spirit, diminished productivity, and suboptimal blood transfusion service delivery [329]. The healthcare delivery system in the West African sub region faces many challenges including human resource inadequacy. Migration of health workers (brain drain) defined as the movement of health personnel in search of a better standard of living and life quality, higher remuneration, better working condition, wellbeing, access to advanced technology and more stable political conditions has made the human resource challenge in the sub region even worse [330]. The best of West African human resources in healthcare who should be offering excellent care to citizens in their home nations have emigrated to developed countries. The physician-to-population ratio is estimated to be 13/100,000 in Africa, compared with 280/100,000 in the United States [331]. Although there is a hypothesis that brain drain could be beneficial and impart positively on medical education fostering international collaboration in healthcare research and development [332]. This argument will only be substantive if these health professionals return periodically or permanently after practicing abroad for a while. The economic effect of brain drain on the economy of developing countries is huge [333]. There are several reasons for the poor retention of healthcare workers in the West African sub region: poor remuneration, lack of opportunity, high unemployment in health labour markets and the deplorable state of healthcare infrastructure in the sub region. Leaders of West African countries must take realistic steps to ensure that all staff involved in blood transfusion service delivery across the sub region are adequately trained, remunerated, motivated, and retained to ensure high morale, increased productivity and to prevent the risk of brain drain. These have the potential to reduce the reduce the error rate, brain drain and suboptimal blood transfusion service delivery.

#### **4.7 Premises and environment**

The premises and environment where all processes involved in blood transfusion delivery is implemented must be enabling and must be conducive for activities

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

being carried out. The work environment (processes, systems, structures and tools or conditions) in the blood transfusion workplace that can potentially impact the staff favourably and by extension their performance and productivity should be provided [334]. The work done must be process oriented, associated with effective cleaning and maintenance protocols, and arranged in such a way as to minimize the risk of errors, injury and to minimize the risk of contamination. There should be a separate area (Donation, testing and processing, storage and waste management) that is optimally endowed (human and materials). Donation area should be endowed with facilities to allow for confidential interviews and assessment of individuals to determine their eligibility to donate blood. Collection area should be appropriately equipped to facilitate the safe collection of blood and blood products as well as manage adverse reactions or injuries from events associated with donation. The safety of the transfusion staff and donors must be maintained**.** The environment where the blood transfusion process is implemented must be enabling in terms of space, safety and infrastructural endowment (equipment, availability of piped borne water, soap, appropriate sanitation facilities, handwashing facilities, availability of adequate infection control measures including personal protective equipment (PPE) and waste management as well as availability of uninterrupted power supplies) [335–337]. The blood transfusion organization should have a dedicated laboratory for donor testing and should be separated from the processing areas to prevent the risk of contamination. There should be restricted access (limited to authorized staff) to the testing and processing areas. There should also be a dedicated storage area for the blood components (red cells, plasma, and platelets). There should be an area set aside for the secure and segregated storage of different blood components including a separate area for quarantine (not fit to use) and released (fit to use) as well as blood products collected for dedicated use (autologous donation) [338]. The storage area must have access to uninterrupted power supply and back up fridges, freezers and alternative sources of power in the event of equipment or power failure. Provision of adequate and safe blood transfusion service delivery is associated with the generation of waste which is potentially hazardous and may carry a potential for infection and injury [339]. Suboptimal and inappropriate handling of healthcare-related waste can have serious public health consequences and a significant impact on the environment [340]. The blood transfusion organization should have a system for the effective management of waste. The waste generated during production of blood and blood component carries a higher potential for infection and injury. Waste generated should be segregated [domestic non-hazardous, hazardous healthcare waste including sharps (needles, hypodermic needles, scalpels, blades, lancet, infusion sets, broken glass and pipettes) and chemical and radioactive waste] and disposed appropriately. In most West African countries, unsustainable management of waste is common. Open dumping and open burning are commonly implemented as waste treatment and final disposal systems. Illegal dumping of waste onto sidewalks, open fields, storm water drains and rivers is commonplace with negative economic, social and environmental impacts. Also, waste management involves the activity of the informal sector including waste pickers and scavengers with a significant associated health risks from potentially hazardous waste [341]. There is need for the implementation of effective waste management across the West African sub region by taking realistic steps at waste reduction, reuse if safe, recycling, recovery and treatment to achieve sustainable and environmentally sound management of all wastes [342, 343].

#### **4.8 Equipment and materials**

All equipment for use in the blood transfusion organization must have Equipment Operating Procedure (EOPs), be validated prior to implementation, regularly calibrated, and maintained [343]. The acquisition of any equipment must be justified and constitute value for money and should be carefully chosen to minimize any hazard to the blood donors, the personnel, or the blood components itself [344]. The transfusion organization must carry out validation of equipment, certification and pre-acceptance testing of all reagents to establish that the performance characteristics of the method meet the requirements for the intended analytical application. Validation is a pre-defined exercise to confirm that equipment or a procedure (either current or proposed) is fit for its intended purpose and meets its pre-defined specification. The benefits of validation include assurance that critical aspects of a process are in control, increased probability of uniform product quality, reduced product waste and reduced customer complaints. Reagent certification of reagents ensures that reagents are performing to the quality standards of the manufacturers and fit for diagnostic work. Only reagents and materials from approved suppliers that meet the documented requirements, certification and specifications shall be used. The blood organization should have a robust computerized LIMS with back-up procedures. The LIMS should be validated before use [345]. All the associated hardware and software shall be protected against unauthorized use and changes. The back-up system must prevent loss of or damage to data [346]. The blood transfusion organization should implement a documented change control process that facilitate the suggestion of changes to the process by staff involved in the process that is beneficial, potentially save cost, remove bureaucratic aspects, and will optimize the safety of donors and personnel. The change control is planned and implemented in a controlled way, the possible re- training for staff involved in the process following the standard operating procedures (SOPs), shall ensure there is a record of the processes operated before and after the change, that the date of the change is known, and that material processed through the changed system can be identified. There should also be a system to ensure that the effectiveness of the newly implemented process is monitored and opportunities for further improvement are investigated and, where relevant, implemented. It shall support the organization in trying to learn from incidents, accidents, near misses, complaints, and other event information. The objective analysis of these and implementation of corrective and preventive measures in an action-planned format will facilitate the delivery of a continually improving quality blood transfusion service across the West African sub region [347, 348].

#### **4.9 Recall and traceability**

Effective blood transfusion service delivery requires that a system be in place to allow 100% accountability of donated blood and blood products [349]. The implementation of traceability facilitates the easy and prompt recall of products that is identified to be suboptimal or have potential to cause the recipient after release from the national blood transfusion service to hospital blood bank or from the hospital blood bank to the ward or satellite fridges can be recalled [350]. The recall system should be such that it is prompt and can be triggered at any time. All recalled products should be separated and kept away from other units that are fit for use to prevent its accidental release until a decision is made on the final fate (release to the pool or discarded). The recall process should be reviewed regularly to ensure its continued

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

effectiveness. Most countries, particularly those in developing countries were poorly implementing sub-indicators of haemovigilance particularly in the area of legal provisions, arrangement for effective organization and human resources indicators [351]. There must be a system to ensure that materials can be traced through the entire process from procurement, testing, production, issue from the NBTS to the hospital blood bank and subsequently to the recipient. There must be 100% traceability for all donated units (who donated the unit, when the blood was released to hospital blood bank and when unit was transfused to the recipient or discarded). For all donated units, traceability must be maintained from vein to vein from donor to the patient. In Morocco for example, the traceability rates were around 51% in Casablanca [352] and 15.5% in Rabat [353].

#### **5. Ensuing a continuous quality improvement-oriented blood transfusion service across the West African sub-region**

The blood transfusion organization must strive for Continuous Quality Improvement (CQI) by the regular and objective evaluation of overall performance using indices such as incidents, errors, near misses, complaints, audit and accreditation (internal and external), litigation and customer satisfaction surveys to determine the quality of service delivered on a continual basis [354]. At the root of CQI is culture of root cause analysis as a problem-solving tool to identify nonconformities with the hope of identifying corrected and preventive actions (CAPA) that needs to be implemented in an action planned format (what is to be done, why, how, by whom and time frame to achieve the task) to nip the non-conformance in the bud. All complaints from the customer and other relevant information, including any serious adverse reactions and serious adverse events lined to a defective blood component should be reported, documented, and promptly investigated to identify the causative factor/s of the defect and promptly recall the affected unit if necessary [355]. All serious adverse reactions or serious adverse events should be reported to appropriate regulatory authorities.

#### **5.1 Quality audit and accreditation**

A Quality audit is a planned systematic, independent and documented process of evaluating elements of a quality management system. It assesses whether quality activities and related results comply with planned arrangements [356]. Audits can either be internal or external and ensure that process are being operated as stated in the SOP and that procedures and associated quality assurance comply with Good Manufacturing Practice (GMP) principles. Audits should be carried out by a competent and trained individual who is knowledgeable about the process. The results of all audits and all non-conformances identified should be documented to allow for the implementation of root causes and action-planned implementation of corrective and preventive actions in a timely manner [357]. Unlike their Western counterparts, many countries in the West African sub region do not have a fit for purpose, centralized and coordinated blood transfusion services and the safety, quality, efficacy and regulatory framework remain significantly poor. The implementation of quality management system in blood transfusion across the West African region is relatively naïve. The issues surrounding the safety of production, supply, distribution, administration, and clinical use is poorly developed. Blood transfusion service delivery across the

West African sub region can be optimized. Audits of practice and incident reporting to national haemovigilance schemes have shown that poor hospital transfusion practice is frequent and occasionally results in catastrophic consequences for patients [358]. There is the need for governments of countries in the sub region to take steps to ensure the implementation of a quality management system-oriented blood transfusion process across the sub-region. Quality efforts should be made to ensure that blood transfusion is efficacious by the objective implementation of a high level of quality and safety throughout the transfusion chain (blood collection, testing, processing, storage, distribution, matching, delivery and clinical use of the blood products.

#### **5.2 Providing safe blood transfusion across the West African sub-region**

Blood transfusion is an indispensable component of modern healthcare delivery and saves millions of lives annually. Blood transfusion is often required to manage anaemia, bleeding following trauma, intra and post- operative, obstetric haemorrhage (ante and post-partum) and to manage several medical diseases including haematological conditions [349]. For blood transfusion to have life- saving potential, it must be safe. Safe blood transfusion is the right blood collected from the right voluntary non remunerated donor and transfused to the right patient at the right quantity, at the right time, in the right place and based on the right clinical indication [359]. Safe blood transfusion is not wishful thinking. It is achieved by implementing evidence-based best practices in key areas including patient identification, documentation, communication, patient consent, request for transfusion, pre transfusion sampling, collection of blood and delivery in the clinical area, safe administration of blood and monitoring during a blood transfusion. A significant number of patients worldwide are administered with wrong blood annually with sometimes fatal consequences. Many of these incidents are preventable and predominantly due to human errors [360]. The common root causes of these errors are poor patient identification, misidentification of patient during pre-transfusion sampling, errors during laboratory testing, error during collection of blood from the blood bank and errors during blood administration. Previous report indicates that as many as 40% of mis transfusions are due to errors in the post-analytic phase: often failures in the final check of the right blood and the right patient at the bedside [361]. There is need for healthcare professionals involved in the blood transfusion process including biomedical scientist, medical doctors and nursing staff practice in environments that recognize the importance of reducing error and improving safety using non-punitive system approaches that encourages the reporting and objective investigation of incidents, accidents, near misses and errors [362, 363].

#### **5.3 Patient identification**

Positive patient identification is fundamental to safe blood transfusion. It is essential to ensure that the right blood is given to the right patient. Patient misidentification can have a potentially fatal consequence for patients [364]. Errors in the whole-blood transfusion chain - from initial recipient identification to final blood administration - occur with a frequency of approximately 1 in 1000 events [365]. Among pre-analytical errors, misidentification and mis transfusion are still regarded as a considerable problem, posing serious risks for patient health and

*Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

carrying huge expenses for the healthcare system [366]. Patient identification errors in pre- transfusion blood sampling ('wrong blood in tube') are a persistent area of risk in blood transfusion errors [367]. Evidenced best practice in the West requires that all patient for which blood transfusion is intended wear an identification band containing the minimum patient identifiers (surname, forename, date of birth and hospital number) to facilitate an unmistakable patient identification during pre-transfusion sample collection and during blood administration. In accident and emergency units, patients presenting in coma who cannot be immediately identified must be given at least one unique identifier (A&E or trauma number and patient gender). Prior to collecting or administering blood to a patient, the patient, carer or parent in case of children should be requested to state their full name and date of birth and this information must be compared to what is on the patient wrist band. It is only when there is a match that a patient is said to have been positively identified for sample collection and administration purposes. All identification discrepancies at any stage of the transfusion process must be investigated and resolved before moving to the next stage to prevent transfusion errors.

#### **5.4 Documentation**

In blood transfusion the golden rule is that anything not written down was done. Blood transfusion documentation is critical to ensuring 100% traceability of all donated donor units. Documentation (hard copy or electronic) to capture events at every stage of the transfusion process (pre-transfusion, during transfusion and post transfusion) should be kept in a clear, legible, readable, auditable, and user-friendly format. Vital information including transfusion prescription sheet, crossmatch worksheet, temperature, monitoring records, reagent storage, equipment validation, reagent certification and monitoring charts must be kept providing a clear audit trail [350]. Previous report indicates that use of barcode reader and related electronic technology can be adapted to improve transfusion safety and reduce the risk of human errors at all steps of the blood transfusion process [368]. All transfusion documentation should include the minimum patient identifiers (name, date of birth and hospital number). Pre-transfusion related information including laboratory data and clinical indication for transfusion, information that the potential risks, benefits and alternatives have been discussed with the patient and that written informed consent was obtained, the dose/volume and rate of transfusion and information of any special transfusion requirement for the patient such as CMV negative, antigen negative blood, gamma irradiated components, etc.). Previous report indicates that bedside ABO-typing and checklist prior to blood transfusion can control the ABO-mismatched transfusion if done timely and correctly [369]. Intra transfusion documentation must contain vital information; medical staff who started the transfusion, date and time transfusion commenced and completed, details of blood component (component type, bag numbers and any special requirement) as well as information on observation prior, during and post transfusion (temperature, blood pressure, respiratory rate and pulse). Post-transfusion documentation must include information on clinical outcome of any transfusion, adverse reaction or events and evidence that transfusion was beneficial and accomplished the desired outcome (HB optimization and improvement in anaemia and related symptoms) [370]. Previous report indicates that training and education of health-care staff on transfusion-related

documentation at the bedside is vital to reducing blood transfusion related errors, morbidities, and mortalities [371].

#### **5.5 Communication**

Communication (verbal and written) between clinical, laboratory staff and porters should be clear and unambiguous as it is critical to patient safety. Misunderstanding and transcription error are common communication- related issues associated with transfusion errors. Effective commination among the healthcare care workers involved in the blood transfusion process is critical to limiting transfusion-related errors [372]. Written or electronic communication should be used wherever possible with request for urgent transfusion supplemented by telephone request with laboratory staff. Good communication is especially important at times of staff handover between shifts, both on the wards and in the laboratory, and can be enhanced by a standardized and documented process. Handovers should be built into transfusion laboratory routine practices, ensuring effective transfer of information and appropriate follow up actions are taken [373]. Hospital transfer of patients is common- place in healthcare delivery. Effective transfer of relevant transfusion information relating to patient care is vital in blood transfusion service delivery [374].

#### **5.6 Patient consent**

Under the principle of medical ethics, a competent patient's autonomy and right to determine his or her treatment is widely recognized in medical practice. Evidence-based best practice recommends that patients are informed about and understand the purpose, benefits and potential risks of transfusion as well as available alternatives. The Advisory Committee on the Safety of Blood, Tissues, and Organs (SaBTO) recommends that 'valid consent' for blood transfusion should be obtained and documented in the clinical record (signed consent) [375]. Blood transfusion is not an entirely safe form of treatment. It is sometimes associated with adverse effects and events. Blood transfusion must not be given lightly but rather it must be given only when there are no safer alternatives. Its use must not only be based on laboratory results alone but also on the clinical presentation and presence of symptoms. The potential risk, benefits and alternatives must be discussed with patients to enable them to make an informed decision. A survey of the use of blood in the UK indicates that 20% or more of transfusions are inappropriate and that many patients could benefit from safer alternatives [376]. However, in emergency situations the inability to obtain a consent must not prevent or delay the need for essential urgent lifesaving transfusion. The only exception is patients that have a valid Advance Decision Document declining transfusion. Most Jehovah's witnesses carry a written advance directive declaring their religious convictions not to take a blood transfusion [377]. The blood refusal card directs that no blood is to be given to the owner under any circumstance, even if physicians believe transfusion will be lifesaving [378]. The right of such patients not to be transfused should be respected [379]. However, in the emergency, in the absence of blood refusal card or if there is a reasonable doubt about the validity of a treatment refusal, the physician has a duty of care to take decision that they believe is in the best interest of the patients and render life-saving treatment [380]. The issue of informed consent to have a transfusion is critical because transfused patients potentially lose their ability to

be blood donors. In many developed countries, transfusion dependent patients are offered a modified form of consent that requires them to go through an annual review and re-consent [381].

#### **5.7 Prescribing and request for transfusion**

The process of prescribing blood components is not necessarily legally restricted to registered medical practitioners. From a safety and efficiency and saving lives point of view, there are clear advantages in allowing non-medical practitioners to authorize transfusion in certain situations. Evidence-based best practice recommends that appropriately trained and competent practitioners including registered nurses and midwives can make clinical decisions and provide written instruction for blood component transfusion. This practice has the potential to deliver a more patient-centred quality service [382, 383]. It is vital that all transfusion prescriptions or written authorization to transfuse a patient blood must be permanent part of a patient clinical records and should contain vital information including patient's minimum identifiers, information on the blood component to be transfused, the dose, volume rate and any special requirements [384].

#### **5.8 Pre transfusion sampling**

Wrong blood in tube' (WBIT) errors and misidentification at blood sampling, where the blood in the tube is not that of the patient identified on the label is a major cause of ABO incompatible transfusion and fatal haemolytic transfusion reactions. The consequence of these errors can be catastrophic [385]. This type of error is difficult to identify particularly when there is no historic blood group documented in the patients records on the LIMS [386]. Sub optimally labelled samples carry a significantly increased risk of containing blood from the wrong patient. There are several steps that can potentially reduce the risk of this kind of errors; use of electronic systems, ensuring that phlebotomist responsible for sample collection are adequately trained and competent tested; patients must be positively identified and their details (name, date of birth and hospital number) on the sample, dated, timed, and must match those on the request form and patient wrist band [386]. It is generally expected that all inpatients must wear an identity band and the collection and labelling of the sample tubes must be performed at the patient bedside as one uninterrupted process involving one trained and competent staff and one patient. Other requirements include; sample tubes must not be pre-labelled prior to sample collection; sample tubes must be hand labelled legibly; addressograph or printed labels must not be used on the transfusion sample and the transfusion laboratory must maintain a zero-tolerance policy for rejecting samples that do not meet the above minimum requirements [387–389]. It is also evidence-based best practice to implement a two- specimen rule to allow for the verification of ABO/Rh for blood transfusion [390, 391]. This implementation of two concordant ABO typing results has the potential to detect wrong blood in the tube and prevent the risk of haemolytic transfusion reaction resulting from the transfusion of ABO incompatible blood particularly when there is a discrepancy in the blood group obtained from both sample [392]. Many countries in the West African sub region do not seem to have a LIMS nor a barcode-based identification. The 2-sample rule is also not being implemented and documentation tends to be hardcopy and paper-based [393]. Countries in the sub

region will need to start implementing these best practices to the latter to enhance the safety of blood transfusion service delivery and to reduce the risk of incompatible blood transfusion.

#### **5.9 Collection of blood and delivery in the clinical area**

Errors during blood collection of blood from the blood bank have been reported as predominant root cause of wrong blood transfusion and associated haemolytic transfusion reaction [393]. All staff responsible for collecting blood from the blood bank or satellite refrigerators must be trained and competency tested. There is increasing advocacy for the replacement of the predominant manual documentation of blood collection using a transfusion register which is predominant in many settings in the West Africa sub region to the less error- prone electronic blood-tracking systems [394]. This manual documentation system in operation in most settings in the sub region is risky particularly because people bear similar names thus increasing the risk of potentially taking blood meant for a different patient [395]. Electronic blood-tracking systems has a number of advantages over the traditional hardcopy register system; improved quality of transfusion service delivery by reducing transfusion errors; it allows for timely collection and delivery to clinical area, enhances the productivity of nursing staff as well as reduced blood wastage, prevent the risk of taking blood for a wrong patient and unallocated or de-reserved units, provides audit trail as only staff who have been trained and competency tested are given barcode and password to identify themselves on the system. Staff collecting blood is expected to scan the patient barcode containing the minimum patient identifiers which must be checked against the details on the transfusion laboratory-generated crossmatch label attached to the blood pack. Normally if there is no blood allocated for the patient in the fridge the staff will be denied access to the fridge. The system only ensures that only blood that is within its expiry time and date and meant for the desired patient is released for collection. Other advantages of the computer-controlled, electronicallylinked information management system is that; minimize the risk of transfusing units that have been out of temperature-controlled storage for too long (>30 minutes); provides a full audit trail of all activity and frees up nursing resources allowing them concentrate on other core nursing duties, prevents the transfusion of incorrectly stored units and out of date product or quarantined; facilitate inventory control management, delivery, tracking and documentation as well as audit trails. Access to electronic databases have greatly facilitated product traceability and biovigilance efforts and it can be linked to LIMS and other IT systems, providing robust documentation and data relevant to transfusion at all stages of the transfusion process (blood sample collection, laboratory testing, blood unit collection from the blood bank and transfusion of blood to the patient, ensuring full documentation and audit trail at every stage [396]. Electronic blood-tracking systems ensure that the right patient receives the right blood component at the right time [397].

#### **6. Receiving blood in the clinical area and safe administration of blood**

Transfusion of wrong blood or blood component is the most important error associated with serious morbidity or mortality. Provision of training and competency for healthcare workers involved in blood transfusion, developing standard safety guidelines, raising of hazards and implementation of appropriate preventative

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

measures are critical during all steps of blood and blood component transfusion [397]. There are evidence-based practices that clinical staff involved in blood transfusion will have to implement to prevent transfusion errors. Before attempting to collect blood from the blood bank they must ensure that patient is wearing an identity band, has given consent for transfusion, the transfusion 'prescription' has been completed, there is venous access and staff are available to start the transfusion promptly and monitor it correctly. Also except in case of major haemorrhage requiring rapid transfusion of large quantities, only one unit should be collected at a time. Also, transfusion of not urgent blood at night should be avoided. Effective identity checks between patient and the blood unit including the component special requirements are key requirements as it constitutes the final opportunity to avoid potentially fatal mis transfusion (last chance/bus stop to prevent mis transfusion). The check must be performed by two clinical staff for every unit transfused. The unit must be inspected thoroughly for signs of leakage, discoloration or clumps. The prescription and other relevant paperwork should be signed by the person administering the component including the component donation number, date, time of starting and stopping the transfusion, dose/volume of component transfused, and name of the administering practitioner should be recorded in the clinical record. Correct patient identification is crucial in transfusion safety. Failure in patient identification can result in wrong blood typing or transfusion of the wrong blood component. Many of these kinds of incidents are preventable by carefully checking patient data at the bedside prior to commencing the transfusion [398]. Changes in vital signs are regularly seen during transfusion. There is need for clinical staff to be aware of common transfusion reaction signs and symptoms to enable them to differentiate between a normal patient response from a life-threatening reaction [399, 400].

#### **6.1 Monitoring during a blood transfusion**

Blood transfusion is associated with adverse reactions or events. Patients having a blood transfusion should be regularly monitored before, during and post transfusion. Patients must be encouraged to report new symptoms. By monitoring and recording vital signs such as temperature, pulse, respiratory rate, and blood pressure regularly we can tell if a patient is having a transfusion reaction. These parameters are determined at baseline (at least 60 minutes) before commencement of the transfusion, 15 minutes after the start and regularly during and after the transfusion. Patient monitoring during transfusion is of paramount importance for prompt detection of transfusion reactions [401]. Transfusion reaction associated with transfusion of ABO incompatibility or bacterial transmission present early after commencing the transfusion [402]. Sometimes patients can have delayed transfusion reaction that will become evident 24 hours post transfusion. It is vital that the transfusion recipient is monitored over the next 24 hours. Any reaction observed during and after the transfusion of a blood component must be reported promptly and investigated. The guidelines of the British Committee for Standards in Haematology recommends that when any of the associated signs and symptoms of transfusion reactions occur, the initial treatment should be based on signs and symptoms rather than on classification [403].

#### **6.2 Enhancing blood transfusion safety across the West African sub-region**

Safe blood is a crucial component in improving health care and in preventing the transmission of infections. The two major challenges associated with blood

transfusion service delivery across the West African sub region is that adequacy and safety [2, 404]. Developing countries have continued to lag behind in contributing her own quota to the allogenic blood pool globally. Out of the 92 million blood units were donated worldwide in 2008, only an insignificant 4 million (4.3%) were donated in sub-Saharan Africa- a continent that is home to approximately 12% of the global population [405]. The rate of blood donation across the region has remained consistently lower than rates in developed economies (4–5 per 1000 compared to 30 donations per 1000) respectively [406]. The World Health Organization recommends blood transfusion from low risk and altruistic regular voluntary non-remunerated blood donors (VNRBDs). However, VNRBDs represent <50% of whole blood donations in low-income countries compared with 76–100% in developed economies. The sub-region will need to abolish the unsafe commercial remunerated blood donation. Efforts should be made to enlighten the sub-region that family replacement donors are unsafe, there is difficulty in replacing blood in quantity and type through family replacement donation and blood donated can put transfusion recipient who are females of childbearing age at risk of developing alloantibodies that can cause HTR and HDFN if they receive blood from their husbands and his relatives. The region will need to look for innovative ways to encourage community members to change their mentality from being family replacement donors to becoming voluntary non-remunerated donors. VNRBDs are key to the maintenance of a safe and adequate blood supply. Education and public enlightenment, innovation, and pragmatic approach in the aspect of recruitment, retention, non-cash motivation and renewal of an active volunteer and non-remunerated donor pool from the massive young population in the sub region is key to safe and sustainable blood transfusion service delivery [407]. Transfusion-transmissible infections, such as HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), syphilis, and malaria are prevalent across the sub region and have remained a source of safety concern for transfusion recipients. Transfusion of sub- optimally screened blood is the cause of 5–10% of HIV infections in sub-Saharan Africa and about 12.5% of transfusion recipients in the region are at risk of posttransfusion hepatitis [408]. Unsafe blood transfusion has a significant effect (socio, economic and health) on the sub region, families, communities, and the wider society [409]. The various markers of infection for these infective agents appear at different times after infection. The window periods (period between infection and availability of screening marker in the blood of the donor) vary depending on the infective agent (range from few days to months), the infectious agent and the screening marker and the technology used. In the window period a screening marker may not be detectable in a recently infected donor even though the donor may be infectious. Nucleic acid (RNA/DNA of the infectious agent) is the first detectable target to appear in blood, followed by the antigen (produced by the infectious agent), and finally the antibody following an immune response in the donor. The sub region will need to implement a policy of universal/mandatory screening of blood donors for HIV-1 and HIV-2, Hepatitis B, Hepatitis C and Syphilis as a minimum requirement [410]. The infectious agent, the screening marker, and the minimum technology to be employed should be defined by way of policy. For HIV-1 and HIV-2 screening using a combination of HIV antigen-antibody or HIV antibodies as a minimum and where possible nucleic acid testing is advocated. Screening for hepatitis B using hepatitis B surface antigen (HBsAg). Hepatitis C screening for either a combination of HCV antigen-antibody or HCV antibodies and where possible nucleic acid testing while for syphilis (Treponema pallidum) screening for specific treponemal antibodies should be implemented across the sub region. The use of only antibody-based test for screening

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

donors for HIV and HCV should be discouraged to prevent the risk of introducing donor blood in the window phase of infection into the blood donor pool [411]. All efforts and energy need to be invested by member countries of ECOWAS to minimize the risks of transfusion-transmitted infection particularly during the window phase of infectious agent to make blood safer [2]. Implementation of stringent donor selection criteria and deferral system is the first step in determining the suitability of a potential blood donor to donate blood [412]. It can determine eligibility and identify donors whose behaviours put them potentially at risk for blood donation warranting either temporal or permanent deferral. The implementation of a robust donor deferral strategy can have a positive impact on transfusion safety in the West African sub-region [413]. A better understanding of the reasons for deferral of potential blood donors across the sub region could assist in donor recruitment planning and gives insight into the general health of the population in terms of prevalence of TTIs and anaemia. The presence of anaemia and risk of TTIs are the predominant contributors to donor deferral among donors [414, 415]. Member countries in the sub region will need to improve on the donor screening and deferral procedures as well as serologic testing. The aim of deferral is to facilitate the exclusion of donors from potentially higher risk populations to enhance patient safety [416]. The sub region will need to develop an efficient donor screening and deferral system to ensure the safety of both prospective donors and recipients [417]. The need for allogenic blood in the West African sub region has continued to be on the increase for several reasons; increase in the number of elective surgeries, failure to match demand and supply, suboptimal functioning of the national blood transfusion services, lack of relevant policies, trained personnel, funding and appropriate infrastructure in member states, dominance of unsafe family replacement and commercial remunerated blood transfusion rather than safe and altruistic voluntary non-remunerated blood donors, old and emerging threats of transfusion-transmitted infection, poor management of coagulopathy, major haemorrhage and bleeding disposition in surgical patients and pregnant women, prevalent insurgencies and communal clashes, increase in road traffic accidents due to poor road infrastructure in some member states, armed conflicts, insurgency and banditry, high prevalence of sickle cell disease, nutritional and malaria associated anaemia and pregnancy-related complications. All these factors have made allogenic blood a vital but limited commodity across the sub region. The region will need to think strategically out of the box to identify innovative ways to recruit and retain voluntary low-risk blood donors. Education, public enlightenment, and collaboration with stakeholders are key to changing the erroneous belief of the people towards donation of blood [418]. Countries in the West African sub region need to be smart, flexible and do things differently to ensure the adequacy and safety of blood transfusion service delivery in the sub region. Efforts should be made to make transfusion safer by implementing best practices in donor selection and screening. The use of other alternatives to allogenic blood (autologous transfusion, use of pharmacologic agents like oral, IV iron and erythropoietin to optimize haemoglobin of patients particularly those going for elective surgery, optimal management of trauma and associated major haemorrhage (trauma, surgical, ante and post-partum) by using haemorrhage limiting medication like antifibrinolytic, prothrombin complex concentrate, Novo7 and vitamin K [419]. The implementation of component therapy and universal leucodepletion of blood products will go a long way in ensuring the optimal management and safety of our limited allogenic blood stock. The need for the National blood transfusion services across the sub region to work synergistically under the umbrella of ECOWAS cannot be over emphasized to drive the organization

and management, blood donor recruitment, collection, testing of donor blood and appropriate clinical use of blood. The sub region will need to invest significantly on human and infrastructural capital development by increasing the budget for training aimed at an increasing the number of transfusions service-related skilled workforce, providing an enabling working environment and proper renumeration of health workers. These implementations have the potential to improve the access to adequate and safe blood transfusion across the sub region.

#### **7. Conclusion and recommendations**

Blood transfusion service delivery across the west African sub region faces daunting but surmountable challenges bordering around adequacy and safety. The challenge of providing adequate and safe blood and blood product across the sub region is multi-dimensional and include; lack of transfusion policies and a fit for purpose National blood transfusion service in some ECOWAS countries, reliance on unsafe family replacement and commercial remunerated donors rather than safe benevolent voluntary non-remunerated donors who donate blood for altruistic purpose, suboptimal funding required to fund a quality blood transfusion service, inadequate number of skilled manpower, lack of political will to implement the haemovigilance system, reliance on suboptimal antibody-based screening method for donor screening for HIV, transfusion of leucocyte rich whole blood rather than leuco-depleted component therapy, suboptimal pre-transfusion screening of patients that require a red cell transfusion, poor cold chain management of blood and blood products, absence of specialized blood products like gamma irradiated blood CMV negative and antigen negative blood etc. required by certain patients group, poor management of Rh negative pregnancy and absence of universal access to anti-D prophylaxis, absence of a quality management system-based blood transfusion service, absence of indication coding tool to facilitate the effective clinical use of blood, lack of alloantibody prevention measures, poor management of haemolytic disease of the foetus and newborn, suboptimal use of laboratory testing to determine the coagulopathic status of patients billed for surgery to facilitate the effective management of the coagulopathy prior to surgery to reduce the risk of haemorrhage, poor management of major haemorrhage, suboptimal use of pharmacologic and nonpharmacologic alternatives to allogenic blood in anaemic and bleeding patients. These factors affect the adequacy and safety of blood transfusion across the sub-region.

#### **8. Recommendations**

We recommend the implementation of the following evidence-based best practices to ensure the safety, adequacy and timely provision of blood and blood products across the West African sub-region.


*Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*


### **Author details**

Osaro Erhabor1,2\*, Josephine O. Akpotuzor3 , Edward Yaw Afriyie4 , Godswill Chikwendu Okara5 , Tosan Erhabor6 , Donald Ibe Ofili6 , Teddy Charles Adias7 , Idris Ateiza Saliu8 , Evarista Osime9 , Alhaji Bukar10, Oyetunde B. Akinloye11, Zakiya Abdul-Mumin12, John Ocquaye-Mensah Tetteh13, Edwin G. Narter-Olaga14, Andrews Yashim-Nuhu15, Folashade Aturamu15, Ayodeji Olusola Olayan16, Adeyinka Babatunde Adedire17, Oyeronke Suebat Izobo18, Kolawole A. Fasakin19, Onyeka Paul20, Collins Ohwonigho Adjekuko21, Elliot Eli Dogbe22 and Uloma Theodora Ezeh23

1 Blood Transfusion Faculty, West African Postgraduate College of Medical Laboratory Science, Wupa, Nigeria

2 Department of Haematology and Blood Transfusion Science, Usmau Danfodiyo University Sokoto, Sokoto, Nigeria

3 Department of Haematology and Blood Transfusion Science, University of Calabar, Nigeria

4 KNUST/KATH, Kumasi, Ghana

5 West African Postgraduate College of Medical Laboratory Science, Nigeria

6 Medical Laboratory Science Council of Nigeria, Abuja Nigeria

7 Federal University Utuoke Bayelsa State, Nigeria

8 Safe Blood for Africa Foundation, South Africa

9 University of Benin, Benin City Edo State, Nigeria

10 Medical Laboratory Science Department, University of Maiduguri/Blood Bank, University of Maiduguri Teaching Hospital, Nigeria

11 Association of Medical Laboratory Scientists of Nigeria (AMLSN), Nigeria

12 Tamale Teaching Hospital, Ghana

13 National Blood Service, Ghana

© 2023 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

14 Department of Blood Bank and Serology, Ghana Association of Medical Laboratory Scientists –GAMLS, Ghana


19 Federal Teaching Hospital, Ido Ekiti, Nigeria/ ELIZADE University, Ilaramokin, Nigeria

20 University of Abuja Teaching Hospital Gwagwalada, Abuja, Nigeria


23 Department of Haematology and blood transfusion, Nnamdi Azikiwe University Teaching Hospital Nnewi, Nigeria

\*Address all correspondence to: n\_osaro@yahoo.com

© 2023 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

#### **References**

[1] Barro L, Drew VJ, Poda GG, Tagny CT, El-Ekiaby M, Ofori SO, et al. Blood transfusion in sub-Saharan Africa: Understanding the missing gap and responding to present and future challenges. Vox Sanguinis. 2018;**113**(8):726-736

[2] Erhabor O, Adias TC. The challenges of meeting the blood transfusion requirements in sub-Saharan Africa: The need for the development of alternatives to allogenic blood. Journal of Blood Medicine. 2011;**2**:7-21

[3] Pape A, Stein P, Horn O, Habler O. Clinical evidence of blood transfusion effectiveness. Blood Transfusion. 2009;**7**(4):250-258

[4] Letowska M. Patient-specific component requirements: 'Right blood, right patient, right time, right place. ISBT Science Series. 2009;**4**:52-55

[5] World Health Organization. Global Status Report on Blood Safety and Availability. Geneva, Switzerland: World Health Organization; 2016

[6] Evans R, Ferguson E. Defining and measuring blood donor altruism: A theoretical approach from biology, economics, and psychology. Vox Sanguinis. 2014;**106**(2):118-126

[7] Tagny CT, Laperche S, Murphy EL. Francophone Africa network for transfusion medicine research. Updated characteristics of blood services, donors and blood products in 11 French-speaking African countries. Vox Sanguinis. 2018;**113**(7):647-656

[8] Kanagasabai U, Michelle S, Chevalier BD, Mili FD, Qualls ML, Bock N, et al. Trends and gaps

in National Blood Transfusion Services — 14 sub-Saharan African countries, 2014-2016. Morbidity and Mortality Weekly Report (MMWR). 2018;**67**(50):1392-1396

[9] Hensher M, Jefferys E. Financing blood transfusion services in sub-Saharan Africa: A role for user fees. Health Policies and Planning. 2000;**15**(30):287-295

[10] Asamoah-Akuoko L, Hassall OW, Bates I, Ullum H. Blood donors' perceptions, motivators and deterrents in sub-Saharan Africa – A scoping review of evidence. British Journal of Haematology. 2017;**177**(6):864-877

[11] Roman L, Armstrong B, Smart E. Donation testing and transfusion transmissible infections. ISBT Science Series. 2020;**15**:192-206

[12] Pruett CR, Vermeulen M, Zacharias P, Ingram C, Tagny CT, Bloch EM. The use of rapid diagnostic tests for transfusion infectious screening in Africa: A literature review. Transfusion Medicine Reviews. 2015;**29**:35-44

[13] Vamvakas EC, Blajchman MA. Universal WBC reduction: The case for and against. Transfusion. 2001;**41**:691-712

[14] Erhabor O, Adias TC. From whole blood to component therapy: The economic, supply/demand need for implementation of component therapy in sub-Saharan Africa. Transfusion Clinique et Biologique. 2011;**18**(5-6):516-526

[15] Samukange WT, Kluempers V, Porwal M, et al. Implementation and performance of haemovigilance systems in 10 sub-Saharan African countries

is sub-optimal. BMC Health Services Research. 2021;**21**:1258. DOI: 10.1186/ s12913-021-07235-0

[16] Patidar GK, Kaur D. Audit and education: Role in safe transfusion practice. Asian Journal of Transfusion Science. 2018;**12**(2):141-145

[17] Stanworth SJ, Walwyn R, Grant-Casey J, et al. Effectiveness of enhanced performance feedback on appropriate use of blood transfusions: A comparison of 2 cluster randomized trials. JAMA Network Open. 2022;**5**(2):e220364

[18] Zomorrodi A, Picciola EA, Hotwagner DT. Determining the need for blood transfusion. [updated 2021 Oct 21]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. [Internet] Available from: https://www.ncbi.nlm. nih.gov/books/NBK564300/

[19] Basu D, Kulkarni R. Overview of blood components and their preparation. Indian Journal of Anaesthesia. 2014;**58**(5):529-537

[20] Erhabor O, Adias TC. From whole blood to component therapy: The economic, supply/demand need for implementation of component therapy in sub-Saharan Africa. Transfusion Clinique et Biologique. 2011;**18**(5-6, 526):516

[21] Kumar H, Gupta PK, Mishra DK, Sarkar RS, Jaiprakash M. Leucodepletion and blood products. Medical Journal, Armed Forces India. 2006;**62**(2):174-177

[22] Pruss A, Kalus U, Radtke H, Koscielny J, Bsumsnn-Zbaretti B. Balzer universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions.

Transfusion and Apheresis Science. 2004;**30**:41-46

[23] Tagny CT, Diarra A, Yahaya R, et al. Characteristics of blood donors and donated blood in sub-Saharan Francophone Africa. Transfusion. 2009;**49**:1592-1599

[24] Stacy A, Gurevitz MD. Update and utilization of component therapy in blood transfusions. Laboratory Medicine. 2010;**41**(2):739-744

[25] Benedict N, Aigberadion U, Nwannadi IA, Aigbe I. Knowledge, attitude, and practice of voluntary blood donation among physicians in a tertiary health facility of a developing country. International Journal of Blood Transfusion and Immunohematology. 2012;**2**(2):4-10

[26] Aliyu I, Michael G, Ibrahim H, Ibrahim ZF, Aliyu G, Isaiah AT. Blood transfusion request pattern in a medical Centre in North-western Nigeria. Global Journal of Transfusion Medicine. 2017;**2**(1):52-55

[27] Arewa OP. One-year clinical audit of the use of blood and blood components at a tertiary hospital in Nigeria. Nigerian Journal of Clinical Practice. 2009;**12**(4):429-433

[28] Obi E, Diette-Spiff C, Omunakwe H. Knowledge and practices of physicians on blood component therapy: A crosssectional study from two tertiary hospitals in Nigeria. African Health Sciences. 2021;**21**(3):1230-1236

[29] Tapko JB, Toure B, Sambo LG. Status of Blood Safety in the Who African Region. Report of the 2010 Survey. Regional Office for Africa: World Health Organization. 2014;**2014**:14-16

[30] Sawadogo S, Nébié K, Kafando E, et al. Preparation of red cell concentrates *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

in low-income countries: Efficacy of whole blood settling method by simple gravity in Burkina Faso. International Journal of Blood transfusion and Immunohematology. 2016;**6**:20-29

[31] Ala F, Allain JP, Bates I, et al. External financial aid to blood transfusion services in sub-Saharan Africa: A need for reflection. PLoS Medicine. 2012;**9**:e1001309

[32] Manning, R. and Grabowski, H. Key economic and value considerations in the U.S. market for plasma protein therapies. 2018. Available from: https://www. bateswhite.com/newsroom-insight-197. html. [Accessed on January 4, 2020].

[33] Burnouf T. Current status and new developments in the production of plasma derivatives. ISBT Science Series. 2016;**11**(2):18-25

[34] Aalaei S, Amini S, Keramati MR, Shahraki H, Eslami S. Monitoring of storage and transportation temperature conditions in red blood cell units: A cross-sectional study. Indian Journal of Hematology & Blood Transfusion. 2019;**35**(2):304-312

[35] Shabihkhani M, Lucey GM, Wei B, Mareninov S, Lou JJ, Vinters HV, et al. The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. Clinical Biochemistry. 2014;**47**(4-5):258-266

[36] Ramirez-Arcos S,

Mastronardi C, Perkins H, Kou Y, Turner T, Mastronardi E, et al. Evaluating the 4-hour and 30-minute rules: Effects of room temperature exposure on red blood cell quality and bacterial growth. Transfusion. 2013;**53**(4):851-859

[37] Norfolk D. UK blood transfusion services. In: Handbook of Transfusion Medicine. 5. London: Stationery Office; 2013

[38] Groth S. Manual on the Management, Maintenance and Use of Blood Cold Chain Equipment. Geneva: World Health Organization; 2005

[39] James V, McClelland B. Guidelines for the Blood Transfusion Services in the United Kingdom. London: The Stationery Office; 2005

[40] Sigle JP, Holbro A, Lehmann T, Infanti L, Gerull S, Stern M, et al. Temperature-sensitive indicators for monitoring RBC concentrates out of controlled temperature storage. American Journal of Clinical Pathology. 2015;**144**(1):145-150

[41] Ramirez-Arcos S, Mastronardi C, Perkins H, Kou Y, Turner T, Mastronardi E, et al. Evaluating the 4-hour and 30-minute rules: Effects of room temperature exposure on red blood cell quality and bacterial growth. Transfusion. 2013;**53**(4):851-859

[42] Dumani D, Goldfinger D, Ziman A. Is the 30-minute rule still applicable in the 21st century? Transfusion. 2013;**53**(6):1150-1152

[43] Thomas S, Wiltshire M, Hancock V, Fletcher S, McDonald C, Cardigan R. Core temperature changes in red blood cells. Transfusion. 2011;**51**(2):442-443

[44] Yu YB, Briggs KT, Taraban MB, et al. Grand challenges in pharmaceutical research series: Ridding the cold chain for biologics. Pharmaceutical Research. 2021;**38**:3-7

[45] Mitra R, Mishra N, Rath GP. Blood groups systems. Indian Journal of Anaesthesia. 2014;**58**(5):524-528

[46] Avent ND, Reid ME. The Rhesus blood group system. Journal of

American Society of Hematology. 2000;**95**(2):375-387

[47] Jeremiah ZA. An assessment of the clinical utility of routine antenatal screening of pregnant women at first clinic attendance for haemoglobin genotypes, haematocrit, ABO and Rh blood groups in Port Harcourt, Nigeria. African Journal of Reproductive Health. 2005;**9**:112-117

[48] Loua A, Lamah MR, Haba NY, Camara M. Frequency of blood groups ABO and rhesus D in the Guinean population. Transfusion Clinique et Biologique. 2007;**14**:435-439

[49] Tagny CT, Fongué VF, Mbanya D. The erythrocyte phenotype in ABO and Rh blood groups in blood donors and blood recipients in a hospital setting of Cameroon: Adapting supply to demand. Revue Médicale de Bruxelles. 2009;**30**:159-162

[50] Bergstrom S, Pereira C, Hagstrom U, Safwenberg J. Obstetric implications of rhesus antigen distribution in Mozambican and Swedish women. Gynecologic and Obstetric Investigation. 1994;**38**:82-86

[51] Weinstein L. Irregular antibodies causing haemolytic disease of the newborn: A continuing problem. Clinical Obstetrics and Gynecology. 1982;**25**:321-332

[52] Bowman J. Hemolytic disease (erythroblastosis fetalis). In: Creasy R, Resnik R, editors. Prevention of Rh Alloimmunization. Philadelphia, PA: WB Saunders Co; 1999. pp. 736-738

[53] Catrina FR. Hemolytic disease of the newborn. REX Lab Bulletin. 2007;**126**:1-4

[54] Belinga S, Ngo SF, Bilong C, Manga J, Mengue MA, Tchendjou P. High prevalence of anti-D antibodies among women of childbearing age at Centre Pasteur of Cameroon. African Journal of Reproductive Health. 2009;**13**:47-52

[55] Gajjar K, Spencer C. Diagnosis and management of non-anti-D red cell antibodies in pregnancy. The Obstetrician and Gynaecologist. 2009;**11**:89-95

[56] Kumar S, Regan F. Management of pregnancies with RhD alloimmunisation. British Medical Journal. 2005;**330**:1255-1258

[57] Erhabor O, Isaac Z, Yakubu A, Adias T. Abortion, ectopic pregnancy, and miscarriage in sub Saharan Africa: Challenges of rhesus isoimmunization in rhesus negative women. Open Journal of Obstetrics and Gynecology. 2013;**3**:15-26

[58] Avent ND. RHD genotyping from maternal plasma: Guidelines and technical challenges. Methods in Molecular Biology. 2008;**444**:185-201

[59] Harkness M, Freer Y, Prescott RJ, Warner P. Implementation of NICE recommendation for a policy of routine antenatal anti-D prophylaxis: A survey of UK maternity units. Transfusion Medicine. 2008;**18**:292-295

[60] McBain RD, Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing rhesus alloimmunisation. Cochrane Database of Systematic Reviews. 2015;**2015**(9):CD000020

[61] Carroli G, Rooney C, Villar J. How effective is antenatal care in preventing maternal mortality and serious morbidity? An overview of the evidence. Paediatric and Perinatal Epidemiology. 2001;**15**:1-42

[62] Correa P, Linhard J, Diebolt G, Diadhiou F. Study of bilirubin in

#### *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

amniotic fluid associated with fetomaternal isoimmunization at Dakar. Bulletin de la Société Médicale d'Afrique Noire de Langue Française. 1969;**14**:262-266

[63] Verkuyl DA. Economics of antirhesus prophylaxis in an African population. The Central African Journal of Medicine. 1987;**33**:32-37

[64] Ahman E, Shah I. Unsafe abortion: Worldwide estimates for 2000. Reproductive Health Matters. 2002;**10**:13-17

[65] Osaro E, Charles AT. Rh isoimmunization in sub-Saharan Africa indicates need for universal access to anti-RhD immunoglobulin and effective management of D-negative pregnancies. International Journal of Women's Health. 2010;**2**:429-437

[66] Cakana AZ, Ngwenya L. Is antenatal antibody screen worthwhile in the Zimbabwean population? The Central African Journal of Medicine. 2001;**47**:26-28

[67] Toure Ecre A, Horo FM, Konan SK, Ble R, Kone M. Management of rhesus alloimmunisation by spectrophotometry: About one case at the Yopougon teaching hospital, Côte- d'Ivoire. Bulletin de la Société de Pathologie Exotique. 2006;**99**:245-249

[68] Darmstadt GL, Lee AC, Cousens S, et al. 60 million non-facility births: Who can deliver in community settings to reduce intrapartum-related deaths? International Journal of Gynaecology and Obstetrics. 2009;**107**(1):S89-S112

[69] Kotila TR, Odukogbe AA, Okunlola MA, Olayemi O, Obisesan KA. The pregnant rhesus negative Nigerian woman. The Nigerian Postgraduate Medical Journal. 2005;**12**:305-307

[70] Lapierre Y, Riga D, Adam J, Josef D, Meyer F, Greber S, et al. The gel test: A new way t~ detect red cell antigenantibody reactions. Transfusion. 1990;**30**:109-113

[71] Dara RC, Tiwari AK, Mitra S, Acharya D, Aggarwal G, Arora D, et al. Comparison of a column agglutination technology-based automated immunohematology analyzer and a semiautomated system in pretransfusion testing. Asian Journal of Transfusion Science. 2019;**13**(2):115-119

[72] Duguid KM. (1997) uses of column technology in blood transfusion. Hematology. 1997;**2**(6):485-489

[73] Varshney L, Gupta S. Comparison between conventional tube technique and column agglutination technique for antibody screening and identification at Mgm blood Bank, Navi Mumbai. Journal of Evolution of Medical and Dental Sciences. 2017;**6**(92):6551

[74] Das SS, Chaudhary R, Khetan D. A comparison of conventional tube test and gel technique in evaluation of direct antiglobulin test. Hematology. 2007;**12**(2):175-178

[75] Raos M. Evaluation of antibody screening and identification pretransfusion tests using DG gel cards. Journal of Applied Health Sciences. 2018;**4**(2):179-186

[76] Finck R, Lui-Deguzman C, Teng SM, et al. Comparison of a gel microcolumn assay with the conventional tube test for red blood cell alloantibody titration. Transfusion. 2013;**53**(4):811-815

[77] Winters JL, Richa EM, Bryant SC, et al. Polyethylene glycol antiglobulin tube versus gel microcolumn: Influence on the incidence of delayed haemolytic transfusion reactions and delayed

serologic reactions. Transfusion. 2010;**50**(7):1444-1452

[78] Patil V, Shetmahajan M. Massive transfusion and massive transfusion protocol. Indian Journal of Anaesthesia. 2014;**58**(5):590-955

[79] Calvert C, Thomas SL, Ronsmans C, Wagner KS, Adler AJ, Filippi V. Identifying regional variation in the prevalence of postpartum haemorrhage: A systematic review and meta-analysis. PLoS One. 2012;**7**(7):e41114

[80] GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality,1990-2015: A systematic analysis for the global burden of disease study 2015. Lancet. 2016;**388**:1775-1812

[81] Lancaster L, Barnes RFW, Correia M, Luis E, Boaventura I, Silva P, et al. Maternal death and postpartum hemorrhage in sub-Saharan Africa - a pilot study in metropolitan Mozambique. Research and Practice in THROMBOSIS AND Haemostasis. 2020;**4**(3):402-412

[82] Kavle JA, Stoltzfus RJ, Witter F, Tielsch JM, Khalfan SS, Caulfield LE. Association between anaemia during pregnancy and blood loss at and after delivery among women with vaginal births in Pemba Island, Zanzibar, Tanzania. Journal of Health, Population, and Nutrition. 2008;**26**:232-240

[83] WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with postpartum haemorrhage (WOMAN): An international, randomised, doubleblind, placebo-controlled trial. Lancet. 2017;**389**:2105-2116

[84] Li B, Miners A, Shakur H, Roberts I. Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: A costeffectiveness analysis of data from the WOMAN trial. The Lancet Global Health. 2018;**6**:e222-e228

[85] Black RE, Levin C, Walker N, Chou D, Liu L, Temmerman M. Reproductive, maternal, newborn, and child health: Key messages from disease control priorities 3rd edition. Lancet. 2016;**388**:2811-2824

[86] Bazirete O, Nzayirambaho M, Umubyeyi A, Karangwa I, Evans M. Risk factors for postpartum haemorrhage in the Northern Province of Rwanda: A case control study. PLoS One. 2022;**17**(2):e0263731

[87] Asamoah-Akuoko L, Hassall OW, Bates I, Ullum H. Blood donors' perceptions, motivators and deterrents in sub-Saharan Africa- a scoping review of evidence. British Journal of Haematology. 2017;**177**:864-877

[88] Nyflot LT, Sandven I,

Stray-Pedersen B, Pettersen S, Al-Zirqi I, Rosenberg M, et al. Riskfactors for severe postpartum haemorrhage: A case-control study. BMC Pregnancy and Childbirth. 2017;**17**:17

[89] Knight M, Callaghan WM, Berg C, Alexander S, Bouvier-Colle MH, Ford JB, et al. Trends in postpartum hemorrhage in high resource countries: A review and recommendations from the international postpartum hemorrhage collaborative group. BMC Pregnancy and Childbirth. 2009;**9**:55

[90] Kyei-Nimakoh M, Carolan-Olah M, McCann TV. Access barriers to obstetric care at health facilities in sub-Saharan Africa-a systematic review. Systematic Reviews. 2017;**6**(1):110

[91] Heitkamp A, Aronson SL, van den Akker T, et al. Major obstetric *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

haemorrhage in metro east, Cape Town, South Africa: A population-based cohort study using the maternal nearmiss approach. BMC Pregnancy and Childbirth. 2020;**20**:14. DOI: 10.1186/ s12884-019-2668-x

[92] Ejekam CS, Okafor IP, Anyakora C, Ozomata EA, Okunade K, Oridota SE, et al. Clinical experiences with the use of oxytocin injection by healthcare providers in a southwestern state of Nigeria: A cross-sectional study. PLoS One. 2019;**14**(10):e0208367

[93] Lalonde A, Davis BA, Acosta A, Herschderefer K. Postpartum haemorrhage today: ICM/FIGO initiative 2004-2006. IJGO. 2006;**94**:243-253

[94] Hill K, Thomas K, AbouZahar C, et al. Estimates of maternal mortality worldwide between 1990 and 2005: An estimate of available data. Lancet. 2007;**370**:1311-1319

[95] Obaid T. No woman should die giving life. Lancet. 2007;**370**:1287-1288

[96] International Federation of Gynecology & Obstetrics. Prevention and treatment of postpartum haemorrhage. New Advances for Low Resource Settings. ICM/FIGO Joint Statement. FIGO Safe Motherhood and Newborn Health (SMNH) Committee / International Journal of Gynecology and Obstetrics. 2012;**70**:108-118

[97] Ronsmans C, Graham W. Maternal mortality: Who, when where and why. Lancet. 2006;**368**:1189-1200

[98] Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: A WHO systematic analysis. The Lancet. Global Health. 2014;**2**:323-333

[99] Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife D, Garrod D, et al. Saving mothers' lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. An Int J Obstet Gynaecol. 2011;**118**:1-203

[100] Booth C, Allard S. Major haemorrhage protocols. ISBT Science Series. 2018;**13**:219-228

[101] Zehtabchi S, Nishijima DK. Impact of transfusion of fresh-frozen plasma and packed red blood cells in a 1:1 ratio on survival of emergency department patients with severe trauma. Academic Emergency Medicine. 2009;**16**:371-378

[102] Murad, M.H., Stubbs, J.R., Gandhi,M.J., Wang, A.T., Paul, A., Erwin, P.J., Montori, V.M. & Roback, J.D. The effect of plasma transfusion on morbidity and mortality: A systematic review and meta- analysis. Transfusion2010; 50:1370– 1383.

[103] Cardenas JC, Rahbar E, Pommerening MJ, Baer LA, Matijevic N, Cotton BA, et al. Measuring thrombin generation as a tool for predicting haemostatic potential and transfusion requirements following trauma. Journal of Trauma and Acute Care Surgery. 2014;**7**:839-845

[104] Davenport RA, Guerreiro M, Rourke C, Platton S, Cohen M, Pearse R, et al. Activated protein C drives the hyperfibrinolysis of acute traumatic coagulopathy. Anesthesiology. 2017;**126**:115-127

[105] Schochl H, Cotton B, Inaba K, Nienaber U, Fischer H, Voelckel W, et al. FIBTEM provides early prediction of massive transfusion in trauma. Critical Care. 2011a;**15**:R265

[106] Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates.

Anesthesia and Analgesia. 1995;**81**:360-365

[107] Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: Fifth edition. Critical Care. 27 Mar 2019;**23**(1):98. DOI: 10.1186/ s13054-019-2347-3

[108] Schöchl H, Maegele M, Solomon C, Görlinger K, Voelckel W. Early and individualized goal- directed therapy for trauma-induced coagulopathy. Scand J trauma Resusc. Emergency Medicine. 2012;**20**:15. DOI: 10.1186/1757-7241-20-15

[109] Joint United Kingdom (UK). Blood transfusion and tissue transplantation services professional advisory committee. Transfusion management of major haemorrhage. Last updated01/04/2020

[110] Ghadimi K, Levy JH, Welsby IJ. Prothrombin complex concentrates for bleeding in the perioperative setting. Anesthesia and Analgesia. 2016;**122**(5):1287-1300

[111] Lau P, Ong V, Tan WT, Koh PL, Hartman M. Use of activated recombinant factor VII in severe bleeding - evidence for efficacy and safety in trauma, postpartum Hemorrhage, cardiac surgery, and gastrointestinal bleeding. Transfusion Medicine and Hemotherapy. 2012;**39**(2):139-150

[112] Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database of Systematic Reviews. 2016;**2016**(8):CD007871

[113] Curry NS, Davenport R. Transfusion strategies for major haemorrhage in

trauma. British Journal of Haematology. 2019;**184**(4):508-523

[114] Cotton BA, Reddy N, Hatch QM, LeFebyre E, Wade CE, Kozar RA, et al. Damage control resuscitation is associated with a reduction in resuscitation volumes and improvement in survival in 390 damage control laparotomy patients. Annals of Surgery. 2011a;**254**:598-605

[115] Hunt BJ, Allard S, Keeling D, et al. A practical guideline for the haematological management of major haemorrhage. British Journal of Haematology. 2015;**170**:788-803

[116] Bates I, Owusu-Ofori S. Blood transfusion. Manson's Tropical Diseases. 2009:229-234. DOI: 10.1016/ B978-1-4160-4470-3.50018-5

[117] World Health Organization (WHO). Screening donated blood for transfusion-transmissible infections: Recommendations. In: 4, Screening for Transfusion-Transmissible Infections. Geneva: World Health Organization; 2009. Available from: https://www.ncbi. nlm.nih.gov/books/NBK142989/

[118] Scott SR, Zunyou W. Risks and challenges of HIV infection transmitted via blood transfusion. Biosafety and Health. 2019;**1**(3):124-128

[119] Bianco C, Kessler D. Donor notification and counselling management of blood donors with positive test results. Vox Sanguinis. 1994;**67**(3):255-259

[120] World Health Organization (WHO). Screening Donated Blood for Transfusion-Transmissible Infections. Geneva: World Health Organization; 2010. [17 August 2012] Available from: http://www.who.int/bloodsafety/ publications/bts\_screendondbloodtransf/ en/index.html

*Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

[121] Polizzotto MN, Wood EM, Ingham H, Keller AJ. Australian red cross blood service donor and product safety team. Reducing the risk of transfusiontransmissible viral infection through blood donor selection: The Australian experience 2000 through 2006. Transfusion. 2008;**48**(1):55-63

[122] Dwyre DM, Fernando LP, Holland PV. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sanguinis. 2011;**100**:92-98

[123] Chaurasia R, Zaman S, Das B, Chatterjee K. Screening donated blood for transfusion transmitted infections by serology along with NAT and response rate to notification of reactive results: An Indian experience. Journal of Blood Transfusion. 2014;**2014**:412105. DOI: 10.1155/2014/412105

[124] Nübling CM, Heiden M, Chudy M, Kress J, Seitz R, Keller-Stanislawski B, et al. Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion. 2009;**49**(9):1850-1858

[125] Hans R, Marwaha N. Nucleic acid testing-benefits and constraints. Asian Journal of Transfusion Science. 2014;**8**(1):2-3

[126] Aneke JC, Okocha CE. Blood transfusion safety; current status and challenges in Nigeria. Asian Journal of Transfusion Science. 2017;**11**(1):1-5. DOI: 10.4103/0973-6247.200781

[127] World Health Organization. Modern list of essential medicines for 2019. Available from: https://apps.who.int/iris/ bitstream/handle/10665/325771/WHO-MVP-EMPIAU-2019.06-eng.pdf. [Last accessed on May 20, 2021]

[128] WHO. Universal Access to Safe Blood. 2010. Feb 11, [Last accessed on 2013 Dec 06]. Available from: http:// www.who.int/bloodsafety/universalbts/ en/index.html

[129] Jeremiah ZA, Koate B, Buseri F, Emelike F. Prevalence of antibodies to hepatitis C virus in apparently healthy Port Harcourt blood donors and association with blood groups and other risk indicators. Blood Transfusion. 2008;**6**:150-155

[130] Buseri FI, Muhibi MA, Jeremiah ZA. Sero-epidemiology of transfusion-transmissible infectious diseases among blood donors in Osogbo, South-West Nigeria. Blood Transfusion. 2009;**7**:293-299

[131] Okocha EC, Aneke JC, Ezeh TU, Ibeh NC, Nwosu GA, Okorie IO, et al. The epidemiology of transfusiontransmissible infections among blood donors in Nnewi, South-East Nigeria. African Journal of Medical and Health Sciences. 2015;**14**:125-129

[132] Ahmed SG, Ibrahim UA, Hassan AW. Adequacy and pattern of blood donations in north-eastern Nigeria: The implications for blood safety. Annals of Tropical Medicine and Parasitology. 2007;**101**:725-731

[133] Emeribe AO, Ejele AO, Attai EE, Usanga EA. Blood donation and patterns of use in Southeastern Nigeria. Transfusion. 1993;**33**:330-332

[134] Okocha EC, Aneke JC, Ezeh TU, Ibeh NC, Nwosu GA, Okorie IO, et al. The epidemiology of transfusiontransmissible infections among blood donors in Nnewi, south-East Nigeria. African Journal of Medical and Health Sciences. 2015;**14**:125-129

[135] Bolarinwa RA, Aneke JC, Olowookere SA, Salawu L. Seroprevalence of transfusion transmissible viral markers in sickle cell disease patients and healthy controls in Ile-Ife, southwestern Nigeria: A case-control study. Journal of Applied Hematology. 2015;**6**:162-167

[136] Kassim OD, Oyekale TO, Aneke JC, Durosinmi MA. Prevalence of seropositive blood donors for hepatitis B, C and HIV viruses at the Federal Medical Centre, Ido-Ekiti, Nigeria. Annals of Tropical Pathology. 2012;**3**:47-55

[137] Ugwu A, Madu A, Efobi C, et al. Pattern of blood donation and characteristics of blood donors in Enugu, Southeast Nigeria. Nigerian Journal of Clinical Practice. 2018;**21**:1438-1444

[138] Loua A, Sonoo J, Musango L, et al. Blood safety status in WHO African region countries: Lessons learnt from Mauritius. Journal of Blood Transfusion. 2017;**2017**:e1970479

[139] Klein HG, Spahn DR, Carson JL. Red blood cell transfusions in clinical practice. Lancet. 2007;**370**:415-436

[140] Tayler VV. Blood Bank Technical Manual, 13th Ed. Maryland, USA: AABB; 1999. pp. 175-176

[141] Kientz D, Laforet M, Isola H, Cazenave JP. Leukodepletion of platelet concentrates and plasma collected with haemonetics MCS+ apheresis system. Experience of EFS-Alsace. Transfusion and Apheresis Science. 2001;**25**:55-59

[142] Pruss A, Kalus U, Radtke H, Koscielny J, Bsumsnn-Zbaretti BB. Universal Luekodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions. Transfusion and Apheresis Science. 2004;**30**:41-46

[143] Begue S. Leukocyte depletion. Transfusion Clinique et Biologique. 1998;**5**:411-414

[144] Hitzler WE. Apherese- und Pool-Thrombozytenkonzentrat--Wertigkeit und Bewertung beider Blutkomponenten [single-donor (apheresis) platelets and pooled whole-blood-derived platelets- significance and assessment of both blood products]. Clinical Laboratory. 2014;**60**(4):S1-S39

[145] Cazzola M, Borgna-Pignatti C, Locatelli F, et al. A moderate transfusion regimen may reduce iron loading in betathalassemia major without producing excessive expansion of erythropoiesis. Transfusion. 1997;**37**:135-140

[146] Schiffer CA. Diagnosis, and management of refractoriness to platelet transfusion. Blood Reviews. 2001;**15**(4):175-180

[147] Cheng CK, Lee CK, Lin CK. Clinically significant red blood cell antibodies in chronically transfused patients: A survey of Chinese thalassemia major patients and literature review. Transfusion. 2010;**52**:2220-2224

[148] Rios M, Hue-Roye K, Storry JR, Reiss RF. Cell typing the sensitized transfusion-dependent patient. Annals of Clinical and Laboratory Science. 2000;**30**(4):379-386

[149] Joint United Kingdom (UK). Blood transfusion and tissue transplantation services professional advisory committee. Transfusion in Surgery. Last updated01/04/2020. 5th edition, Handbook for Transfusion Medicine; Jan 2014

[150] Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Italian Society of Transfusion Medicine and Immunohaematology Working Party. Recommendations for the transfusion management of patients in the peri-operative period. III. The postoperative period. Blood Transfusion. 2011;**9**(3):320-335

*Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

[151] Elmistekawy E, Rubens F, Hudson C, McDonald B, Ruel M, Lam K, et al. Preoperative anaemia is a risk factor for mortality and morbidity following aortic valve surgery. European Journal of Cardio-Thoracic Surgery. 2013;**44**(6):1051-1056

[152] Thachil J, Gatt A, Martlew V. Management of surgical patients receiving anticoagulation and antiplatelet agents. The British Journal of Surgery. 2008;**95**(12):1437-1448

[153] Polania Gutierrez JJ, Rocuts KR. Perioperative anticoagulation management. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. [Updated 2022 Jan 26] Available from: https://www.ncbi.nlm. nih.gov/books/NBK557590/

[154] Kay LA, Noble RS. Systematic pre-deposit autologous blood provision for elective surgery: An important contribution to hospital blood supply. Vox Sanguinis. 1990;**59**(1):23-25

[155] Kawahara Y, Ohtsuka K, Tanaka K, et al. Use of laboratory testing for prediction of postoperative bleeding volume in cardiovascular surgery. Thrombosis. 2021:70. DOI: 10.1186/ s12959-021-00324-4

[156] Jakoi A, Kumar N, Vaccaro A, et al. Perioperative coagulopathy monitoring. Musculoskeletal Surgery. 2014;**98**:1-8

[157] Themistoklis T, Theodosia V, Konstantinos K, Georgios DI. Perioperative blood management strategies for patients undergoing total knee replacement: Where do we stand now? World Journal of Orthopedics. 2017;**8**(6):441-454

[158] Pei Z, Szallasi A. Prevention of surgical delays by pre-admission type and screen in patients with scheduled surgical procedures: Improved efficiency. Blood Transfusion. 2015;**13**(2):310-312

[159] Spahn DR, Spahn GH, Stein P. Evidence base for restrictive transfusion triggers in high-risk patients. Transfusion Medicine and Hemotherapy. 2015;**42**(2):110-114

[160] Loor G, Rajeswaran J, Li L, et al. The least of 3 evils: Exposure to red blood cell transfusion, anemia, or both? The Journal of Thoracic and Cardiovascular Surgery. 2013;**146**:1480-1487

[161] Vaglio S, Prisco D, Biancofiore G, Rafanelli D, Antonioli P, Lisanti M, et al. Recommendations for the implementation of a patient blood management programme. Application to elective major orthopaedic surgery in adults. Blood Transfusion. 2016;**14**(1):23-65

[162] Lawson T. Ralph, C, Perioperative Jehovah's witnesses: A review. BJA: British Journal of Anaesthesia. 2015;**115**(5):676-687

[163] Mundy GM, Birtwistle SJ, Power RA. The effect of iron supplementation on the level of Hb after lower limb arthroplasty. Journal of Bone and Joint Surgery. British Volume (London). 2005;**87-B**:213-217

[164] Muñoz M, Naveira E, Seara J, Cordero J. Effects of postoperative intravenous iron on transfusion requirements after lower limb arthroplasty. British Journal of Anaesthesia. 2012;**108**:532-534

[165] Hofmann A, Farmer S, Shander A. Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. The Oncologist. 2011;**16**(3):3-11

[166] Steuber TD, Howard ML, Nisly SA. Strategies for the Management of Postoperative Anemia in elective Orthopedic surgery. The Annals of Pharmacotherapy. 2016;**50**(7):578-585

[167] Thavarajah S, Choi MJ. The use of erythropoiesis-stimulating agents in patients with CKD and cancer: A clinical approach. American Journal of Kidney Diseases. 2019;**74**(5):667-674

[168] Singer ST, Wu V, Mignacca R, Kuypers FA, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood. 2000;**96**:3369-3373

[169] Thompson AA, Cunningham MJ, Singer ST, et al. Red cell alloimmunization in a diverse population of patients with thalassaemia. British Journal of Haematology. 2011;**153**:121-128

[170] Ugwu NI, Awodu OA, Bazuaye GN, Okoye AE. Red cell alloimmunization in multi-transfused patients with sickle cell anemia in Benin City, Nigeria. Nigerian Journal of Clinical Practice. 2015;**18**:522-526

[171] Ugwu A, O, Madu AJ, Anigbogu IO. Blood transfusion in sub-Saharan Africa: Historical perspective, clinical drivers of demand and strategies for increasing availability. African Sanguine. 2021;**23**(1):14-20

[172] Ugwu NI, Awodu OA, Bazuaye GN, Okoye AE. Red cell alloimmunization in multi-transfused patients with sickle cell anemia in Benin City, Nigeria. Nigerian Journal of Clinical Practice. 2015;**18**:522-526

[173] Kangiwa U, Ibegbulam O, Ocheni S, Madu A, Mohammed N. Pattern and prevelence of alloimmunization in

multiply transfused patients with sickle cell disease in Nigeria. Biomarker Research. 2015;**3**:26

[174] Jeremiah ZA, Mordi A, Buseri FI, Adias TC. Frequencies of maternal red blood cell alloantibodies in Port Harcourt, Nigeria. Asian J Transfus Sci. 2011;**5**:39-41

[175] Nadarajan SN, Hlaing AA, Maung TH, Jeyajoti I, Kyu TN, Ranjana KJ, et al. Incidence of red cell alloantibodies in a multi-ethnic hospital patient population. Vox Sanguinis. 2007;**93**:63-64

[176] Schonewille H, van de Watering LMG, Loomans DSE, Brand A. Red blood cell alloantibodies after transfusion: Factors influencing incidence and specificity. Transfusion. 2006;**46**:250-256

[177] Yousuf R, Abdul Aziz S, Yusof N, Leong CF. Incidence of red cell alloantibody among the transfusion recipients of Universiti Kebangsaan Malaysia medical Centre. Indian Journal of Hematology and Blood Transfusion. 2013;**29**(2):65-70

[178] Qureshi H, Massey E, Kirwan D, Davies T, Robson S, White J, et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the foetus and newborn. Transfusion Medicine. 2014;**24**(1):8-20

[179] Clausen FB, Christiansen M, Steffensen R, et al. Report of the first nationally implemented clinical routine screening for fetal RHD in D− pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion. 2012;**52**:752-758

[180] Lindemburg ITM, van Kamp IL, van Zwet EW, et al. Increased perinatal *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation. BJOG: An International Journal of Obstetrics andGynaecology. 2013;**120**:847-852

[181] Smith HM, Shirey RS, Thoman SK, Jackson JB. Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary care facility. Immunohematology. 2013;**29**:127-130

[182] Wassie GT, Belete MB, Tesfu AA, Bantie SA, Ayenew AA, Endeshaw BA, et al. Association between antenatal care utilization pattern and timely initiation of postnatal care checkup: Analysis of 2016 Ethiopian demographic and health survey. PLoS One. 2021;**16**(10):e0258468

[183] Okeke TC, Ocheni S, Nwagha UI, Ibegbulam OG. The prevalence of rhesus negativity among pregnant women in Enugu, Southeast Nigeria. Nigerian Journal of Clinical Practice. 2012;**15**(4):400-402

[184] Smith HM, Shirey RS, Thoman SK, Jackson JB. Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary care facility. Immunohematology. 2013;**29**:127-130

[185] Pegoraro V, Urbinati D, Visser GHA, Di Renzo GC, Zipursky A, Stotler BA, et al. Hemolytic disease of the fetus and newborn due to Rh(D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children. PLoS One. 2020;**15**(7):e0235807

[186] Krywko DM, Yarrarapu SNS, Shunkwiler SM. Kleihauer Betke test. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. [Updated 2021 Aug 11] Available from: https://www.ncbi.nlm.nih.gov/books/ NBK430876/

[187] Kim YA, Makar RS. Detection of fetomaternal hemorrhage. American Journalof Hematology. 2012;**87**(4):417-423

[188] Tiblad E, Taune Wikman A, Ajne G, Blanck A, Jansson Y, Karlsson A, et al. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program. PLoS One. 2013;**8**(8):e70984

[189] Urgessa F, Tsegaye A, Gebrehiwot Y, Birhanu A. Assessment of feto-maternal haemorrhage among rhesus D negative pregnant mothers using the Kleihauerbetke test (KBT) and flow cytometry (FCM) in Addis Ababa, Ethiopia. BMC Pregnancy and Childbirth. 2014;**14**(1):358

[190] Golassa L, Tsegaye A, Erko B, Mamo H. High rhesus (Rh(D)) negative frequency and ethnic- group based ABO blood group distribution in Ethiopia. BMC Research Notes. 2017;**10**(1):330

[191] McBain RD, Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing rhesus alloimmunisation. Cochrane Database of Systematic Reviews. 2015;**2015**(9):CD000020

[192] Ayenew AA. Prevalence of rhesus D-negative blood type and the challenges of rhesus D immunoprophylaxis among obstetric population in Ethiopia: A systematic review and meta-analysis. Maternal Health, Neonatology and Perinatology. 2021;**7**(1):8

[193] National Institute for Health and Clinical Excellence (NICE G156). 2008 WHO Reproductive Health Library. WHO Recommendation on Antenatal Anti-D Immunoglobulin Prophylaxis. December 2016

[194] Chanko KP. Frequency of ABO blood group and Rh (D) negative mothers among pregnant women attending at antenatal Care Clinic of Sodo Health Center, SNNPR, Ethiopia. American Journal of Clinical and Experimental Medicine. 2020;**8**:10-14

[195] Chilcott J, Lloyd JM, Wight J, Forman K, Wray J, Beverley C, et al. A Review of the Clinical Effectiveness and Cost-Effectiveness of Routine Anti-D Prophylaxis for Pregnant Women Who Are Rhesus-Negative. United Kingdom: NICE Technology Appraisal Guidance; 2022. p. 41

[196] Nadarajan SN, Hlaing AA, Maung TH, Jeyajoti I, Kyu TN, Ranjana KJ, et al. Incidence of red cell alloantibodies in a multi-ethnic hospital patient population. Vox Sanguinis. 2007;**93**:63-64

[197] Schonewille H, van de Watering LMG, Loomans DSE, Brand A. Red blood cell alloantibodies after transfusion: Factors influencing incidence and specificity. Transfusion. 2006;**46**:250-256

[198] Yousuf R, Abdul Aziz S, Yusof N, Leong CF. Incidence of red cell alloantibody among the transfusion recipients of Universiti Kebangsaan Malaysia medical Centre. Indian Journal of Hematology and Blood Transfusion. 2013;**29**(2):65-70

[199] Xie XFQ, Bao Z, Zhang Y, Zhou D. Clinical value of different anti-D immunoglobulin strategies for preventing Rh haemolytic disease of the foetus and newborn: A network metaanalysis. PLoS One. 2020;**15**(3):e0230073

[200] American College of Obstetricians and Gynaecologists. ACOG practice bulletin No. 181: Prevention of Rh D alloimmunization. Clinical

management guidelines for obstetriciangynaecologists. Obstetrics & Gynaecology. 2017;**130**(2):e57-e70

[201] De Vries RR, Faber JC, Strengers PF. Haemovigilance: An effective tool for improving transfusion practice. Vox Sanguinis. 2011;**100**:60-67

[202] Wood EM, Ang AL, Bisht A, Bolton-Maggs PH, Bokhorst AG, Flesland O, et al. International haemovigilance: What have we learned and what do we need to do next? Transfusion Medicine. 2019;**29**:221-230

[203] Diekamp U, Gneißl J, Rabe A, Kießig ST. Donor Hemovigilance with blood donation. Transfusion Medicine and Hemotherapy. 2015;**42**(3):181-192

[204] Stainsby D, Faber JC, Jorgensen J. Overview of hemovigilance. In: Simon TL, Solheim BG, Straus RG, Snyder EL, Stowell CP, editors. Rossi's Principles of Transfusion Medicine. 4th ed. West Sussex: Blackwell Publishing; 2009. p. 694

[205] Jean-Claude F. Hemovigilance: Definition and overview of current Hemovigilance systems. Transfusion Alternatives in Transfusion Medicine. 2008;**5**(1):237-245

[206] Ministry of Health and Family Welfare, Government of India. National Blood Policy. New Delhi: National AIDS Control Organisation; 2003

[207] Faber JC. The European blood directive: A new era of blood regulation has begun. Transfusion Medicine. 2004;**14**:257-273

[208] Watson R. EU tightens rules on blood safety. BMJ. 2005;**331**:800

[209] Proposed standard definitions for surveillance of noninfectious

*Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

adverse transfusion rections [Internet] International Haemovigilance Network. 2011. [Last Accessed on 2012 Jun 25]. Available from: http://www.isbtweb. org/fileadmin/user\_upload/WP\_on\_ Haemovigilance/ISBT\_definitions\_ final\_2011\_.pdf

[210] Samukange WT, Kluempers V, Porwal M, Mudyiwenyama L, Mutoti K, Aineplan N, et al. Implementation and performance of haemovigilance systems in 10 sub-saharan African countries is sub-optimal. BMC Health Services Research. 2021;**21**(1):1258

[211] Lemssahli I, Hajjout K, Benajiba M, Belmekki A. Haemovigilance recipients at the Rabat regional blood transfusion Center 2015-2019. Acta Scientific Paediatrics. 2021;**4**(3):56-62

[212] Dahourou H, Tapko JB, Nébié Y. et al, Implementation of hemovigilance in sub-Saharan Africa. Transfusion clinique et biologique : journal de la Société française de transfusion sanguine. 2012;**19**:39-45

[213] Ogunbanjo G. Are there alternatives to the shortage of blood in South Africa? South African Family Practice. 2014;**56**:5. DOI: 10.1080/20786190.2014.1002985

[214] Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfusion Medicine Reviews. 2003;**17**:120-162

[215] Jimenez K, Kulnigg-Dabsch S, Gasche C. Management of iron deficiency anemia. Gastroenterología y Hepatología. 2015;**11**(4):241-250

[216] Muñoz M. Editorial: Iron therapy in clinical practice: An overview. Transfusion Alternatives in Transfusion Medicine. 2012;**12**(3-4):41-43. DOI: 10.1111/j.1778-428X.2012.01179.x

[217] Mpoya A, Kiguli S, Olupot-Olupot P, et al. Transfusion and treatment of severe anaemia in African children (TRACT): A study protocol for a randomised controlled trial. Trials. 2015;**6**:593. DOI: 10.1186/s13063-015-1112-4

[218] Khalafallah A, Dennis A, Bates J, Bates G, Robertson IK, Smith L, et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J intern med. 2010 Sep;268(3):286-95Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: A systematic review of the literature. Critical Care Medicine. 2008;**36**:2667-2674

[219] Villanueva C, Alan C, Alba B, et al. Transfusion strategies for acute upper gastrointestinal bleeding. The New England Journal of Medicine. 2013;**368**(1):11-21

[220] Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoeisis. Transfusion. 2012;**52**:1584-1592

[221] KDOQI, National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anaemia in chronic kidney disease in adults. American Journal of Kidney Diseases. 2006;**47**(5):S16-S85

[222] Hofmann A, Farmer S, Towler SC. Strategies to preempt and reduce the use of blood products: An Australian perspective. Current Opinion in Anaesthesiology. 2012;**25**:66-73

[223] Munoz M, Gomez-Ramirez S, Bhandari S. The safety of available treatment options for iron- deficiency anemia. Expert Opinion on Drug Safety. 2018;**17**(2):149-159

[224] Shin HW, Park JJ, Kim HJ, You HS, Choi SU, Lee MJ. Efficacy of perioperative intravenous iron therapy for transfusion in orthopedic surgery: A systematic review and meta-analysis. PLoS One. 2019;**14**(5):e0215427

[225] Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: A review of its use in iron-deficiency anaemia. Drugs. 2009;**69**:739-756

[226] Fishbane S. Review of issues relating to iron and infection. American Journal of Kidney Diseases. 1999;**34**(4):S47-S52

[227] Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomized clinical trials. BMJ. 2015;**347**:f4822.

[228] Ionescu A, Sharma A, Kundnani NR, et al. Intravenous iron infusion as an alternative to minimize blood transfusion in peri-operative patients. Scientific Reports. 2020;**10**:18403. DOI: 10.1038/ s41598-020-75535-2

[229] Jelkmann, W. Physiology and Pharmacology of Erythropoietin. Transfusion Medicine Hemotherapy (Switzerland). 2013;**40**(5):302-309

[230] Jelkmann W. Erythropoietin. Frontiers of Hormone Research. 2016;**47**:115-127

[231] Zarychanski R, Turgeon AF, McIntyre L, et al. Erythropoietinreceptor agonists in critically ill patients: A meta-analysis of randomized controlled trials. CMAJ. 2007;**177**:725-734

[232] Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. The New England Journal of Medicine. 2007;**357**:965-976

[233] Shin HJ, Ko E, Jun I, Kim HJ, Lim CH. Effects of perioperative erythropoietin administration on acute kidney injury and red blood cell transfusion in patients undergoing cardiac surgery: A systematic review and meta-analysis. Medicine (Baltimore). 2022;**101**(9):e28920

[234] Alghamdi AA, Albanna MJ, Guru V, Brister SJ. Does the use of erythropoietin reduce the risk of exposure to allogeneic blood transfusion in cardiac surgery? A systematic review and metaanalysis. Journal of Cardiac Surgery. 2006;**21**(3):320-326

[235] Jelkmann W. Physiology and pharmacology of erythropoietin. Transfusion Medicine and Hemotherapy. 2013 Oct;**40**(5):302-309

[236] McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, et al. Cardiovascular toxicity of epoetinalfa in patients with chronic kidney disease. American Journal of Nephrology. 2013;**37**(6):549-558

[237] Gershanik J, Boecler B, Ensley H, McCloskey S, George W. The gasping syndrome and benzyl alcohol poisoning. The New England Journal of Medicine. 1982;**307**(22):1384-1388

[238] Adias TC, Jeremiah Z, Uko E, Osaro E. Autologous blood transfusion – A review. SAJS. 2006;**44**(3):114-118

[239] Blumberg N, Vanderlinde ES, Heal JM. Autologous transfusion. BMJ. 2002;**324**:772-775

[240] Parker-Williams EJ. Autologous blood transfusion. Postgraduate Doctor: Africa. 1989;**11**:52-56

*Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

[241] Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion medicine. Second of two parts — Blood conservation. The New England Journal of Medicine. 1999;**340**:525-533

[242] Huet C, Salmi LR, Fergusson D, et al. A meta-analysis of the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac and orthopedic surgery. International Study of Perioperative Transfusion (ISPOT) Investigators Anesth Analg. 1999;**89**:861-869

[243] Hayden SJ, Albert TJ, Watkins TR, Swenson ER. Anemia in critical illness: Insights into etiology, consequences, and management. American Journal of Respiratory and Critical Care Medicine. 2012;**185**(10):1049-1057

[244] Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care investigators, Canadian critical care trials group. The New England Journal of Medicine. 1999;**340**:409-417

[245] Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in paediatric intensive care units. The New England Journal of Medicine. 2007;**356**:1609-1619

[246] Tinmouth AT, McIntyre LA, Fowler RA. Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients. CMAJ. 2008;**178**(1):49-57

[247] Kirpalani H, Whyte RK, Andersen C, et al. The premature infants in need of transfusion (PINT) study: A randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. The Journal of Pediatrics. 2006;**149**:301-307

[248] Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. The New England Journal of Medicine. 2001;**345**:1230-1236

[249] Hardy JF, de Moerloose P, Samama CM. The coagulopathy of massive transfusion. Vox Sanguinis. 2005;**89**:123-127

[250] Snyder EL. Component therapy to cellular therapy and beyond—A Darwinian approach to transfusion medicine. Transfusion. 2008;**48**(9):2000-2007

[251] Makarovska-Bojadzieva T, Blagoevska M, Kolevski P, Kostovska S. Optimal blood grouping and antibody screening for safe transfusion. Contributions / Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences. 2009;**30**(1):119-128

[252] Hoeltge GA, Domen RE, Rybicki LA, Schaffer PA. Multiple red cell transfusions and alloimmunization. Experiences with 6996 antibodies detected in a total of 159,262 patients from 1985-1993. Archives of Pathology & Laboratory Medicine. 1995;**119**:42-45

[253] Boisen ML, Collins RA, Yazer MH, Waters JH. Pretransfusion testing and transfusion of uncrossmatched erythrocytes. Anesthesiology. 2015;**122**:191-195

[254] Makarovska-Bojadzieva T, Velkova E, Blagoevska M. The impact of extended typing on red blood cell Alloimmunization in transfused patients. Open Access Macedonian Journal of Medical Sciences. 2017;**5**(2):107-111

[255] Azarkeivan A, Ansari S, Ahmadi MH, Hajibeigy B, Maghsudlu M, Nasizadeh S, et al. Blood transfusion

and alloimmunization in patients with thalassemia: Multicenter study. Pediatric Hematology and Oncology. 2011;**28**(6):479-485

[256] Sanz C, Nomdedeu M, Belkaid M, Martinez I, Nomdedeu B, Pereira A. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion. 2013;**53**(4):710-715

[257] Vichinsky EP, Luban NL, Wright E, Olivieri N, Driscoll C, Pegelow CH, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anaemia: A multicenter transfusion trial. Transfusion. 2001;**41**(9):1086-1092

[258] Mark HY, Jonathan HW, Philip C. Spinella on behalf of the AABB (formerly known as the American Association of Blood Banks)/trauma, Hemostasis, oxygenation resuscitation network (THOR) working party; use of Uncrossmatched erythrocytes in emergency bleeding situations. Anesthesiology. 2018;**128**:650-656

[259] Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. The New England Journal of Medicine. 1990;**323**:315-321

[260] Kopolovic I, Ostro J, Tsubota H, Lin Y, Cserti-Gazdewich CM, Messner HA, et al. A systematic review of transfusion-associated graft-versushost disease. Blood. 2015;**126**:406-414

[261] Manduzio P. Transfusionassociated graft-versus-host disease: A concise review. Hematology Reports. 2018;**10**(4):7724

[262] Hutchinson K, Kopko PM, Muto KN, Tuscano J, O'Donnell RT, Holland PV, et al. Early diagnosis and successful treatment of a patient with transfusion associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion. 2002;**42**:1567-1572

[263] Leitman SF, Tisdale JF, Bolan CD, Popovsky MA, Klippel JH, Balow JE, et al. Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion. 2003;**43**:1667-1671

[264] Slivnick DJ, Ellis TM, Nawrocki JF, Fisher RI. The impact of Hodgkin's disease on the immune system. Seminars in Oncology. 1990;**17**:673-682

[265] Treleaven J, Gennery A, Marsh J, Norfolk D, Page L, Parker A, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in haematology blood transfusion task force. British Journal of Haematology. 2011;**152**:35-51

[266] Robinson S, Harris A, Atkinson S, Atterbury C, Bolton-Maggs P, Elliott C, et al. The administration of blood components: A British Society for Haematology guideline. Transfusion Medicine. 2018;**28**(1):3-21

[267] Vassallo RR, Murphy S. A critical comparison of platelet preparation methods. Current Opinion in Hematology [Review]. 2006;**13**(5):323-330

[268] Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, et al. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. [Comparative Study Evaluation Studies]. 2007;**40**(5):461-464

*Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

[269] Schrezenmeier H, Seifried E. Buffycoat-derived pooled platelet concentrates and apheres is platelet concentrates: Which product type should be preferred? Vox Sanguinis [Review]. 2010;**99**(1):1-15

[270] Heddle NM, Arnold DM, Boye D, et al. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: A systematic review. 2008. In: Database of Abstracts of Reviews of Effects (DARE): Quality-Assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995. Available from: https://www. ncbi.nlm.nih.gov/books/NBK75900/

[271] Andreu G, Vasse J, Sandid I, Tardivel R, Semana G. Use of random versus apheresis platelet concentrates. Transfusion Clinique et Biologique. 2007;**14**(6):514-521

[272] Hod E, Schwartz J. Platelet transfusion refractoriness. British Journal of Haematology. 2008;**142**(3):348-360

[273] Belizaire R, Makar RS. Non-Alloimmune mechanisms of thrombocytopenia and refractoriness to platelet transfusion. Transfusion Medicine Reviews. 2020;**34**(4):242-249

[274] Kekomäki R. Use of HLAand HPA—Matched platelets in alloimmunized patients. Vox Sanguinis. 1998;**74**(2):359-363

[275] Saris A, Pavenski K. Human leukocyte antigen Alloimmunization and Alloimmune platelet refractoriness. Transfusion Medicine Reviews. 2020;**34**(4):250-257

[276] Rebulla P. A mini review on platelet refractoriness. Haematologica. 2005;**90**(2):247-253

[277] Marktel S, Napolitano S, Zino E, et al. Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation. Pediatric Transplantation. 2010;**14**(3):393-401

[278] Cohn CS. Platelet transfusion refractoriness: How do I diagnose and manage? Hematology. American Society of Hematology. Education Program. 2020;**2020**(1):527-532

[279] Amemiya Y. Platelet transfusion refractoriness and effective management of platelet alloimmunization. Nihon Rinsho. 1997;**55**(9):2392-2398

[280] Cardigan R, New HV, Tinegate H, Thomas S. Washed red cells: Theory and practice. Vox Sanguinis. 2020;**115**(8):606-616

[281] Acker JP, Hansen AL, Yi QL, et al. Introduction of a closed-system cell processor for red blood cell washing post implementation monitoring of safety and efficacy. Transfusion. 2016;**56**(1):49-57

[282] Masalunga C, Cruz M, Porter B, Roseff S, Chui B, Mainali E. Increased hemolysis from saline pre-washing RBCs or centrifugal pumps in neonatal ECMO. Journal of Perinatology. 2007;**27**(6):380-384

[283] Liu C, Liu X, Janes J, et al. Mechanism of faster NO scavenging by older stored red blood cells. Redox Biology. 2014;**2**:211-219

[284] Razonable RR, Humar A. AST infectious diseases Community of Practice. Cytomegalovirus in solid organ transplantation. American Journal of Transplantation. 2013;**13**(4):93-106

[285] Kotton CN. CMV: Prevention, diagnosis and therapy. American Journal of Transplantation. 2013;**13**(3):24-40

[286] Azevedo LS, Pierrotti LC, Abdala E, Costa SF, Strabelli TM, Campos SV, et al.

Cytomegalovirus infection in transplant recipients. Clinics (São Paulo, Brazil). 2015;**70**(7):515-523

[287] Jebakumar D, Bryant P, Linz W. Risk of cytomegalovirus transmission by blood products after solid organ transplantation. Proceedings (Baylor University. Medical Center). 2019;**32**(2):222-226

[288] Sharma RR, Marwaha N. Leukoreduced blood components: Advantages and strategies for its implementation in developing countries. Asian Journal of Transfusion Science. 2010;**4**:3-8

[289] Myers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. The Journal of Infectious Diseases. 1986;**153**:478-488

[290] Kotton CN, Kumar D, Caliendo AM, et al. Transplantation society international CMV consensus group. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;**102**:900-931

[291] Tagny CT, Mbanya D, Tapko JB, Lefrère JJ. Blood safety in sub-Saharan Africa: A multi- factorial problem. Transfusion. 2008;**48**(6):1256-1261

[292] World Health Assembly resolution WHA28.72 Utilization and Supply of Human Blood and Blood Products. 1975

[293] World Health Assembly resolution WHA58.13 (Blood Safety) Proposal to Establish World Blood Donor Day. 2005WHA58/2005/REC/1. 2005

[294] World Health Organization Global database on blood safety: report 2001-2002. Available from: http://

www.who.int/bloodsafety/GDBS\_ Report\_2001-2002.pdf. [Accessed Nov 8 2010]

[295] Murphy E, Sanchez-Guerrero SA, Valiente-Banuet L, et al. Demographic characteristics, and infectious disease markers in blood donors in the Mexico-US border region (abstract). Vox Sanguinis. 2010;**99**:2

[296] Urbaniak SJ, Greiss MA. RhD haemolytic disease of the foetus and the newborn. Blood Reviews. 2000;**14**:44-461

[297] Liu KL, Li N, Li BJ, Peng JY, Shu XW, Yu YY. Clinical significance of anti-D IgG screening and titer detection in 286 RhD negative pregnant women. Zhongguo Dang Dai Er Ke Za Zhi. 2009;**11**(3):185-187

[298] Mari G, Deter RL, Carpenter RL, Rahman F, Zimmerman R, Moise KJ Jr, et al. Non-invasive diagnosis by Doppler ultrasonography of foetal anaemia due to maternal red cell alloimmunization. Collaborative Group for Doppler Assessment of the blood velocity in anaemic foetuses. The New England Journal of Medicine. 2000;**342**:9-14

[299] Moise KJ. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Seminars in Fetal & Neonatal Medicine. 2008;**13**:207-214

[300] Nordvall M, Dziegiel M, Hegaard HK, Bidstrup M, Jonsbo F, Christensen B, et al. Red blood cell antibodies in pregnancy and their clinical consequences: Synergistic effects of multiple specificities. Transfusion. 2009;**49**:2070-2075

[301] Eryilmaz M, Müller D, Rink G, Klüter H, Bugert P. Introduction of non-invasive prenatal testing for blood group and platelet antigens from *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

cell-free plasma DNA using digital PCR. Transfusion Medicine and Hemotherapy. 2020;**47**(4):292-301

[302] Armstrong-Fisher S, Koushki K, Mashayekhi K, Urbaniak SJ, Schoot E, Varzi AM. Confirmed non-invasive prenatal testing for foetal Rh blood group genotyping along with bi-allelic short insertion/deletion polymorphisms as a positive internal control. Transfusion Medicine. 2022;**32**(2):141-152. DOI: 10.1111/tme.12858

[303] Rieneck K, Clausen FB, Dziegiel MH. Non-invasive antenatal determination of foetal blood group using next-generation sequencing. Cold Spring Harbor Perspectives in Medicine. 2015;**6**(1):a023093

[304] Clausen FB, Jakobsen TR, Rieneck K, Krog GR, Nielsen LK, Tabor A, et al. Pre-analytical conditions in non-invasive prenatal testing of cellfree fetal RHD. PLoS One. 2013;**8**:e76990

[305] Rieneck K, Bak M, Jønson L, Clausen FB, Krog GR, Tommerup N, et al. Next-generation sequencing: Proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free foetal DNA in maternal plasma. Transfusion. 2013;**53**:2892-2898

[306] Condero D, Stampalija T, Bolzicco D, Castro Silva E, Candolini M, Cortivo C, et al. Fetal RHD detection from circulating cell-free fetal DNA in maternal plasma: Validation of a diagnostic kit using automatic extraction and frozen DNA. Transfusion Medicine. 2019;**29**(6):408-414

[307] Finning KM, Martin PG, Soothill PW, Avent ND. Prediction of fetal D status from maternal plasma: Introduction of a new non-invasive foetal RHD genotyping service. Transfusion. 2002;**42**:1079-1085

[308] Van der Schoot CE, Hayn S, Chitty LS. Non-invasive prenatal diagnosis and determinism of fetal Rh status. Seminars in Fetal & Neonatal Medicine. 2008;**13**(2):63-68

[309] Zipursky A, Paul VK. The global burden of Rh disease. Archives of Disease in Childhood. Fetal and Neonatal Edition. 2011;**96**:84-85

[310] Tagny CT, Fongué VF, Mbanya D. Erythrocyte phenotype in ABO and Rh blood groups in blood donors and blood recipients in a hospital setting of Cameroon: Adapting supply to demand. Revue Médicale de Bruxelles. 2009;**30**:159-162

[311] Mwangi J. Blood group distribution in an urban population of patient targeted blood donors. East African Medical Journal. 1999;**76**:615-618

[312] Loua A, Lamah MR, Haba NY, Camara M. Frequency of blood groups ABO and rhesus D in the Guinean population. Transfusion Clinique et Biologique. 2007;**14**:435-439

[313] NICE. The clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for RhD-negative women in pregnancy. Technology appraisals TA41. 2002

[314] Ford J, Soothill P. Cell-free DNA foetal blood group testing for RhDnegative pregnant women: Implications for midwifery. Clinical Practice. British Journal of Midwifery. 2016;**2**(2)

[315] Finning K, Martin P, Summers J, et al. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: Prospective feasibility study. BMJ. 2008;**336**(7648):816-818

[316] Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish hepatology research group. The New England Journal of Medicine. 1999;**340**(16):1228-1233

[317] van der Schoot CE, Soussan AA, Koelewijn J, Bonsel G, Paget-Christiaens LG, de Haas M. Noninvasive antenatal RHD typing. Transfusion Clinique et Biologique. 2006;**13**(1-2):53-57

[318] Natukunda B, Schonewille H, Smit Sibinga CT. Assessment of the clinical transfusion practice at a regional referral hospital in Uganda. Transfusion Medicine. 2010;**20**(3):134-139

[319] Smit-Sibinga CT. Total quality management in blood transfusion. Vox Sanguinis. 2000;**78**(2):281-286

[320] Berte LM. Tools for improving quality in the transfusion service. American Journal of Clinical Pathology. 1997;**107**(4 Suppl 1):S36-S42

[321] Commission directive 2005/61/EC of 30 September 2005 implementing directive 2002/98/EC of the European Parliament and of the council as regards traceability requirements and notifications of serious adverse reactions and events. Official Journal of the European Union. 2005;**L256**:32

[322] Strengers P. Key elements of a blood transfusion quality management system, the tools and objectives. Special Issue: State of the Art Presentations. 21st Regional Congress of the ISBT. Europe-Lisbon, Portugal, Vox Sanguine. 2011;**101**(1):1-370

[323] Chaffe B, Glencross H, Jones J, Staves J, Capps-Jenner A, Mistry H, et al. UK transfusion laboratory collaborative: Minimum standards for staff

qualifications, training, competency and the use of information technology in hospital transfusion laboratories 2014. Transfusion Medicine. 2014;**24**(6):335-340

[324] NHS England. 2014. Pathology quality assurance review. Available from: http://www.england.nhs.uk/ publications/ind-rev/ [Accessed 21/10/14]

[325] Najafpour Z, Hasoumi M, Behzadi F, Mohamadi E, Jafary M, Saeedi M. Preventing blood transfusion failures: FMEA, an effective assessment method. BMC Health Services Research. 2017;**17**(1):453

[326] Sazama K. Reports of 355 transfusion-associated deaths:1976 through 1985. Transfusion. 1990;**30**:583-590

[327] Kohn LT, Corrigan JM, Donaldson MS. To err is human: Building a safer health system. In: Committee on Health Care in America. Institute of Medicine. Washington (DC): National Academy Press; 1999

[328] Osaro E, Chima N. Challenges of a negative workload and implications on morale, productivity and quality of service delivered in NHS laboratories in England. Asian Pacific Journal of Tropical Biomedicine. 2014;**4**(6):421-429

[329] Misau YA, Al-Sadat N, Gerei AB. Brain-drain and health care delivery in developing countries. Journal of Public Health in Africa. 2010;**1**(1):e6

[330] Hagopian A, Thompson MJ, Fordyce M, et al. The migration of physicians from sub-Saharan Africa to the United States of America: Measures of the African brain drain. Human Resources for Health. 2004;**2**:17

*Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

[331] Astor A, Akhtar T, Matallana MA, et al. Physician migration: Views from professionals in Colombia, Nigeria, India, Pakistan and the Philippines. Social Science & Medicine. 2005;**61**:2492-2500

[332] Kirigia JM, Gbary AR, Muthuri LK, et al. The cost of health professionals' brain drain in Kenya. BMC Health Services Research. 2006;**6**:89

[333] Haynes BP. An evaluation of the impact of the office environment on productivity. Facilities. 2008;**26**(5/6):178-195

[334] Cronk R, Bartram J. Environmental conditions in health care facilities in lowand middle- income countries: Coverage and inequalities. International Journal of Hygiene and Environmental Health. 2018;**221**(3):409-422

[335] World Health Organization. Essential Environmental Health Standards in Health Care WHO. Geneva: Switzerland; 2008

[336] Erasmus V, Daha TJ, Brug H, Richardus JH, Behrendt MD, Vos MC, et al. Systematic review of studies on compliance with hand hygiene guidelines in hospital care. Infection Control and Hospital Epidemiology. 2010;**31**(3):283-294

[337] Basu D, Kulkarni R. Overview of blood components and their preparation. Indian Journal of Anaesthesia. 2014;**58**(5):529-537

[338] Altin S, Altin A, Elevli B, Cerit O. Determination of hospital waste composition and disposal methods: A case study. Polish Journal of Environmental Studies. 2003;**12**(2):251-255

[339] Diaz LF, Eggerth LL, Enkhtsetseg SH, Savage GM. Characteristics of health carewaste. Waste Management. 2008;**28**(7):1219-1226

[340] Imam A, Mohammed B, Wilson DC, Cheeseman CR. Solid waste management in Abuja, Nigeria. Waste Management. 2008;**28**:468-472

[341] Wilson DC, Velis CA. Waste management—Still a global challenge in the 21st century: An evidence-based call for action. Waste Management & Research. 2015;**33**(12):1049-1051

[342] Godfrey L, Ahmed MT, Gebremedhin KG, Katima JH, Oelofse S, Osibanjo O, et al. Solid waste Management in Africa: Governance failure or development opportunity? In: Edomah N, editor. Regional Development in Africa [Internet]. London: IntechOpen; 2019. DOI: 10.5772/intechopen.86974

[343] Wilkinson R. Equipment and materials management. Introduction to Blood Transfusion Technology. 2006;**3**(2):248-253

[344] Guide to the preparation, use and quality assurance of blood components. In: European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS ). 19th Edition. 2007:45-49

[345] Jones RG, Johnson OA, Batstone G. Informatics and the clinical laboratory. Clinical Biochemist Reviews. 2014;**35**(3):177-192

[346] Nevalainen DE. Documentation and record keeping: The key to compliance. In: Sibinga CTS, Das PC, Heiniger HJ, editors. Good Manufacturing Practice in Transfusion Medicine. Developments in Hematology and Immunology. Vol. 29. Boston, MA: Springer; 1994. DOI: 10.1007/978-1-4615-2608-7\_16

[347] Ardenghi D, Martinengo M, Bocciardo L, Nardi P, Tripodi G. Near miss errors in transfusion medicine: The experience of the G. Gaslini transfusion medicine service. Blood Transfusion. 2007;**5**(4):210-216

[348] Jersild C, Hafner V. Blood transfusion services. International Encyclopedia of. Public Health. 2017:247-253. DOI: 10.1016/ B978-0-12-803678-5.00037-0

[349] Uríz MJ, Antelo ML, Zalba S, Ugalde N, Pena E, Corcoz A. Improved traceability and transfusion safety with a new portable computerised system in a hospital with intermediate transfusion activity. Blood Transfusion. 2011;**9**(2):172-181

[350] Samukange WT, Kluempers V, Porwal M, Mudyiwenyama L, Mutoti K, Aineplan N, et al. Implementation and performance of haemovigilance systems in 10 sub-Saharan African countries is sub-optimal. BMC Health Services Research. 2021;**21**(1):1258

[351] Tazi I, Loukhmas L, Benchemsi N. Hémovigilance: bilan 1995- 2003 Casablanca. Transfusion Clinique et Biologique. 2005;**12**(3):257-274

[352] Ouadghiri S, Atouf O, Brick C, Benseffaj N, Essakalli M. Traçabilité des produits sanguins labiles au Maroc: expérience de l'hôpital Ibn-Sina de Rabat entre 1999 et 2010. Transfusion Clinique et Biologique. 2012;**19**(1):1-4

[353] Hughes RG. Tools and strategies for quality improvement and patient safety. In: Hughes RG, editor. Patient Safety and Quality: An Evidence-Based Handbook for Nurses. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008. Chapter 44 Available from: https:// www.ncbi.nlm.nih.gov/books/NBK2682/ [354] Rodziewicz TL, Houseman B, Hipskind JE. Medical error reduction and prevention. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2022. [Updated 2022May1] Available from: https://www.ncbi.nlm. nih.gov/books/NBK499956/

[355] Hergon E. L'audit qualité dans l'établissement de transfusion sanguine [The quality audit in a blood transfusion center]. Transfusion Clinique et Biologique. 1998;**5**(6):422-430

[356] John DC. Quality assurance in the blood transfusion services. Proceedings of the Royal Society of Edinburgh, Section B: Biological Sciences. 1993;**101**:241-249

[357] Murphy MF, Stanworth SJ, Yazer M. Transfusion practice and safety: Current status and possibilities for improvement. Vox Sanguinis. 2011;**100**(1):46-59

[358] World Health Organization (WHO). Towards 100% voluntary blood donation: A global framework for action. In: 2, Voluntary Blood Donation: Foundation of a Safe and Sufficient Blood Supply. Geneva: World Health Organization; 2010. Available from: https://www.ncbi. nlm.nih.gov/books/NBK305666/

[359] Stainsby D, Russell J, Cohen H, Lilleyman J. Reducing adverse events in blood transfusion. British Journal of Haematology. 2005;**131**:8-12

[360] Fastman BR, Kaplan HS. Errors in transfusion medicine: Have we learned our lesson? Mount Sinai Journal of Medicine. 2011;**78**(6):854-864

[361] Mancini ME. Performance improvement in transfusion medicine. What do nurses need and want? Archives of Pathology & Laboratory Medicine. 1999;**123**(6):496-502

*Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

[362] Lau FY, Cheng G. To err is human nature. Can transfusion errors due to human factors ever be eliminated? Clinica Chimica Acta. 2001;**313**:59-67

[363] Stout L, Joseph S. Blood transfusion: Patient identification and empowerment. The British Journal of Nursing. 2016;**25**(3):138-143

[364] Pagliaro P, Rebulla P. Transfusion recipient identification. Vox Sanguinis. 2006;**91**(2):97-101

[365] Lippi G, Plebani M. Identification errors in the blood transfusion laboratory: A still relevant issue for patient safety. Transfusion and Apheresis Science. 2011;**44**(2):231-233

[366] Oldham J. Blood transfusion sampling and a greater role for error recovery. The British Journal of Nursing. 2014;**23**(8):S28, S30-S28, S34

[367] Marconi M, Langeberg AF, Sirchia G, Sandler SG. Improving transfusion safety by electronic identification of patients, blood samples, and blood units. Immunohematology. 2000;**16**(2):82-85

[368] Moiza B, Siddiquib AK, Sanac N, Sadiqb MW, Karimd F, Alia N. Documentation errors in transfusion chain: Challenges and interventions. Transfusion and Apheresis Science. 2020;**59**:102812

[369] Robinson S, Harris A, Atkinson S, Atterbury C, Bolton-Maggs P, Elliott C, et al. The administration of blood components: a British Society for Haematology Guideline. Transfusion Medicine. 2018;**28**(1):3-21

[370] Fatima N, Anwar N, Ul Mujtaba H, Shamsi T. Compliance of documentation by health-care professionals: Evaluation of transfusion practices at bedside. Glob J Transfus Med. 2021;**6**:183-188

[371] O'Leary KJ, Buck R, Fligiel HM, et al. Structured interdisciplinary rounds in a medical teaching unit: Improving patient safety. Archives of Internal Medicine. 2011;**171**(7):678-784

[372] Tuckley V, Davies J, Poles D, Robbie C, Narayan S. Safe handovers: Safe patients-why good quality structured hand overs in the transfusion laboratory are important. Transfusion Medicine. 2022;**32**(2):135-140

[373] Zakrison TL, Rosenbloom B, McFarlan A, et al. Lost information during the handover of critically injured trauma patients: A mixedmethods study. BMJ Quality and Safety. 2016;**25**(12):929-936

[374] Murphy MF, Harris A, Neuberger J. SaBTO consent for transfusion working group. Consent for blood transfusion: Summary of recommendations from the advisory Committee for the Safety of blood, tissues, and organs (SaBTO). Clinical Medicine (London, England). 2021;**21**(3):201-203

[375] Serious Hazards of Transfusion. Annual SHOT Report 2019. SHOT. 2020. Available from: www.shotuk.org/ wp-content/uploads/myimages/SHOT-REPORT-2019-Final-Bookmarked-v2.pdf

[376] Watson SB. Jehovah's witnesses and blood transfusion. Clinical Ethics Report. 1991;**5**(1):1-16

[377] Migden DR, Braen GR. The Jehovah's witness blood refusal card: Ethical and medicolegal considerations for emergency physicians. Academic Emergency Medicine. 1998;**5**(8):815-824

[378] Kleinman I. Written advance directives refusing blood transfusion: Ethical and legal considerations. The American Journal of Medicine. 1994;**96**(6):563-567

[379] Adams J. Respecting the right to be wrong. Academic Emergency Medicine. 1998;**5**(8):753-755

[380] Murphy MF, Harris A, Neuberger J. SaBTO consent for transfusion working group. Consent for blood transfusion: Summary of recommendations from the advisory Committee for the Safety of blood, tissues and organs (SaBTO). Clinical Medicine (London, England). 2021;**21**(3):201-203

[381] Pirie E, Green J. Should nurses prescribe blood components? Nursing Standard. 2007;**21**(39):35-41

[382] Latter S, Courtenay M. Effectiveness of nurse prescribing: A review of the literature. Journal of Clinical Nursing. 2004;**13**(1):26-32

[383] Klein AA, Arnold P, Bingham RM, Brohi K, Clark R, Collis R, et al. AAGBI guidelines: The use of blood components and their alternatives. Anaesthesia. 2016;**71**(7):829-842

[384] Bolton-Maggs PHB, Wood EM, Wiersum-Osselton JC. Wrong blood in tube – Potential for serious outcomes: Can it be prevented? British Journal of Haematology. 2015;**168**(1):3-13

[385] Askeland RW, McGrane SP, Reifert DR, Kemp JD. Enhancing transfusion safety with an innovative bar-code-based tracking system. Healthcare Quarterly. 2009;**12**:85-89

[386] BCSH, Milkins C, Berryman J, Cantwell C, Elliott C, Haggas R, et al. Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. Transfusion Medicine. 2013;**23**:3-35

[387] Lumadue JA, Boyd JS, Ness PM. Adherence to a strict specimen-labeling policy decreases the incidence of

erroneous blood grouping of blood bank specimens. Transfusion. 1997;**37**:1169-1172

[388] Gonzalez-Porras JR, Graciani IF, Alvarez M, Pinto J, Conde MP, Nieto MJ, et al. Tubes for pretransfusion testing should be collected by blood bank staff and hand labelled until the implementation of new technology for improved sample labelling. Results of a prospective study. Vox Sanguinis. 2008;**95**:52-56

[389] Thomas W, Davies J, Asamoah A, Scott-Molloy C, Sansom V, Kerr J. Two samples for blood transfusion: Single Centre experience. Transfusion Medicine. 2014;**24**:209-212

[390] Ashford P, Gozzard D, Jones J, Revill J, Wallis J, Bruce M. Guidelines for blood bank computing. Transfusion Medicine. 2000;**10**:307-314

[391] Davies A, Staves J, Kay J, Casbard A, Murphy MF. End-to-end electronic control of the hospital transfusion process to increase the safety of blood transfusion: Strengths and weaknesses. Transfusion. 2006;**46**:352-364

[392] Strobel E. Hemolytic transfusion reactions. Transfusion Medicine and Hemotherapy. 2008;**35**(5):346-353

[393] Dubin CH. Technology, vigilance, and blood transfusions: How U.S. hospitals and the federal government are working to reduce adverse events. P T. 2010;**35**(7):374-376

[394] Olaniyi JA. Blood transfusion reactions. In: Tombak A, editor. Blood Groups. London, UK, London: Intech Open; 2019. DOI: 10.5772/ intechopen.85347

[395] Sharma G, Parwani AV, Raval JS, Triulzi DJ, Benjamin RJ, Pantanowitz L. *Optimizing Blood Transfusion Service Delivery across the West African Sub-Region DOI: http://dx.doi.org/10.5772/intechopen.108628*

Contemporary issues in transfusion medicine informatics. Journal of Pathology Informatics. 2011;**7**(2):3

[396] Wong KF. Virtual blood bank. Journal of Pathology Informatics. 2011;**2**:6. DOI: 10.4103/2153-3539.76155

[397] Najafpour Z, Hasoumi M, Behzadi F, Mohamadi E, Jafary M, Saeedi M. Preventing blood transfusion. Failures: FMEA, an effective assessment method. BMC Health Services Research. 2017;**17**(1):453

[398] Bolton-Maggs P. Blood transfusion safety: Patients at risk from human errors. British Journal of Hospital Medicine (London, England). 2013;**74**(10):544-545

[399] Crookston KP, Koenig SC, Reyes MD. Transfusion reaction identification and management at the bedside. Journal of Infusion Nursing. 2015;**38**(2):104-113

[400] Cottrell S, Davidson V. National audit of bedside transfusion practice. Nursing Standard. 2013;**27**(43):41-48

[401] Todd O, Sikwewa K, Kamp J, et al. Inadequate monitoring risks safety of blood transfusion in rural Zambia. Critical Care. 2015;**19**:P338. DOI: 10.1186/cc14418

[402] Tinegate H, Birchall J, Gray A, et al. Guideline on the investigation and management of acute transfusion reactions. Prepared by the BCSH blood transfusion task force. British Journal of Haematology. 2012;**159**:143-153

[403] Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: A literature review of infectious disease and organizational challenges. Transfusion Medicine Reviews. 2012;**26**(2):164-180

[404] World Health Organisation (WHO). Blood Safety and Availability: Facts and Figures from the 2007 Blood Safety Survey. Geneva, Switzerland: World Health Organisation (WHO); 2007

[405] Diane MK, Dembele B, Konate S. Blood collection to cover national needs in sub-Saharan Africa: The reality of the Ivory Coast. Blood Transfusion. 2014;**12**(4):624-625

[406] Godin G, Sheeran P, Conner M, et al. Factors explaining the intention to give blood among the general population. Vox Sanguinis. 2005;**89**:140-149

[407] Nagalo MB, Sanou M, Bisseye C, Kaboré MI, Nebie YK, Kienou K. Seroprevalence of human immunodefi ciency virus, hepatitis B and C viruses and syphilis among blood donors in Koudougou (Burkina Faso) in 2009. Blood Transfusion. 2011;**9**:419-424

[408] Shiferaw E, Tadilo W, Melkie I, Shiferaw M. Sero-prevalence and trends of transfusion-transmissible infections among blood donors at Bahir Dar district blood bank, Northwest Ethiopia: A four-year retrospective study. PLoS One. 2019;**14**(4):e0214755

[409] World Health Organization (WHO). Screening donated blood for transfusion-transmissible infections: Recommendations. In: 4, Screening for Transfusion-Transmissible Infections. Geneva: World Health Organization; 2009. Available from: https://www.ncbi. nlm.nih.gov/books/NBK142989/

[410] Song Y, Bian Y, Petzold M, Ung COL. Prevalence, and trend of major transfusion-transmissible infections among blood donors in Western China, 2005 through 2010. PLoS One. 2018;**9**(4):e94528

[411] World Health Organization. Blood Donor Selection and Counselling. Available from: http:www.who.int/ bloodsafety/voluntary\_donation/blood\_ donor\_selection/en/. [Last assessed on 2016 Mar 03].

[412] Schutz R, Savarit D, Kadjo JC, Batter V, Kone N, La Ruche G, et al. Excluding blood donors at high risk of HIV infection in a west African city. BMJ. 1993;**307**:1517-1519

[413] Ekwere T, Ino-Ekanem M, Motilewa O, Ibanga I. Pattern of blood donor deferral in a tertiary hospital, southsouth, Nigeria: A three-year study review. International Journal of Blood Transfusion and Immunohematology. 2014;**4**:7-13

[414] McFarland W, Kahn JG, Katzenstein DA, Mvere D, Shamu R. Deferral of blood donors with risk factors for HIV infection saves lives and money in Zimbabwe. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1995;**9**:183-192

[415] Beattie RH, Sturrock SM. What is the evidence for the change in the blood donation deferral period for high-risk groups and does it go far enough? Clinical Medicine. 2018;**18**(4):304-307

[416] Aneke CJ, Ezeh UT, Nwosu AG, Anumba EC. Retrospective evaluation of prospective blood donor deferral in a tertiary hospital-based blood bank in south-East Nigeria. Journal of Medicine in the Tropics. 2016;**18**:103-107

[417] Allain JP, Sarkodie F, Boateng P, et al. A pool of repeat blood donors can be generated with little expense to the blood center in sub-Saharan Africa. Transfusion. 2008;**48**:735-741

[418] Bates I, Chapotera GK, McKew S, et al. Maternal mortality in sub-Saharan Africa: The contribution of ineffective

blood transfusion services. BJOG : An International Journal of Obstetrics and Gynaecology. 2008;**115**:1331-1339

[419] Tapko JP, Toure B, Sambo LG, et al. Status of Blood Safety in the WHO African Region: Report of the 2006 Survey. Available from: http://www.afro. who.int/en/divisions-a-programmes/dsd/ health-technologies-a-laboratories.html

#### **Chapter 8**

## Clinical Effects and Possible Mechanisms of Transfusion-Related Immunomodulation

*Yavuz Memis Bilgin*

#### **Abstract**

Allogeneic blood components are commonly transfused in trauma, surgery, and intensive care units and are related with adverse effects, such as postoperative infections, multi-organ failure, and mortality. The adverse effects of blood transfusions on the immune system are called as transfusion-related immunomodulation (TRIM). Many clinical trials are conducted to show the clinical effects of TRIM. They found in different clinical settings controversial results. There are many possible mechanisms of TRIM. Although until now, the exact mechanisms are not elucidated resulting in a challenge to unravel this complex interaction between immunomodulation and clinical events leading to morbidity and mortality. It has been postulated that allogeneic leukocytes are associated with the clinical adverse effects of TRIM that predominantly is observed in high-risk patients as cardiovascular surgery. Allogeneic leukocytes could activate inflammation cascade leading to adverse events in high-risk patients. Also other blood components as red cells, plasma, and platelets can play a role in the development of inflammatory complications after blood transfusions. In this review, we will discuss the clinical effects and the possible mechanisms of TRIM in relation with allogeneic leukocytes and mediators derived from allogeneic blood transfusions.

**Keywords:** transfusion-related immunomodulation, red cells, leukocytes, plasma, platelets, infections, multi-organ dysfunction syndrome, mortality, inflammatory response, coagulation system

#### **1. Introduction**

Until the discovery of the *ABO blood groups* in the early 1900s blood transfusions were a high-risk procedure: more than 50% of the recipients of blood did not survive. The discovery of the ABO blood groups followed by the development of citrate as anticoagulant to prevent clotting of blood enabled the start of a long history of transfusion medicine. Since blood component transfusion of red blood cells (RBCs), platelet concentrates, and plasma became possible over time, blood transfusions became gradually considered as safe for the treatment of blood loss and other causes

of anemia [1]. Allogeneic blood components are commonly transfused in trauma, surgery, and intensive care units (ICUs); up to 60% of these patients receives a blood transfusion [2, 3]. It is known that allogeneic blood transfusions have adverse effects which can lead to deleterious outcome in recipients. These effects of allogeneic blood transfusions are called transfusion-related *immunomodulation* (TRIM). The clinical effects of TRIM are most seen in high-risk patients as to cardiac surgery [4]. In this review, we will focus on the clinical effects and possible mechanisms of TRIM, especially in patients at high risk.

#### **2. Transfusion-related immunomodulation (TRIM) in different clinical settings**

The existence and possible mechanisms of TRIM are not yet fully *disc*overed. Many factors might contribute to TRIM. Allogeneic leukocytes and (leukocyte-derived) soluble mediators in blood products were considered as most important [4]. Through filtration, the number of allogeneic leukocytes in donated blood can be reduced by more than 99.9% with a residual leukocyte count of less than 1x106 /L. Leukocyte-depleted blood transfusions were applied since the 1980s to reduce nonhemolytic febrile transfusion reactions, human leukocyte *antigen (HLA*) allo-immun*iza*tion, and *Cytomegalovirus* **(***CMV) transmission* in patients at risk. In early 2000s, in *many Western* countries, universal leukocyte depletion of allogeneic blood transfusion was implemented.

In the 1970s, it was *disc*overed that pre*transplantation* allogeneic blood transfusions improved a subsequent renal allograft survival [5]. It was hypothesized that allogeneic leukocytes present in the blood components could lead to an *immunosuppressive* transfusion effect resulting in impaired cancer surveillance and to su*scept*ibility for postoperative infections [4, 6, 7]. *Although, two* randomized controlled *trials (RCT*s) compared *buffy-coat-poor red* blood *cells (RBC*) with filtered RBC on cancer recurrence after colorectal surgery. Both studies found no difference in recurrence after 5 years [8, 9]. Therefore, a possible immu*nosup*pressive effect of allogeneic blood transfusion on cancer recurrence is not found.

On the other hand, many observational studies showed an association between postoperative infections *and allogeneic* blood transfusions. The presumption was that the immunosuppressive effect of *leuko*cyte-containing RBC transfusions was responsible for postoperative infections. *Many RCTs* were conducted in various clinical settings, evaluated postoperative after *leukoreduced (LR) RBC transfusions*. These studies varied as to *single- or multiple-center* design, clinical *diagnosis, methods* to document infections and proportion of transfused patients ranging between 14 and 95% and revealed different outcomes.

Several meta-analyses were performed investigating the effects of, allogeneic leukocyte-containing, buffy-coat-depleted (BCD) RBC transfusions, but these came also to controversial conclusions. Meta-analyses using intention-to-treat analyses seldom found an association between LR transfusions and postoperative infections [10]. A meta-analysis, restricted to transfused patients only, thereby excluding 36% of the study population, reported up to almost 60% reduction in postoperative infection after transfusion of LR RBC [11]. The effect of LR RBC was mainly observed in patients undergoing cardiac surgery. On the other hand, mortality was also investigated in different clinical settings. Overall, no adverse effect of leukocyte-containing transfusions on short-term mortality has been found. Only in cardiac surgery, the mortality rate was significantly decreased in patients who received LR RBC [10].

#### **3. Cardiac surgery and allogeneic blood transfusions**

Coronary artery bypass graft (CABG) surgery is a frequently performed intervention to re-vascularize the myocardium. Worldwide, approximately 1 million patients are undergoing cardiac surgery annually. The current mortality rate after cardiac surgery is low, and cardiac surgery has become a routine procedure. Although the number of patients who receive blood transfusions and the numbers of transfused blood products became lower in time, patients undergoing cardiac surgery still receive more blood transfusions compared to other surgical settings. Due to hemodilution and consumption of coagulation factors and platelets in the extracorporeal circuit, patients undergoing cardiac surgery can develop severe bleeding complications. In cardiac surgery, transfusion rate varies between 27 and 92% and estimated approximately 10% of the total blood supply worldwide [12]. Also platelets and plasma are frequently transfused to patients undergoing cardiac surgery.

After cardiac surgery, patients generally stay at an intensive care unit (ICU) for as long as mechanical ventilation and cardiac inotropic drug support is needed. Anemia is often encountered in the ICU in surgical patients and is of multifactorial origin. Besides, hemodilution by abundant intravenous infusions, decreased RBC production due to iron deficiency and inappropriate erythropoietin response due to inflammatory mediators in critically ill patients, reduced RBC survival, and increased (druginduced) hemolysis may contribute further to postoperative anemia in ICU patients [13–15]. A prospective observational study in several ICUs found that approximately 29% of the patients reached a hemoglobin value of less than 6.2 mmol/l (10.0 gr/dl) with a transfusion rate of 37%. Of the patients with an ICU stay >7 days, 73% had received allogeneic RBC transfusions. Overall mortality was almost twice as high in patients who received RBC transfusions compared to patients who were not transfused. In critically ill patients, blood transfusions have been associated with mortality, ventilator-associated pneumonia, acute respiratory distress syndrome (ARDS), and bloodstream infections [16–20]. Also transfusion of platelets and plasma were reported to contribute to the development of these complications [21, 22].

The effect of allogeneic blood transfusions containing leukocytes was predominantly present in cardiac surgery. This was observed in two RCTs. One randomized controlled trial, aimed to investigate the development of HLA antibodies and postoperative infections after RBC transfusions in cardiac surgery (CABG +/− valve surgery), found surprisingly a higher mortality rate in patients receiving leukocytecontaining RBC transfusions [23]. Mortality due to multi-organ dysfunction syndrome (MODS) was the major cause of excess deaths after non-LR transfusions. In this study, patients were randomized to three different blood products; BCD RBCs were compared with two filtered RBCs: either fresh filtered RBCs before storage (FF) or stored filtered RBCs (SF). Between the two types of filtered RBCs, the mortality rate was not different. A subsequent RCT conducted in high-risk cardiac surgery (anticipating higher transfusion needs) investigated the effect of leukoreduction on the incidence of MODS but found no difference after BCD or LR RBCs [24]. However, MODS (with the presence of postoperative infections) as a cause of death occurred more often in patients who received BCD RBC [25]. Recently, in 150 patients undergoing cardiac surgery, it was found that patients receiving leukocytecontaining blood transfusions had longer ICU stay and hospital stay, and the duration of mechanical ventilation was longer. These patients had more risk for developing postoperative kidney injury [26]. A meta-analysis in patients undergoing cardiovascular surgery concluded that leukocyte-depleted blood transfusions resulted in

significant reduction in postoperative infections (OR = 0.77, 95% CI = 0.66–0.91) and all-cause mortality (OR = 0.69, 95% CI = 0.53–0.90) [27]. Further, a large analysis enrolling >14.000 patients undergoing cardiac surgery and hip surgery or admitted to ICU after surgery or trauma observed after universal leukoreduction significant lower in-hospital mortality and decreased incidence of fever and antibiotic use in patients receiving blood transfusions [28]. The available findings support the standard use of LR in cardiac surgery, if universal leukoreduction is not implemented [29].

As possible explanation for these differences in cardiac surgery, it was postulated that patients undergoing cardiopulmonary bypass develop a systemic inflammatory response syndrome (SIRS), where allogeneic blood transfusions could have a complementary role. Generation of inflammatory mediators may be associated with more complex and longer surgery, whereas these patients receive also larger amounts of blood transfusions. During cardiac surgery, blood is exposed to the extracorporeal circuit, hypothermia, and ischemia/reperfusion injury. These insults are potent inducers of a stress response. SIRS usually resolves with adequate supportive therapy, and most of the patients recover. However, overwhelming SIRS can dominate and progress to MODS, which may lead to mortality [30]. Transfusion of leukocyte-containing RBCs to a patient with an already existing inflammatory cascade can contribute to an increased morbidity and mortality (second hit). It has been hypothesized that leukocyte-containing RBC transfusions can further imbalance SIRS leading to aggravation of MODS and could finally result in death [31].

#### **4. Possible mechanisms of TRIM**

Many factors present in allogeneic blood products have been proposed to induce TRIM. These can due to factors derived from leukocytes, red blood cells, platelets, and plasma [32, 33].

#### **4.1 Leukocyte-derived factors**

Clinical studies suggested that allogeneic leukocytes are responsible for the deleterious effects of (leukocyte-containing) blood transfusions. In blood products up to 5x106 /L, residual leukocytes can present. Probably by apoptosis, these residual leukocytes and leukocyte-derived mediators or residual leukocytes may induce immunomodulation [34]. Also after transfusion, microchimerism may be present 2 years after transfusion in 25% of trauma survivors, which can contribute to the development of immune suppression [35]. Further, interaction between residual leukocytes from allogeneic blood transfusion and recipient's lymphocytes may result in allo-immunization [36]. Also leukocytes became apoptotic during the storage of blood products. These factors can lead to immunomodulation [37, 38]. One study in cardiac surgery showed as a marker for apoptosis an increase in Fas ligand in patients receiving leukocyte-containing blood [26]. Although a direct causal interaction between residual leukocytes and postoperative complications related with allogeneic blood transfusions remains uncertain.

Soluble leukocyte-derived factors, like cytokines and HLA molecules, can modulate recipient's immune system. It has been suggested that pro-inflammatory and anti-inflammatory cytokines can accumulate during the storage of allogeneic blood transfusions [39]. Also degranulation products of remaining leukocytes like histamine, serotonin, elastase, and acid phosphatase can contribute to an

#### *Clinical Effects and Possible Mechanisms of Transfusion-Related Immunomodulation DOI: http://dx.doi.org/10.5772/intechopen.107228*

immunomodulatory effect [40]. In a multivariate analysis, the number of contaminating leukocytes and the storage duration of RBCs were the most significant factors associated with febrile nonhemolytic transfusion reactions [41]. Further, it has been suggested that interleukin-8 may be the cause of transient posttransfusion leukocytosis in critically ill patients [42]. Few studies investigated the effect of allogeneic (leukocyte-containing) blood products on the cytokine balance. These studies compared cytokine profiles in patients receiving leukocyte-containing RBC transfusions with patients who did not receive any transfusions. In one study in cardiac surgery, an association was found between allogeneic RBC transfusions and postoperative increase of bactericidal/permeability-increasing protein (BPI), a marker of neutrophil activation, and the pro-inflammatory mediator IL-6 [43]. However, the interaction between blood products and the concentrations of inflammatory mediators in relation with the outcome of the patients is unknown. Although, in one RCT between stored and then filtered and fresh filtered (lacking soluble mediators) RBCs, no association was found in postoperative mortality. This finding suggests that there is not a causal role for soluble mediators [23].

It has been observed that allogeneic leukocytes can increase a T-helper-2 (Th-2) response and suppress Th-1 response [44]. This was supported by one RCT that measured the profiles of some inflammatory mediators investigating the differences between LD and BCD RBCs [45]. The IL-6 levels were significantly higher at arrival at ICU in patients after transfusion of >3 units BCD RBCs compared with LD. The IL-10 levels were not associated with number and type of transfusions in patients with or without complications, although higher IL-10 concentrations were associated with hospital mortality in both randomization arms. These results suggested that leukocyte-containing blood transfusions can aggravate the pro-inflammatory response after surgery.

#### **4.2 Red blood cell-derived factors**

During the storage of blood products, red blood cells alter and undergo rheologic changes, as impaired deformability, shape, and rigidity. Further, biochemical changes can occur as depletion of 2,3-diphosphoglycerate and nitric oxide scavenging, which result in impaired oxygen delivery [46, 47].

Hemolysis of red blood cells occurs during storage that can lead to accumulation of iron and heme, which can cause the formation of reactive oxygen species (ROS) and expression leading to tissue damage. Iron released during storage can lead to increased levels of non-transferrin-bound iron (NTBI) that can result in changes in leukocyte activation resulting in immunomodulation and production and release of pro-inflammatory cytokines [48]. Although, no difference in pro-inflammatory cytokine release was found in healthy individuals and prematures receiving old versus fresh red blood cell transfusions, while NTBI levels were significantly higher in patients receiving older RBCs [49, 50]. Also, phagocytosis of stored red blood cells in monocytes and macrophages can induce immunomodulation that results in production and release of pro-inflammatory cytokines [51]. Further, it was observed that microparticles from red blood cells accumulated during storage have also an inflammatory effect [52].

Several observational trials investigated the effect of storage time of red blood cells. These studies found controversial conclusions in different clinical settings [53–55]. Retrospective analysis suggested an association between transfusion of RBCs older than 14 days and postoperative infections after cardiac surgery. However, other studies could not confirm this and found also no association between mortality, infections, and hospital-stay [56]. However, others found no

effect of storage of red blood cells on mortality in critically ill patients [57]. Metaanalysis concluded that the heterogeneity among available studies could not the question whether the storage of red blood cells can influence prognosis [58]. Until now, RCTs could not find any deleterious effects of transfusion of older RBCs compared with younger RBCs.

#### **4.3 Platelet-derived factors**

There are few data suggesting that platelets in stored blood products play a role in the development of TRIM. Platelets and platelet-derived particles can induce immune suppression and activation of an inflammatory response [59]. Also, platelets interact with leukocytes which results in the formation of aggregates and can involve in apoptosis and can thereby play a role in immunomodulation [60]. Leukocyte-containing RBCs contain prothrombotic soluble mediators, such as CD40L, which induce the synthesis of pro-inflammatory mediators that can further activate the coagulation system. Soluble CD40L and other cytokines released by platelets may play a key role in endothelial activation and can in turn activate the immune system leading to inflammation [61]. Whether platelets present in allogeneic red blood cell bags are involved in the development of TRIM is so far not known.

#### **4.4 Plasma-derived factors**

Plasma-derived products and all plasma-containing products can contribute to the development of transfusion-related acute lung injury (TRALI). Bioactive lipids which accumulate during the storage of plasma are involved in an immunomodulatory effect. In combination with neutrophil activation in plasma, bioactive lipids can induce TRALI [62]. TRALI is a life-threatening transfusion reaction with an estimated incidence of 1:1000 to 5000 plasma-containing blood transfusions. TRALI is defined as non-cardiogenic lung edema presenting within 6 hours after the completion of transfusion [63]. Endogenous neutrophil priming associated with the patient's underlying illness, combined with bioactive lipids and modifiers in blood products, can result in neutrophil-induced pulmonary endothelial damage leading to capillary leakage. It has been hypothesized that the presence of leukocytes contributes to the generation of bioactive lipids during storage, enhancing the accumulation of lipid-priming agents and neutrophil-priming factors [64]. Besides leukocyte-reactive antibodies present in donor plasma, soluble factors accumulating during the storage of red cells and platelet products have been associated with TRALI [65].

#### **5. Effect of platelet and plasma transfusions on TRIM**

A substantial proportion of patients undergoing major surgery and trauma receive, besides red blood cells, also platelet transfusions. In cardiac surgery, approximately 20% of patients suffer from bleeding and receive platelet transfusion. Studies in cardiac surgery showed that platelet transfusion was associated with threefold increase in stroke and fivefold increase in mortality [66]. In another study in cardiac surgery, platelet transfusions were associated with mortality in patients with postoperative infections [67]. However, other studies found not an association between platelet transfusions and postoperative complications [68–70]. Patients who receive

#### *Clinical Effects and Possible Mechanisms of Transfusion-Related Immunomodulation DOI: http://dx.doi.org/10.5772/intechopen.107228*

platelet transfusions could be more sicker and have more complex course, so transfusion of platelets could be a surrogate marker.

Plasma transfusions are predominantly transfused to patients who also receive large numbers of RBC transfusions. It has been suggested that plasma transfusions are associated with adverse outcome after cardiac surgery. A predominant role of plasma transfusions in cardiac surgery outcome was reported in one study in cardiac surgery [71]. Other studies that focused on plasma transfusions reported inconsistent findings [68, 72]. In another study, plasma transfusions were associated with mortality (with the presence of infections) [67]. This suggests that plasma transfusions (with the presence of soluble mediators) can contribute to postoperative inflammation in cardiac surgery. Because patients who need plasma transfusions often receive red blood cell and platelet transfusions, it is difficult to determine whether plasma transfusions are independent risk factors or are only confounders. Also one study found in >10,000 patients that the storage time of plasma transfusions was associated with early mortality, although late mortality was not [73].

The presented findings underscore the need for further studies to investigate the effects of all the various blood components transfused in cardiac surgery, as well as differentiate between adverse effects possibly associated with a specific blood component(s).

#### **6. Allogeneic transfusion and thrombosis**

Patients undergoing surgery or who suffer from cancer have a higher risk for the development of venous thromboembolism (VTE). Most observational studies investigating VTE ignored the role of allogeneic blood transfusion as a causal factor. Few studies found in cancer and after surgery that blood transfusions were dosedependently associated with VTE [74–76]. One study in 1070 patients undergoing cardiac surgery found a dose-dependent association with transfusion of blood products and VTE [77]. In patients receiving red blood cells, the incidence of VTE was 16.7% and patients who received also plasma transfusions, this was almost doubled. The hypercoagulability and immobility after surgery could result in the activation of coagulation system, and in combination with blood transfusions this could result in higher risk in VTE.

It has been shown that platelets contain prothrombotic soluble mediators, which interact with leukocytes preceding apoptosis subsequently producing microparticles with procoagulant activity [60]. Leukocyte-containing RBCs contain soluble mediators, such as CD40L, which induce the synthesis of pro-inflammatory mediators that can further activate the coagulation system [58]. Recently, one study found in the bronchoalveolar lavage fluid, besides an increase in pro-inflammatory mediators IL-8 and TNF-alpha and also an increase in trombine-antithrombin complex (TATc), indicating the activation of the coagulation system in the lung [78]. Another study found an increase in levels of von-Willebrand-factor antigen in critically ill patients receiving a RBC transfusion. The von Willebrand factor antigen has a causal role in the activation of endothelium and also in the development of thrombi formation [79]. After cardiovascular surgery, the levels of plasma tissue factor are persistent high for 30 days, which can increase the risk of VTE [80]. In combination with plasmaderived products in stored blood products, this can result in an increased activation of the coagulation system.

#### **7. Interaction between inflammation and coagulation associated with blood transfusions**

Patients undergoing major surgery or after trauma have a higher risk for the development of both inflammation and thrombo-embolic complications. In these patients, both the inflammatory response and the release of pro-inflammatory mediators lead to an activation of the coagulation system and downregulate the anticoagulant system [81]. Activation of the coagulation factors can in turn activate inflammation. This may enhance the development of infections and microvascular thrombi [82]. Both thrombi and infections can be involved in the development and aggravation of MODS [83]. Further, by increasing the circulating red blood cell mass and vascular rheologic deformations by red blood cell transfusions, this process can be more pronounced. Also plasma and platelet transfusions can aggravate the activation of coagulation and inflammatory response.

There is a possible association between allogeneic blood transfusions and the formation of thrombosis, as a factor aggravating VTE and having a role in the development of MODS which can lead to increased mortality in patients at high risk as in

**Figure 1.** *Association between blood transfusions inflammation, coagulation and MODS.*

cardiac surgery (**Figure 1**). This complex interaction and the role of allogeneic blood transfusions should be investigated in detail.

#### **8. Conclusions**

Nowadays, allogeneic blood transfusions are unavoidable. Although blood transfusions are safe today, there are still concerns about transfusion-related complications. The immune-mediated complications of blood transfusions are referred as transfusion-related immunomodulation. The effects of transfusion-related immunomodulation are mainly observed in major cardiovascular surgery. Patients undergoing cardiovascular surgery are transfused with large numbers of red cells, plasma, and platelets. Although, the exact mechanisms of these immune-mediated complications are still not elucidated. The past studies showed that allogeneic leukocytes in blood transfusions play a pivotal role in the development of transfusion-related immunomodulation. Nowadays, in many countries, leukocytes are removed from transfused blood components, although the discussion about the immunologic effects of blood transfusions is continuing. In addition, by the activation of inflammatory system and release of mediators, the storage of blood components and transfusion of plasma and platelets can contribute to the development of transfusion-related immunomodulation. Further, it has been suggested that allogeneic blood transfusions are associated with the development of thrombo-embolic events in high-risk patients as cancer and surgery. It has been suggested that allogeneic blood transfusions can activate an inflammatory response and a coagulation response. Both cascades can result in worse outcome in a high-risk patient. Probably, the term transfusion-related immunomodulation is not sufficient for both inflammation and coagulation activation after blood transfusion. The term transfusion-related inflammation and coagulation (TRIC) could be more comprehensive and includes the activation of both cascades. More research (clinical and laboratory) are needed to unravel the effects of allogeneic blood transfusions in the activation of the inflammatory and coagulation cascades.

### **Conflict of interest**

The author declares no conflict of interest.

#### **Author details**

Yavuz Memis Bilgin Department of Internal Medicine, Adrz, Goes, the Netherlands

\*Address all correspondence to: y.bilgin@adrz.nl

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### **References**

[1] Ness P. Introduction: Recent evolution of transfusion medicine. In: Murphy MF, Pamphilon DH, Heddle NM, editors. Practical Transfusion Medicine. 4th ed. Chichester: Wiley-Blackwell; 2013. pp. 1-8

[2] Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet. 2007;**370**:415-426

[3] Corwin HL. Anemia and red blood cell transfusion in the critically ill. Seminars in Dialysis. 2006;**19**:513-516

[4] Blumberg N, Heal JM. Effects of transfusion on immune function: Cancer recurrence and infection. Archives of Pathology & Laboratory Medicine. 1994;**118**:371-379

[5] Opelz G, Sengar DDS, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplantation Proceedings. 1973;**5**:253-259

[6] Gantt CL. Red blood cells for cancer patients. Lancet. 1981;**2**:363

[7] Burrows L, Tartter PI. Effect of blood transfusions on colonic malignancy recurrence rate. Lancet. 1982;**2**:662

[8] Skanberg J, Lundholm K, Haglind H. Effects of blood transfusion with leucocyte depletion on length of hospital stay, respiratory assistance and survival after curative surgery for colorectal cancer. Acta Oncologica. 2007;**46**:1123-1130

[9] van de Watering LMG, Brand A, Houbiers JGA, et al. Perioperative blood transfusions, with or without allogeneic leukocytes, relate to survival, not to cancer recurrence. The British Journal of Surgery. 2001;**88**:267-272

[10] Vamvakas EC. White-blood-cellcontaining alloegenic blood transfusions and postoperative infection and mortality: An updated meta-analysis. Vox Sanguinis. 2007;**92**:224-232

[11] Blumberg N, Zhao H, Wang H, et al. The intention-to-treat principle in clinical trials and meta-analysis of leukoreduced blood transfusions in surgical patients. Transfusion. 2007;**47**:573-581

[12] Snyder-Ramos SA, Mohnle P, Weng YS, et al. The ongoing variability in blood transfusion practices in cardiac surgery. Transfusion. 2008;**48**:1284-1299

[13] Jelkman WE, Hellwig-Buergel T. Inhibition of erythropoetin production by cytokines. Implications for the anemia involved in inflammatory states. Annals of the New York Academy of Sciences. 1994;**718**:300-309

[14] Shander A. Anemia in the critically ill. Critical Care Clinics. 2004;**20**:159-178

[15] Rodriguez RM, Corwin HL, Gettinger A, et al. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. Journal of Critical Care. 2001;**16**:36-41

[16] Shorr AF, Duh MS, Kelly KM, et al. Red blood cell transfusion and ventilator-associated pneumonia: A potential link? Critical Care Medicine. 2004;**32**:666-674

[17] Shorr AF, Jackson WL, Kelly KM, et al. Transfusion practice and blood stream infections in critically ill patients. Chest. 2005;**127**:1722-1728

[18] Zilberberg MD, Carter C, Lefebre P, et al. RBC transfusions and the risk of

*Clinical Effects and Possible Mechanisms of Transfusion-Related Immunomodulation DOI: http://dx.doi.org/10.5772/intechopen.107228*

ARDS among the critically ill: A cohort study. Critical Care. 2007;**11**:R63

[19] Taylor RW, Manganaro L, O'Brien J, et al. Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in critically ill patient. Critical Care Medicine. 2002;**30**:2249-2254

[20] Gong MN, Thompson BT, Williams P, et al. Clinical predictors of and mortality in acute respiratory distress syndrome: Potential role of red cell transfusion. Critical Care Medicine. 2005;**33**:1191-1198

[21] Khan H, Belsher J, Yilmaz M, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest. 2007;**131**:1308-1314

[22] Sarani B, Dunkman WJ, Dean L, et al. Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. Critical Care Medicine. 2008;**36**:1114-1118

[23] van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: A randomized clinical trial. Circulation. 1998;**97**:562-568

[24] Bilgin YM, van de Watering LM, Eijsman L, et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation. 2004;**109**:2755-2760

[25] Bilgin YM, van de Watering LM, Eijsman L, et al. Is increased mortality associated with post-operative infections after leukocytes containing red blood

cell transfusions in cardiac surgery? An extended analysis. Transfusion Medicine. 2007;**17**:304-311

[26] Khan AI, Patidar GK, Lakshmy R, et al. Effect of leukoreduction on transfusion-related immunomodulation in patients undergoing cardiac surgery. Transf Med. 2020;**30**:497-504

[27] Simancas-Racines D, Arevalo-Rodriguez I, Urrutia G, et al. Leukodepleted packed red blood cells transfusion in patients undergoing major cardiovascular surgical procedure: Systemic review and meta-analysis. Cardiology Research and Practice. 2019;**2019**:7543917

[28] Hebert PC, Fergusson D, Blachjman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA. 2003;**289**:1941-1949

[29] Boer C, Meesters MI, Milojevic M, et al. 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia. 2018;**32**:88-120

[30] Guidet B, Aegerter P, Gauzit R, et al. Incidence and impact of organ dysfunctions associated with sepsis. Chest. 2005;**127**:942-951

[31] Bilgin YM, van de Watering LM. Complications after cardiac surgery due to allogeneic blood transfusions. Journal of Clinical and Experimental Cardiology. 2013;**S7**:5

[32] Remy KE, Hall MW, Cholette J, et al. Mechanisms of red blood cell transfusionrelated immunomodulation. Transfusion. 2018;**58**:804-815

[33] Maitta RW. Transfusion-related immunomodulation. In: Maitta RW, editor. Immunologic Concepts in Transfusion Medicine. St.Louis: Elsevier; 2020. pp. 81-95

[34] Sut C, Tariker S, Chou ML, et al. Duraton of red blood cell storage and inflammatory marker generation. Blood Transfusion. 2017;**15**:145-152

[35] Lee TH, Paglieroni T, Ohto H, et al. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: Frequent longterm microchimerism in severe trauma patients. Blood. 1999;**93**:3127-3139

[36] Saas P, Angelot F, Bardiaux L, et al. Phosphatidylserine-expressing cell by-products in transfusion: A proinflammatory or an anti-inflammatory effect? Transfusion Clinique et Biologique. 2012;**19**:90-97

[37] Frabetti F, Musiani D, Marini M, et al. White cell apoptosis in packed red cells. Transfusion. 1998;**38**:1082-1089

[38] Hod EA, Zhang N, Sokal SA, et al. Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood. 2010;**115**:4284-4292

[39] Nagura Y, Tsuno NH, Tanaka M, et al. The effect of pre-storage wholeblood leukocyte reduction on cytokines/ chemokines levels in autologous CPDA-1 whole blood. Transfusion and Apheresis Science. 2013;**49**:223-230

[40] Nielsen HJ, Reinert CM, Pedersen AN, et al. Time-dependent spontaneous release of white cell-and platelet-derived bioactive substances from stored human blood. Transfusion. 1996;**36**:960-965

[41] Heddle NM, Klama LN, Griffith GR, et al. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion. 1993;**33**:794-797

[42] Izbicki G, Rudensky B, Na'amad M, et al. Transfusion-related leukocytosis in critically ill patients. Critical Care Medicine. 2004;**32**:439-442

[43] Fransen E, Maessen J, Dentener M, et al. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest. 1999;**116**:1233-1239

[44] Aguilar-Nascimento JE, Zampieri-Filho JP, Bordin JO. Implications of perioperative allogeneic red blood cell transfusion on the immune-inflammatory response. Hematol Transfus Cell Ther. 2021;**43**:58-64

[45] Bilgin YM, van de Watering LMG, Versteegh MIM, et al. Effects of allogeneic leukocytes in blood transfusions during cardiac surgery on inflammatory mediators and postoperative complications. Critical Care Medicine. 2010;**38**:546-552

[46] Ho J, Sibbald WJ, Chin-Yee IH. Effects of storage on efficacy of red cell transfusion: When is it safe? Critical Care Medicine. 2003;**31**:S687-S697

[47] Donadee C, Raat NJ, Kanias T, et al. Nitric oxide scavenging by red blood cell microparticles and cell-free haemoglobin as a mechanism for the red cell storage lesion. Circulation. 2011;**124**:465-476

[48] Baek JH, D'Aguillo F, Vallelian F, et al. Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in Guinea pigs by haptoglobin therapy. The Journal of Clinical Investigation. 2012;**122**:1444-1458

#### *Clinical Effects and Possible Mechanisms of Transfusion-Related Immunomodulation DOI: http://dx.doi.org/10.5772/intechopen.107228*

[49] Hod EA, Spitalnik SL. Stored red blood cell transfusions: Iron, inflammation, immunity, and infection. Transfusion Clinique et Biologique. 2012;**19**:84-89

[50] Stark MJ, Keir AK, Andersen CC. Does non-transferrin bound iron contribute to transfusion related immune-modulation in preterms? Archives of Disease in Childhood. Fetal and Neonatal Edition. 2013;**98**:F424-F429

[51] Yazdanbaksh K, Bao W, Zhong H. Immunoregulatory effects of stored red blood cells. Hematology. American Society of Hematology. Education Program. 2011;**2011**:466-469

[52] Straat M, Böing AN, Tuip-De Boer A, et al. Extracellular vesicles from red blood cell products induce a strong proinflammatory host response, dependent on both numbers and storage duration. Transfusion Medicine and Hemotherapy. 2016;**43**:302-305

[53] Koch GC, Li L, Sessler DI, Figueroa P, et al. Duration of red-cell storage and complications after cardiac surgery. New Engl J Med. 2008;**358**:1229-1239

[54] van de Watering L, Lorinser J, Versteegh M, et al. Effects of storage time of red blood cell transfusions on the prognosis of coronary artery bypass graft patients. Transfusion. 2006;**46**:1712-1718

[55] van Straten AH, Soliman Hamad MA, van Zundert AA, et al. Effect of duration of red blood cell storage on early and late mortality after coronary artery bypass grafting. The Journal of Thoracic and Cardiovascular Surgery. 2011;**141**:231-237

[56] van de Watering LM. Age of blood: Does older blood yield poorer outcomes? Current Opinion in Hematology. 2013;**20**:526-532

[57] Cooper DJ, McQuilten ZK, Nichol A, et al. Age of red cells for transfusion and outcomes in critically ill adults. The New England Journal of Medicine. 2017;**377**:1858-1867

[58] Lelubre C, Vincent JL. Relationship between red cell storage duration and outcomes in adults receiving red cell transfusions: A systematic review. Critical Care. 2013;**17**:R66

[59] Sadallah S, Schmeid L, Eken C, et al. Platelet-derived ectosomes reduce NK cell function. Journal of Immunology. 2016;**197**:1663-1671

[60] Keating FK, Butenas S, Fung MK, et al. Platelet-white blood cell (WBC) interaction, WBC apoptosis, and procoagulant activity in stored red blood cells. Transfusion. 2011;**51**:1086-1095

[61] Blumberg N, Gettings KF, Turner C, et al. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion. 2006;**46**:1813-1821

[62] Silliman CC, Moore EE, Kelher MR, et al. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. Transfusion. 2011;**51**:2549-2554

[63] Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;**105**:2266-2273

[64] Goldman M, Webert KE, Arnold DM, et al. Proceedings of a consensus conference: Towards an understanding of TRALI. Transfusion Medicine Reviews. 2005;**19**:2-31

[65] Silliman CC, Paterson AJ, Dickey WO, et al. The association of biologically active lipids with the development of transfusion-related

acute lung injury: A retrospective study. Transfusion. 1997;**37**:719-726

[66] Spiess BD, Royston D, Levy JH, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion. 2004;**44**:1143-1148

[67] Bilgin YM, van de Watering LM, Versteegh MI, et al. Postoperative complications associated with transfusion of platelets and plasma in cardiac surgery. Transfusion. 2011;**51**:2603-2610

[68] Sreeram GM, Welsby IJ, Sharma AD, et al. Infectious complications after cardiac surgery: Lack of association with FFP or platelet transfusions. J Cardiothoracic Vasc Anesthesia. 2005;**19**:430-434

[69] Karkouti K, Wijeysundera DN, Yau TM, et al. Platelet transfusions are not associated with increased morbidity or mortality in cardiac surgery. Canadian Journal of Anesthesia. 2006;**53**:279-287

[70] McGrath T, Koch CG, Xu M, et al. Platelet transfusion in cardiac surgery does not confer increased risk for adverse morbid outcomes. The Annals of Thoracic Surgery. 2008;**86**:543-553

[71] Ranucci M, Pazzaglia A, Bianchini C, et al. Body size, gender, and transfusions as determinants of outcome after coronary operations. The Annals of Thoracic Surgery. 2008;**85**:481-486

[72] Banbury MK, Brizzio ME, Rajeswaran J, et al. Transfusion increases the risk of postoperative infection after cardiac surgery. Journal of the American College of Surgeons. 2006;**202**:131-138

[73] van Straten AH, Soliman Hamad MA, Martens EJ, et al. Effect of storage time of transfused plasma on

early and late mortality after coronary artery bypass grafting. The Journal of Thoracic and Cardiovascular Surgery. 2011;**141**:238-243

[74] Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Archives of Internal Medicine. 2008;**168**:2377-2381

[75] Shohat N, Ludwick L, Goh GS, et al. Blood transfusions increase the risk for venous thromboembolism events following total joint arthroplasty. Scientific Reports. 2021;**11**:21240

[76] Marusic AP, Locatelli I, Mrhar A, et al. Influence of prescribed blood products on the incidence of deep vein thrombosis and pulmonary embolism in surgical patients. Clinical and Applied Thrombosis/Hemostasis. 2017;**23**:938-942

[77] Ghazi L, Schwann TA, Engoren MC, et al. Role of blood transfusion product type and amount in deep vein thrombosis after cardiac surgery. Thrombosis Research. 2015;**136**:1204-1210

[78] Tuinman PR, Vlaar AP, Cornet AD, et al. Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: A case control study. Critical Care. 2011;**15**:R59

[79] van Manen L, van Hezel ME, Boshuizen M, et al. Effect of red blood cell transfusion on inflammation, endothelial cell activation and coagulation in the critically ill. Vox Sanguinis. 2022;**117**:64-70

[80] Parolari A, Mussoni L, Frigerio M, et al. Increased prothrombotic state lasting as long as one month after on-pump and off-pump coronary surgery. The Journal of Thoracic

*Clinical Effects and Possible Mechanisms of Transfusion-Related Immunomodulation DOI: http://dx.doi.org/10.5772/intechopen.107228*

and Cardiovascular Surgery. 2005;**130**:303-308

[81] Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints. Lancet. 1999;**354**:1940-1947

[82] Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Critical Care Medicine. 2010;**38**:S35-S42

[83] Levi M, Keller TT, van Gorp E, et al. Infection and inflammation and the coagulation system. Cardiovascular Research. 2003;**60**:23-29

#### **Chapter 9**

## Personnel for Blood Transfusion Services in Nigeria: A Multicenter Cooperative Study

*Abdulrahman Abdulbasit Opeyemi, Adesola Precious Oyeyemi and Adeyeye Kamaldeen*

#### **Abstract**

The intravenous infusion of blood components into someone's circulation is known as a blood transfusion. For a variety of medical disorders, transfusions are performed to replenish lost blood components. In the past, whole blood was used for transfusions, but in modern medicine, just the blood's constituent parts—such as red blood cells, white blood cells, plasma, clotting factors, and platelets—are frequently employed. A typical blood service is a multidisciplinary system that requires a wide range of specialists. These people include medical scientists, and technical professionals as well as the nursing staff. Several elements, including the workplace environment, the availability of essentials like PPE, gloves, and water, the training of employees, and the formulation of policies, affect how effective a transfusion service is. To comprehend Personnel for Blood Transfusion Services in Nigeria: A multicentre cooperative study, the study reviews pertinent literature.

**Keywords:** blood, hemorrhage, transfusion, blood products, blood transfusion

#### **1. Introduction**

Richard Lower at Oxford carried out the first known animal-to-animal (a dog) blood transfusion in 1665, and Jean-Denis carried out the first known animal-to-human blood transfusion in 1667. James Blundell carried out the first human-to-human blood transfusion in 1818 [1, 2]. Ottenberg performed the first pre-transfusion cross-match in 1907 using Landsteiner's classification of the ABO blood grouping system, which was created in the year 1900. In the year 1940, Landsteiner and Wiener developed the Rh-type system. Following this, significant discoveries in the twentieth century enabled the use of component therapy, including the development of anticoagulant and preservative solutions, refrigeration, plastic blood bags, component delivery, infectious disease testing, high-risk donor screening, etc. [1, 2].

Since its beginning in the early twentieth century, transfusion medicine has advanced. Among these was the realization that blood can be separated into its parts and supplied individually [1, 2]. Nowadays, blood transfusions almost invariably

involve the infusion of one or more blood products. Whole blood transfusions are now only performed in cases requiring intensive restoration (trauma). The most well-known cellular constituents are packed red blood cells (PRBC), washed PRBC, leuko-reduced PRBC, and pooled or aphaeresis platelets. Hemophilic factor (CRYO), FFP, and cryoprecipitate are examples of plasma-derived products [1, 2]. In perioperative and peripartum settings, the transfusion of red blood cells (RBCs), platelets, fresh frozen plasma (FFP), and cryoprecipitate has the potential to improve clinical outcomes.

Blood transfusions can save lives, but they can carry hazards, such as noninfectious and infectious consequences [3]. Despite significant advancements in blood safety since the 1980s, when it was revealed that HIV could be transmitted through blood transfusions, blood transfusions still carry a distinct risk of poor patient outcomes [1–4]. Blood transfusions have been linked to higher mortality rates, longer hospital stays due to infections and sepsis, and malfunction of several organ systems [4, 5]. In a recent meta-analysis of 19 prospective, randomized studies comparing restricted with liberal transfusions in more than 6000 patients, it was discovered that adherence to restrictive blood transfusion reduced hospital mortality and postoperative infections. These observed negative patient outcomes may be partially explained by erythrocyte damage related to the length of blood storage. Old blood may have a predisposition to hemolyze in vivo, producing vaso-constrictive cell-free hemoglobin, according to canine studies. Post-transfusion, patients also have lower erythrocyte membrane deformability that is correlated with blood storage time [4–6]. Finally, some people appear to limit the use of blood transfusions due to potential recognized and unknown hazards such as the spread of blood-borne viruses. Similar to the last example, transfusion is only necessary to enhance viscosity in extreme cases of hemodilution. Circulation may be hampered by high viscosity on its own. Additionally, the delivery or consumption of oxygen at the tissue level is not instantly increased by transfused blood [6, 7]. There are, therefore, few clinical circumstances in which a blood transfusion is advantageous to the patient and improves results. After assessing the advantages and disadvantages of blood transfusion, the decision to administer blood should be made [6, 7].

All medical professionals who deliver blood or blood-derived products must complete specialized training regarding safe transfusion techniques and have a comprehensive understanding of the transfusion administration procedure. Most commonly, people refer to them as Transfusion Personnel (TP). The phrase "Transfusion Personnel" or "Transfusion Practitioner" (TP) is a term used in the workplace to refer to a variety of positions, including those of transfusion nurse, transfusion instructor, transfusion health and safety committee, transfusion control officer, transfusion clinical nurse, and hemovigilance officer. The TP role has been in place for many years in some nations [7, 8], and more lately, additional nations are putting it into practice.

The majority of the TP activity is concentrated on patient blood management, transfusion governance, monitoring practice, adverse event management, and education (PBM). Very frequently, the TP serves as the informational hub, bringing together the available resources, studying the activities carried out by transfusion colleagues in other centers, gathering audit data, and assessing how these efforts might be advantageous within their healthcare facility [7, 8]. However, there is a need for all personnel involved in transfusion service to have a common goal and work together efficiently, this research will examine Personnel for Blood Transfusion Services in Nigeria: A multicentre cooperative Study.

*Personnel for Blood Transfusion Services in Nigeria: A Multicenter Cooperative Study DOI: http://dx.doi.org/10.5772/intechopen.107301*

#### **2. Blood transfusion**

The World Health Organization (WHO) recommends 10 units of blood per 1000 people, which means that in order to meet the demand for transfusions for an estimated 800 million people, 8 million units of blood are now required [7–9]. Blood transfusion is still a life-saving medication. While blood supply and blood safety are well recognized in developed countries, access to blood is extremely limited in Africa, and the availability of hazardous blood raises serious public health concerns about blood safety. A blood transfusion may be necessary in cases of obstetric hemorrhage, auto accidents, armed conflicts, sickle cell disease, anemia, particularly in youngsters, malnutrition, HIV, malaria, parasitic diseases, cases obstetric hemorrhage, auto accidents, violent conflicts, sickle cell disease, anemia, particularly in youngsters, malnutrition, HIV, malaria, and parasitic diseases, a blood transfusion may be necessary. Therefore, it is crucial to consistently draw attention to the reaction to blood transfusions, potential causes, anticipated symptoms and indicators, preventive measures, and suitable therapy [9, 10].

Intravenous infusion of blood components into a person's circulation is known as a blood transfusion [3, 11]. For a number of medical disorders, transfusions are performed to replenish lost blood products. Early transfusions used whole blood, but in contemporary medical practice, only blood components including red blood cells, white blood cells, plasma, clotting factors, and platelets are frequently employed. Hemoglobin is a component of red blood cells (RBC), which carry oxygen to the body's cells. White blood cells, which are a component of the immune system and combat infections, are not frequently employed during transfusion [10, 11].

Transfusion of blood employs either the donor's or the recipient's own (autologous transfusion) blood as a supply of blood (allogeneic or homologous transfusion). The second is significantly more typical than the first. Blood donation is the initial step in the process of using someone else's blood. Whole blood taken intravenously and combined with an anticoagulant is the most common type of blood donated. Donations are typically anonymous to the recipient in developed nations, but blood bank products are always individually traceable throughout the entire cycle of donation, testing, component separation, storage, and administration to the recipient [3, 4]. As a result, any suspected infection transfer or transfusion reaction can be managed and investigated. In less developed nations, the donor may occasionally be specifically sought out by or for the receiver, who is often a family member, and the donation takes place right before the transfusion. It is not known whether using an alcohol swab alone or in addition to the use of an antiseptic can lessen contamination of the donor's blood [10, 11].

Blood and blood products cannot be synthesized or kept in storage for an extended period of time, making blood transfusion services a vital component of healthcare services. Therefore, it is essential to control blood demand and availability properly to maintain a sufficient provision of safe blood [12]. Because sustaining a sufficient supply of safe blood is essential for many patients, the inability to manage blood inventory and the ensuing blood shortage is regarded as dangers to national and worldwide health security. If health officials do not take rapid corrective action, blood shortages cause the failure of blood transfusion services, which leads to the breakdown of the health system and health insecurity [11–15]. In addition to endangering public health, an imbalance between blood supply and demand is one of the biggest dangers to the stability of the national and global economies and security. The view of

health concerns as a danger to global health security has advantages because it gets the support and attention of government and policy-makers. The management of blood supply and demand should be handled in accordance with international health rules and policies, which should be periodically updated [12, 16].

Replace the entirety of this text with the main body of your chapter. The body is where the author explains experiments and presents and interprets data of one's research. Authors are free to decide how the main body will be structured. However, you are required to have at least one heading. Please ensure that either British or American English is used consistently in your chapter.

#### **2.1 Personnel for blood transfusion services in Nigeria: a multicentre cooperative study**

A typical blood service is a multidisciplinary organization that employs a wide range of specialists. These people include laboratory scientists and technical professionals, as well as the nursing staff. The efficiency of the staff who are properly trained for the jobs they must do in the service determines the effectiveness of a blood service in addition to the availability of appropriate tools and other working materials in a supportive working environment. Different fundamental academic and professional requirements apply to each category of professionals, although blood handling and management skills are exclusive to this workforce and are necessary for all cadres. One of the elements that contribute to an effective and efficient blood service is the availability of facilities and mechanisms for pertinent training [17, 18].

Any health intervention approach needs organization and oversight to be successful, and both are essential when developing a blood safety infrastructure. In order to build a working blood transfusion service, there must be national cooperation, backing from the government, and policy that is tailored to the requirements of a specific nation. One size does not, however, suit all [18]: despite their geographic proximity, the regional nations frequently have wildly dissimilar resources and infrastructure, thus it is important to understand each environment and customize policy making to it. In contexts with limited resources, it is crucial to develop goals that take into account the nation's overall health issues as well as the logistics and cost. Although legislation can be used to enforce policy, it should not be utilized as a substitute for organized development [17, 18]. Liberal transfusion practice with poor standards is a result of prescribing physicians' lack of expertise and training. Similar to this, strict adherence to laboratory transfusion triggers rather than clinical anemia leads to needless blood supply depletion. Additionally, the transfusion service is usually fragmented, resulting in little connection between the blood center and the hospitals or prescribing physician, which makes it impossible to supervise transfusion practice [19].

The requirement for strong organizational support is reiterated in strategies addressing the policy. The ministry of health collaborated with international and nongovernmental organizations, such as WHO-African Region, who would be potential candidates to oversee this on a regional basis [19, 20]. Regional transfusion services with more advanced infrastructures can potentially take the lead and support their neighbors. For instance, the South African National Blood Service (SANBS) now conducts donation serology and Nucleic Acid Testing (NAT) laboratory testing for Namibia blood transfusion service. Utilizing transfusion committees prepared to track blood usage and audit practice in accordance with established logical principles, national frameworks must be disseminated at the hospital level. Staff members who

#### *Personnel for Blood Transfusion Services in Nigeria: A Multicenter Cooperative Study DOI: http://dx.doi.org/10.5772/intechopen.107301*

hold dual appointments at the hospital and the blood center may also help to close the gap between the two institutions. Finally, the successful implementation of clinical recommendations depends on education and training [20, 21].

Currently, a large number of both private and public institutions in Nigeria operate hospital-based transfusion services to sustain the country's blood supply [20, 21]. In this case, each institution finds its own blood donors, checks them for TTIs, and then stores the units for use in clinical procedures. Blood units are frequently saved for intended recipients in hospital-based transfusion services [12, 16, 22], even if they might not need them until after their shelf life has passed. Due to this technique, there are more discarded blood products and few available blood products. Another significant drawback of decentralized hospital-based transfusion programs is the tendency for blood units to be "mal-distributed;" at one hospital, there may be an abundance with a propensity for waste due to expiration, while in a nearby hospital, there may be a severe shortage [20, 21, 23].

Effective blood usage is a part of rational blood use. Differential fractionation of whole blood into derived red cells, plasma, cryoprecipitate, and platelets—also known as component therapy—is a method to increase effectiveness [24]. In the developed world, when parent blood products can be varied, this is the predominant practice. In contrast, given the significant plasma portion that contains antibodies, entire blood must be transfused to a patient whose ABO type matches the donor. A group O unit of whole blood, for instance, must be given to group O receivers only until it has been determined that the recipient has a low antibody titer. Group O red cell components, however, can be safely given to any recipient. Additionally, the enormous amount of whole blood puts recipients at risk for circulatory overload brought on by transfusion. In the WHO study from 2006, only seven of the 46 nations had a national policy for the distribution of fractionated plasma products, and 24 of the 39 responding countries were still transfusing more than 75% of their blood as whole blood. The more recent assessment of 7 blood centers in Francophone, Africa [24] confirmed these findings.

Critical steps that must be taken to guarantee the safety of blood units include screening donor blood and quarantining blood and blood components. They should be released for clinical or manufacturing use, or they should be discarded, depending on the screening results. Blood samples taken at the time of donation should undergo laboratory testing for TTIs. All blood tests must be carried out and recorded using standardized protocols in laboratories that are fully equipped to do so [23–25].

TTI indicators (HIV antigen-antibody, HBsAg, anti-HCV, and syphilis) are regularly screened for in blood transfusion facilities at the same time [25, 26]. In order for the blood or blood components, particularly labile ones like platelets, to be discharged right away, screening time must be minimized. Reactive contributions are initially isolated and separated. The donor is then either disregarded or additional testing is done, depending on the technique the laboratory utilized. Sequential screening may be used in some labs by initially looking for one or two infection indicators. No additional testing is done on this donor if a reactive outcome is received. The prevalence of infections in the population of blood donors will have an impact on the screening approach for selecting the test or tests that are conducted first. In nations where the incidence of one TTI is higher than that of another, sequential screening may be used. For instance, HBsAg may be checked first when the prevalence of hepatitis B is higher than that of HIV and HCV [25–27]. Only HBsAg negative contributions would subsequently be subjected to syphilis, HIV antigen-antibody, and anti-HCV testing in this scenario. On donations that show a positive result on the HBsAg screening

test, no assays for these viral markers would be run. There is hence a chance for cost reductions, particularly if donations that have already tested positive for HBsAg do not require the more expensive assays [25–27].

#### **2.2 The need for laboratory staff in transfusion services**

When performing the tests and assessing the data, laboratory staff should always follow the national screening approach, protocol, and standardized methods. The likelihood of analytical and transcribing errors, particularly false negative results, will be reduced when laboratory tests are conducted in a high-quality environment with knowledgeable employees and a functional documentation system [27]. Blood screening seeks to identify infection-related indicators in order to stop the distribution of contaminated blood and blood components for clinical use. Strategies for blood screening are intended to ensure the security of blood units; nevertheless, they should not be utilized to inform blood donors of reactive test findings. Before informing donors of their infectivity status, the proper confirmatory testing technique for blood donor management should be used. When deciding whether to release blood units for clinical use, all testing for infection indicators for TTIs and blood group serology should be considered.

In most cases, donors must consent to the procedure; as a result, minors cannot donate without the approval of a parent or legal guardian. In some nations, such as the United States, names are maintained in order to compile lists of ineligible donors, while in others, such as several European nations, only the donor's blood is associated with the responses to ensure anonymity. A potential donor is "delayed" if they do not meet these requirements. Due to the possibility of later approval for many ineligible donors, this word is utilized.

The following skills are anticipated of a competent Medical Laboratory Scientist in the field of blood transfusion services [12, 17]:


With these skills in place, Nigerian medical laboratory scientists are trained to produce professionals who can work productively in the core laboratory functions of any blood service or hospital blood transfusion department.

#### **2.3 Role of nurses in transfusion services**

Nursing plays a significant part in ensuring transfusion safety since the nurse practitioner is responsible for understanding the indications for transfusions, doublechecking data to prevent errors, educating patients on blood transfusion, identifying and responding appropriately to transfusion responses, and recording the procedure [27, 28]. Nursing's role is essential for the effective management of transfusion reactions to achieve the desired outcomes for two primary reasons: nurses are the final link in the chain of the transfusion process and nursing-related tasks dominate the transfusion process. As a result, nurses must possess sufficient skills and knowledge in the transfusion of blood and blood products [29].

As the nursing team is responsible for recognizing the indications for blood transfusion, examining data to prevent errors, disseminating information about blood transfusion, diagnosing transfusion responses, and documenting the processes, a nurse plays a critical role in ensuring blood transfusion safety [29, 30]. As a crucial process, blood transfusion requires knowledge and skilled specialists to preserve patient safety. The risk of blood transfusion is reduced by qualified and experienced nurses. There are four phases associated with nursing performance, including pretransfusion preparation, pre-transfusion actions, blood bag collection, and posttransfusion activities to maintain the patient's safety. The preparation phase includes checking the written prescription of the physician [29, 30]. This gives sufficient details regarding the indications, risks, and advantages of blood transfusion. The second stage involves drawing blood from the blood bank, which is crucial for enhancing patient safety. In order to prevent blood incompatibility, the nurse must accurately match the patient's identification details on the blood bag and collection paper. Transporting blood from the blood bank to the ward should be done using a special blood carrier box. Two authorized individuals verified the blood's compatibility prior to transfusion. Checking the patient's vital signs is necessary. Since this is the final opportunity to introduce any unsuitable blood component, it is a very sensitive step in the safety of blood transfusions. Blood transfusion must begin slowly during posttransfusion activities during the first 15 min after it begins. The nurse should continue to monitor the patient to look for any reactions. While receiving a blood transfusion, it is advised to take normal saline intravenously and morphine at 1 mg/ml, but no more medication is permitted [30]. To save a patient's life, the nurse must be aware of any blood response signs and know how to treat them [31]. A handbook manual on blood transfusion services must be provided to nurses in order to continue their education in all healthcare institutions, and they must be continuously urged to attend national and worldwide blood transfusion workshops and conferences.

#### **2.4 Establishing multicenter cooperative transfusion service**

The community must get high-quality medical care through hospitals, which serve as the primary organization for the delivery of public services. In accordance with these provisions, there are four sections pertaining to hospitals' obligations in providing medical services, namely: Responsibility for employees: competent personnel must be hired through an open and transparent hiring process, professional

responsibility for quality: Professional bodies are always required to set up ongoing training programs for their members in blood transfusion services in order to comply with international best practices, responsibility for facilities and equipment; appropriate financing should be available to supply the tools and supplies that medical professionals, particularly those working in blood transfusion units, need; and Last but not least, the hospital is responsible for the building's safety and upkeep [32–34]. This includes making sure that both patients and staff are safe inside the institution. Therefore, blood transfusion services must be safe for the patient, and the patient must be protected against the risk of developing an infectious disease through blood transfusion and even death.

Toward this shared objective, medical practitioners must collaborate. Every important participant in the transfusion chain must, therefore, share a shared objective. Healthcare facilities in Nigeria should make every attempt to keep everyone's values and presumptions in mind as it may affect interactions with team members who are other professionals. Regardless of the talents and limitations of various team members, effective teamwork contributes to the provision of high-caliber and safe healthcare [33, 34]. Hospitals must create a blood transfusion committee that meets regularly to examine the current transfusion strategy, and best practices, compile a transfusion manual and handbook, as well as to take training sessions to stay informed about the current state of transfusion services [34].

#### **3. Conclusions**

In Nigeria, health professionals who provide transfusion-dependent patients' care have a real and compelling responsibility to uphold their end of the bargain when it comes to being held accountable for the human, financial, clinical, and other resources involved in managing blood donations. All parties involved—from patients to laboratory scientists, physicians, blood collectors, and distributors—must collaborate if they are to use these priceless donations of human blood with judiciousness and excellence.

#### **Acknowledgements**

All glory to the Almighty for making it possible to write this paper. Likewise, I thank my mentors whose guidance and constructive criticism yielded this write-up in the person of Professor A.O Hassan, Professor Abubakar, A.A., Dr. Adeniyi T.D., and Mr. Ismail A. The contributory effort of Mr. Abdulkareem Aliyu is well appreciated and we say special thanks to all of you. We will also like to note that this review receives no funding.

#### **Notes/thanks/other declarations**

Special thanks to the publisher and editor of this journal for finding it worthy to place this review in their reputable journal.

*Personnel for Blood Transfusion Services in Nigeria: A Multicenter Cooperative Study DOI: http://dx.doi.org/10.5772/intechopen.107301*

#### **Author details**

Abdulrahman Abdulbasit Opeyemi\*, Adesola Precious Oyeyemi and Adeyeye Kamaldeen Department of Medical Laboratory Science, Achievers University, Owo, Ondo State, Nigeria

\*Address all correspondence to: aabdulbasit5@gmail.com

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### **References**

[1] Karim S, Hoque E, Hoque M, Rahman SM, Islam K. Blood component therapy. Anwer Khan Modern Medical College Journals. 2018;**9**(2):142-147. DOI: 10.3329/akmmcj.v9i2.39211

[2] Poterjoy BS, Josephson CD. Platelets, frozen plasma, and cryoprecipitate: What is the clinical evidence for their use in the neonatal intensive care unit? Seminars in Perinatology. 2009;**33**(1):66-74. DOI: 10.1053/j.semperi.2008.10.004

[3] Lacroix J, Hébert PC, Hutchison JS, TRIPICU Investigators. Canadian critical care trials group; Pediatric acute lung injury and Sepsis investigators network. Transfusion strategies for patients in pediatric intensive care units. New England Journal of Medicine. 2007;**356**(16):1609-1619. DOI: 10.1056/ NEJMoa066240

[4] Isbister JP, Shander A, Spah DR, Erhard J, Farmer SL, Hofmann A. Adverse blood transfusion outcomes: Establishing causation. Transfusion Medicine Reviews. 2011;**25**:89-101. DOI: 10.1016/j.tmrv.2010.11.001

[5] Musallam KM, Tamim HM, Richards T. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: A retrospective cohort study. Lancet. 2011;**378**:1396-1407. DOI: 10.1016/S0140-6736(11)61381-0

[6] Frank SM, Abazyan B, Ono M. Decreased erythrocyte deformability after transfusion and the effects of erythrocyte storage duration. Anesthesia and Analgesia Journal. 2013;**116**:975-981. DOI: 10.1213/ANE.0b013e31828843e6

[7] Yaddanapudi S, Yaddanapudi L. Indications for blood and blood product transfusion. Indian Journal of

Anaesthesia. 2014;**58**(5):538-542. DOI: 10.4103/0019-5049.144648

[8] WHO. Global Database on Blood Safety. Geneva: World Health Organization; 2015

[9] Olaniyi JA. Blood transfusion reactions. In: Tombak A, editor. Blood Groups. London: IntechOpen; 2019

[10] Land KJ, Townsend M, Goldman M, Whitaker BI, Perez GE, Wiersum-Osselton JC. International validation of harmonized definitions for complications of blood donations. Transfusion. 2018;**58**(11):2589-2595. DOI: 10.1111/trf.14948

[11] Adjepong KO, Otegbeye F, Adjepong YA. Perioperative management of sickle cell disease. Mediterrian Journal of Hematology and Infectious Disease. 2018;**1**(10):e20

[12] Yahia AI. Management of blood supply and demand during the COVID19 pandemic in king Abdullah Hospital, Bisha, Saudi Arabia. Transfusion and Apheresis Science. 2020;**4**:102836

[13] Siddon AJ, Kenney BC, Hendrickson JE, Tormey CA. Delayed haemolytic and serologic transfusion reactions: Pathophysiology, treatment and prevention. Current Opinion in Hematology. 2018;**25**(6):459-467. DOI: 10.1097/MOH.0000000000000462

[14] Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews. 2016;**12**(10):CD002

*Personnel for Blood Transfusion Services in Nigeria: A Multicenter Cooperative Study DOI: http://dx.doi.org/10.5772/intechopen.107301*

[15] Webster J, Bell-Syer SE, Foxlee R. Skin preparation with alcohol versus alcohol followed by any antiseptic for preventing bacteraemia or contamination of blood for transfusion. Cochrane Database of Systematic Reviews. 2015;**12**(2):CD007

[16] Yahia AIO. Management of blood supply and blood demand to ensure international health security. In: Stawicki SP, Papadimos TJ, Galwankar SC, Miller AC, Firstenberg MS, editors. Contemporary Developments and Perspectives in International Health Security. London: IntechOpen; 2021

[17] Medical Laboratory Science Council of Nigeria (MLSCN). New curriculum for training programme. 2013. https://web.mlscn.gov.ng/index.php/ mdocs-posts/mlscn-act/

[18] Shander A, Goodnough LT. Objectives and limitations of bloodless medical care. Current Opinion in Hematology. 2006;**13**(6):462-470. DOI: 10.1097/01.moh.0000245692.32085.bd

[19] W.H.O. Blood transfusion safety—Safe and appropriate use. 2010. https://www.who.int/health-topics/ blood-transfusion-safety#tab=tab\_1

[20] Allain JP, Sarkodie F, Boateng P, Asenso K, Kyeremateng E, Owusu-Ofori S. A pool of repeat blood donors can be generated with little expense to the blood center in sub-Saharan Africa. Transfusion. 2008;**48**(4):735-741

[21] Barro L, Drew VJ, Poda GG, Tagny CT, El-Ekiaby M, Owusu-Ofori S, et al. Blood transfusion in sub-Saharan Africa: Understanding the missing gap and responding to present and future challenges. Vox Sanguinis. 2018;**113**(8):726-736. DOI: 10.1111/ vox.12705

[22] Chand NK, Subramanya HB, Rao GV. Management of patients who refuse blood transfusion. Indian Journal of Anaesthesia. 2014;**58**(5):658-664

[23] Bates I, Hassall O, Mapako T. Transfusion research priorities for blood services in sub-Saharan Africa. British Journal of Haematology. 2017;**177**(6):855- 863. DOI: 10.1111/bjh.14577

[24] Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: A literature review of infectious disease and organizational challenges. Transfusion Medicine Reviews. 2012;**26**(2):164-180. DOI: 10.1016/j. tmrv.2011.07.006

[25] WHO. Global Database on Blood Safety, World Health Organization. Geneva; 2008

[26] Roback JD. CMV and blood transfusions. Review in Medical Virology. 2002;**12**(4):211-219. DOI: 10.1002/ rmv.353

[27] Obeagu E. Safe blood transfusion through proper donor screening correspondence to. 2019;**6**:01-07

[28] Tavares JL, Barichello E, De Mattia AL, Barbosa MH. Factors associated with knowledge of the nursing staff at a teaching hospital on blood transfusion. Revista Latino America Enfermagem. 2015;**23**(4):595-602. DOI: 10.1590/0104-1169.0024.2593

[29] Bediako AA, Ofosu-Poku R, Druye AA. Safe blood transfusion practices among nurses in a major referral center in Ghana. Advances in Hematology. 2021;**2021**:13

[30] Haseena M, Kousar P, Muhammad H, Muhammad A, Sayed AG. Assessment of Nurses' practices regarding blood transfusion. Merit Research Journal

of Medicine and Medical Sciences. 2020;**8**(8):396-402

[31] Elhy AHA, Kasemy ZAAJ. Nurses' Knowledge Assessment Regarding Blood Transfusion to Ensure Patient Safety2011. pp. 104-111. DOI: 10.9790/ 1959-060202104111

[32] Kusumaningrum A. Hospital responsibilities in blood transfusion services as a patient protection. Advances in Economics, Business and Management Research. 2021;**14**:34-38

[33] Katib IK. Quality management in the Nigerian health system; A case study of Isalu hospital limited, Ogba Lagos. International journal of economic development Research and investment. 2011;**2**(1):161-169

[34] Muhammed SSA, Bahia GA, Magda AA, Mamdou MA. Nurses performance regarding care of patients undergoing blood transfusion. Port Said Scientific Journal of Nursing. 2015;**3**(2):1-13. DOI: 10.21608/ pssjn.2016.32525

*Edited by Marwa Zakaria, Tamer Hassan, Laila Sherief and Osaro Erhabor*

The thalassemia syndromes are a diverse group of hereditary anemias caused by decreased or absent production of one type of globin chain. Genetic counseling, prenatal diagnosis, and newborn screening are all issues of importance in these inherited disorders. This book provides a comprehensive overview of thalassemia, including information on its mechanisms and treatment modalities. Chapters elucidate the mechanism of disordered synthesis of hemoglobin in thalassemia and present recent studies of the genetic mechanisms that underlie this abnormal biosynthetic process.

Published in London, UK © 2023 IntechOpen © Jezperklauzen / iStock

Thalassemia Syndromes - New Insights and Transfusion Modalities

Thalassemia Syndromes

New Insights and Transfusion Modalities

*Edited by Marwa Zakaria, Tamer Hassan,* 

*Laila Sherief and Osaro Erhabor*